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ABSTRACT 
Blood and urine are routinely used for toxicological analysis but there could be some 
circumstances where the analysis of alternative matrices may prove to be more 
relevant or more convenient. It is not uncommon for blood and / or urine to not be 
available, e.g. in some post-mortem cases and it can be difficult to analyse and 
interpret results for matrices that are not routinely used. Oral fluid, stomach contents, 
vitreous humour, bile and liver were analysed alongside blood and / or urine. 
Techniques used included immunoassay, HPLC-DAD, LC-MS, GC-MS and GC-FID 
depending on the analytes to be detected. The results revealed that for drug 
screening the majority of drugs and metabolites that were detected in blood and 
urine were also detected in the alternative matrices. Where it was possible to 
quantify drug concentrations, little correlation was found between blood and the 
alternative matrices. The alternative matrices investigated have proved to be very 
effective for the screening of drugs and when analysed alongside traditional matrices 
or in conjunction with each other, the results can provide a very good insight into an 
individual’s drug use.  
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1.1 GENERAL INTRODUCTION 
Toxicology can be described as the science of poisons, where a poison can be any 
substance that causes a harmful effect, when administered to living organisms. 
Therefore, most drugs can act as poisons as they usually produce toxic effects at a 
particular dose.  
Within this definition the term poison is quantitative and dose-dependent, as most 
substances can be harmful at a particular dose but can usually be taken without 
harm at some lower dose. Somewhere between these levels there exists chronic 
toxicity and lethal toxicity, and these levels could be effected by different 
circumstances, e.g. in the presence of other poisons.  
Toxicity is a biological concept that is not only different from species to species but 
also between individuals due to differences in age, gender, size, genetics and 
health, (Hodgson, 2010).  
As well as these complexities, some pharmacological considerations are also 
required when interpreting toxicological results such as method / route of exposure, 
how the drug or poison is absorbed, distributed, metabolised and finally excreted 
from the body.  
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1.2 AIMS AND OBJECTIVES 
Blood and urine have been the traditional matrices for drug detection for many years 
and still provide reliable results but they are not always available. This research 
project aimed to determine the usefulness of a selection of alternative matrices in 
both Clinical and Post-mortem Toxicology.  
1. To develop and evaluate methods for detecting drugs in oral fluid. 
2. To evaluate the effectiveness of oral fluid monitoring for illicit drug use using 
marker compounds.  
3. To compare toxicological findings for alternative matrices with traditional 
matrices. 
4. Assess the interpretive usefulness of alternative matrices 
1.3 CLINICAL TOXICOLOGY  
This usually involves the diagnosis or treatment of patients in a hospital or clinic 
setting. Such uses include:- 
 Unknown drug screens - to determine or exclude drug use, for example if 
someone was found collapsed.   
 Therapeutic drug monitoring - if an individual is on long-term treatment for a 
treatable illness then it is important to measure drug levels to assess if the patient is 
getting the required effect from a particular dose.   
 Compliance testing for patients on replacement therapy – if an individual has 
become addicted to illicit drugs, they can be prescribed less harmful drugs that have 
similar but less harmful effects. However, it is important to test that the substitution 
drugs are been taken.  
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1.4  FORENSIC TOXICOLOGY 
This assists with judicial proceedings and usually involves work for the police, HM 
Coroner or criminal law courts. 
 Workplace drug testing – this can be a requirement set out by some 
employers, usually its either pre-employment screening - which is carried out on all 
potential employers prior to them being employed, or post-incident -  after an injury, 
damage or near miss has occurred, or random – selecting employees at random for 
testing at regular intervals 
 Post-mortem toxicology – this is used to determine whether drugs of poisons 
have caused or contributed to a death 
1.5 ANALYTICAL TOXICOLOGY 
The application of analytical toxicology can in effect, bring together both clinical and 
forensic toxicology. It can be used to describe the process and techniques, used to 
detect and / or measure, or exclude compounds associated with a particular 
investigation.  
It is common practice for toxicology laboratories to perform analysis in two stages. 
Initially drug screening methods will be used, followed by confirmation and / or 
quantitative methods, where appropriate. 
 DRUG SCREENING 1.5.1
A drug screening technique is a qualitative assay, initially performed to test if any 
drugs are present in a specimen. Their main purpose is usually to provide a quick 
20 
solution for the determination of any negative samples, so that further more 
complicated work can be avoided, 
There are many different analytical techniques that can be used for this and they 
can range from simple colour change or spot tests, to thin-layer chromatography 
(TLC), to a whole range of immunoassay procedures.  
In addition, many more sophisticated analytical techniques can be used as 
screening methods, where this is seen as advantageous.  
 DRUG CONFIRMATION AND QUANTITATION 1.5.2
In forensic toxicology, courts require that the identification of a compound be beyond 
reasonable scientific doubt. In order to achieve this, it is important that the presence 
of every analyte is confirmed by a secondary method of identification. Some 
screening techniques already have this ability, e.g. LC-MS has both a retention 
parameter and a mass-spectrum parameter, to absolutely identify a particular 
compound and this can easily be achieved either by matching the analytical profile 
to a database or library on the system, or if it is not already on the system analysing 
a pure reference standard under the same conditions. 
Some types of assay, such as immunoassay, need to be confirmed by a different 
technique, e.g. GC or LC. It is preferable that drugs are identified using 
complimentary techniques (e.g. GC and LC) or methods of detection (e.g. LC-UV 
and LC-MS). However, this is not always possible due to the difference in 
amenability of some drugs, e.g. polar or thermolabile compounds are less amenable 
to GC analysis. 
After the presence of a drug has been absolutely confirmed, quantitation will usually 
be required, using the most appropriate technique. This usually involves the 
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extraction of a set of calibration standards, along with the test sample (in duplicate 
where possible) and at least one quality control (QC) standard. Results should only 
be accepted if the QC result is close to the expected spiked value (usually 
acceptable within 20%, but ideally within 10%). An appropriate internal standard 
should be used for all GC and HPLC techniques to help minimise matrix effects and 
correct for other slight variables in extraction procedures, e.g. transfer volumes. The 
internal standard should ideally be similar in structure to the target analyte, (Jones, 
2004), (Elliott, 2009). 
1.6 DRUG MATRICES 
In principle, a whole range of biological specimens could be analysed to assess the 
presence of drugs, but in practice their suitability is limited by the ease in which the 
samples can be obtained and by the availability of technology to analyse them 
(Bennett, et al., 2003).  
As blood and urine have different detection times, they are often both analysed in 
conjunction, and depending on the question being asked the results will usually 
provide a good insight to drug use and/ or exposure.  
 Blood / plasma and serum 1.6.1
Blood / plasma and serum are commonly used to detect and measure drugs, they 
can be used to determine recent or current drug use, as they have  detection 
windows of approximately 24-48h. For this reason they are commonly used in 
therapeutic monitoring, as in living patients the dose of a drug is most closely 
correlated with its concentration in these matrices. For the same reason, blood has 
also been one of the primary specimens in post-mortem toxicology, as this relates to 
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the drug status at the time of death (Jones, 2004). However, plasma and serum are 
not usually an option due to the nature of post-mortem blood and extent of 
putrefaction. It is important to note that although the concentration of a drug or 
poison, found in post-mortem blood was previously assumed to be equivalent to that 
obtained in the blood or plasma of the deceased at the time of death, this is simply 
not the case. Many factors need to be taken into consideration when interpreting 
drug levels, as changes in drug distribution after death do occur, depending on 
circumstances of death, e.g. If trauma is involved and the pharmacology of the 
drugs, as well as the age and general health of the deceased, (Flanagan, 2011), 
(Elliott, 2009). 
In life, blood collection can be both invasive and painful so for patients requiring 
long-term drug monitoring, so that blood specimens are not seen as ideal and a 
non-invasive alternative is sought.  
 Urine 1.6.2
Urine is also commonly used to detect drugs. It can be used to determine previous 
drug use as the detection window for most drugs is 2-3 days. It is an ideal matrix for 
drug screening, as it is mostly made up of water and contains relatively few 
endogenous compounds that interfere with analysis, (Jones, 2004).  
It tends to be metabolites that are present in urine, rather than parent drugs and for 
some types of testing this can be seen as an advantage. For example, it is possible 
to distinguish illicit morphine use, from an over the counter preparation or prescribed 
variety, by detection of the specific metabolite  
6-monoacetylmorphine (6-MAM).  
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In a clinic setting where drug of abuse monitoring is required, urine has become the 
preferred drug matrix of choice. The non-invasive technique of obtaining the sample 
is largely acceptable and if the individuals are supposed to be abstaining from illicit 
drugs then a measurement of drug is not necessarily needed as a qualitative 
positive or negative result will be sufficient.  
However, with this type of testing, specimen adulteration, can be an issue, as some 
substitution drugs, such as methadone, have a high street value. For some patients 
the temptation to sell on their medication is too great, especially if the profit earned 
will be enough to buy the drug that they are addicted to. Measures will therefore 
need to be put into place to prevent or detect this. Addiction patients have been 
known to “spike” their urine with their prescribed drugs, in an attempt to get a 
positive result and maintain their prescription, so the testing for metabolites that 
urine allows can be very important. 
Observed collection could eliminate these problems but due to privacy issues, the 
acceptability of this has raised ethical questions.  Therefore, in order to guarantee 
the integrity of the specimens, additional tests are often performed, such as the 
measurement of creatinine. This is a breakdown product found in urine and a low 
level could suggest that the sample is not urine or has been diluted. Tests for pH will 
detect for any acid or alkali adulterants. 
In post-mortem toxicology urine analysis can be useful, especially when used in 
conjunction with blood. However, although it can give a good indication of what 
drugs the deceased has had access to, due to the drug detection window; it is not 
that useful in determining the cause of death.  
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Also urine is not always available, in about 50% of deaths, the bladder is voided in 
the dying process, (Jones, 2004).  
In blood the parent: metabolite ratio can help to interpret results, for example an 
elevated morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) 
compared to a lower morphine level, could indicate chronic use, but this comparison 
is not usually possible in urine as the parent drug is very often eliminated to the 
extent that it is not detected. 
 Alternative matrices 1.6.3
In certain circumstances the use of alternative matrices or unconventional matrices 
for detection of drugs can be very useful. The type of matrices will vary, but will 
largely depend on availability, ease of collection, analytical and testing 
considerations as well as interpretation of results, (Caplan, 2001).    
The drug detection windows, or the length of time that a drug can be detected after 
ingestion, must be considered carefully when interpreting the results from different 
drug matrices, (Table 1.1). 
As scientific techniques have become more advanced and the possibility of 
detecting drugs at very low concentrations has become a reality, the interest in 
alternative matrices has grown. Specimens of particular interest include oral fluid, 
sweat and hair as they benefit from non-invasive collection that can be performed 
relatively easily and under supervision where necessary.  
Although, they are only usually available in relatively small samples, again, due to 
the development of more sensitive techniques, such as LC-MS, and GC-MS-MS, 
accurate detection and measurement of drugs is possible.  
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These advances have also been helped by commercial availability of collection 
devices, e.g. sweat patches.     
A particular advent for these matrices was that they were deemed suitable to be 
evaluated for work place drug testing, and were included in drafts of proposed 
mandatory guidelines, by the regulatory board Substance Abuse and Mental Health 
Services Administration (SAMHSA), (SAMHSA, 2004).  
Although both sweat and hair can be collected by non-invasive techniques, 
comparatively there are still disadvantages associated with sample collection. Sweat 
can be collected using a patch but this is a prolonged process where the individual 
is usually required to wear it for 2-3 days, which can be both inconvenient and 
uncomfortable. 
The collection of hair is actually quite a precise science in itself. Guidelines have 
been proposed by Society of Hair Testing (SoHT), (Cooper, et al., 2012), for the 
correct methods of collection, and if these are not adhered to then any sample 
collected could prove useless for analysis and accurate interpretation.  
Therefore, oral fluid seems to have a distinct advantage, over sweat and hair, it can 
be collected easily either by the old method of expectoration, (spitting), or by using a 
collection device which is simple, quick and easy. 
In post-mortem toxicology, in some circumstances both blood and urine are not 
available so other specimens such as stomach contents, vitreous humour, bile, liver 
and other tissues, muscle or bone marrow are submitted for analysis.  
In these cases it can be difficult to analyse and interpret results as these matrices 
are not routinely used and therefore there are often limited published data to refer 
to, (Fernández, et al., 2006), (Lin, et al., 1997), (Politi, et al., 2004).  
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Hair can be useful to determine drug history and sometimes in post-mortem 
toxicology this can be useful, e.g. to provide evidence of tolerance to a particular 
drug. However, due to the time detection window for drugs, (see Table 1.1), it is 
generally not very useful for determining if drugs have caused or contributed to a 
death, so it has limited use in this type of analysis, (Elliott, 2009).  
Drug matrix Detection times of drugs after 
ingestion 
Stomach Contents / Saliva Hours 
Blood / Plasma Up to 1 day 
Vitreous Humour Days 
Urine / Sweat / Liver / Bile Days – weeks 
Hair   Weeks – months 
Nails Weeks – months – years 
 
Table 1.1 Comparison of drug detection windows in different matrices  
1.7 COMMON DRUGS 
 OPIATES 1.7.1
Opiates are any drugs or compounds derived from the opium poppy. They are a 
type of analgesic, which means that they are used for pain relief. The most 
commonly known opiates are morphine and codeine.  
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Figure 1.1 Structures of morphine (left) and codeine (right) 
 
Morphine is available as “morphine sulphate”, and it can also be prescribed in the 
more potent form “diamorphine”, but it can also be used to produce illicit morphine 
or heroin which is a known drug of abuse. Heroin is usually smoked, injected or 
snorted if it’s in its pure form. 
 COCAINE 1.7.2
Cocaine is a naturally occurring alkaloid found in some varieties of plant from the 
genus, Erythroxylum. It is a local anaesthetic, a vasoconstrictor and a powerful 
pyschostimulant and due to this last action, it is widely abused, (Jones, 2008). It is 
often “cut” with other substances, these include sugar, caffeine, lignocaine, 
procaine, hydroxyzine and benzocaine. 
 
Figure 1.2 Structure of cocaine 
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 AMPHETAMINES 1.7.3
This group of drugs, have been derived from phenylethylamine, a naturally occurring 
chemical. They are central nervous system (CNS) stimulants and this effect, led to 
these drugs being abused. 
Amphetamine is still prescribed (as dexamphetamine) for narcolepsy and attention-
deficit hyperactivity disorder (ADHD) in children. “Street” amphetamine is usually a 
powder that can be rubbed into the gums, orally ingested or snorted.  
CH3
NH2
 
Figure 1.3 Structure of amphetamine 
 
Methamphetamine a related drug is not prescribed. It is abused less in the UK but is 
very popular some areas of the world, e.g. America, Japan.  
3,4-methylenedioxymethamphetamine (MDMA) sometimes known as a “designer-
drug” has been abused as a stimulant since the mid to late 1980s. Other “designer-
drugs” include; 4-methylthioamphetamine (4-MTA), para-methoxyamphetamine 
(PMA), para-metoxymetamphetamine (PMMA), 2,5-dimethoxy-4-
methylamphetamine (DOM) and 2,5-dimethoxy-4-bromoamphetamine (DOB), 
(Elliott, 2009).  
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 OPIOIDS 1.7.4
These contain synthetic compounds that provide the pharmacological properties as 
opiates; they are generally used as analgesics. They have a wide range of 
potencies, e.g. etorphine used in veterinary medicine is about 1000 times more 
potent than morphine. Due to their opiate-like action they are often prescribed for 
drug substitution programs for opiate addiction. However for the same reason, it is 
not unusual for them to be abused. Examples include methadone, buprenorphine, 
dihydrocodeine (DHC), oxycodone, tramadol and pethidine.   
 BENZODIAZEPINES 1.7.5
Sedative drugs prescribed for insomnia and anxiety, originally thought to be a “safer” 
alternative to the older sedative drugs “barbiturates”. They can also be used to 
control seizures and treatment of alcohol or drug withdrawal symptoms. However, 
they are prone to be abused themselves, (Elliott, 2009). Examples include; 
diazepam, temazepam, lorazepam, clobazam and chlordiazepoxide. 
 ANTIDEPRESSANTS 1.7.6
These drugs are used to reduce the feelings of depression by altering the 
concentration of specific neurotransmitters in the brain. They are divided into 
different sub classes according to their structure and mechanism of action. 
Examples include citalopram, fluoxetine, venlafaxine, duloxetine, amitriptyline, 
dosulepin (dothiepin) and mirtazepine, (Elliott, 2009). 
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 ANTICONVULSANTS / ANTIEPILEPTICS 1.7.7
These drugs are used to control seizures and / or fitting, e.g. they are often 
prescribed for epilepsy sufferers. Examples include carbamazepine, phenytoin, 
lamotrigine and sodium valproate. 
 ANTIPSYCHOTICS 1.7.8
These drugs produce tranquilising effects but without impairing consciousness. 
Prescribed for treating psychoses, e.g. such as schizophrenia, as well as severe 
anxiety. Examples include; chlorpromazine, promazine, clozapine, haloperidol and 
olanzapine. 
 β-BLOCKERS 1.7.9
These drugs are used to treat hypertension, angina, arrhythmias and anxiety. 
Examples include propranolol and atenolol. 
 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 1.7.10
These drugs are analgesics, used for long lasting pain relief and anti-inflammatory 
effects. Examples include; ibuprofen, diclofenac, salicylate and naproxen.  
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2.1 ANALYTICAL TECHNIQUES 
  IMMUNOASSAY 2.1.1
All immunoassay techniques are based on the interaction of a target molecule 
(antigen) with the antibody. For drug testing, an antibody specific for the drug or 
drug class is used and the assay is usually based on competitive binding.  
A known quantity of antibody is introduced, with a fixed quantity of labelled drug, 
and the test sample. Specific binding sites on the antibody bind both the drug in the 
test sample and the labelled drug in the assay. There is an inversely proportional 
relationship between labelled drug bound and unlabelled drug bound, (Hand & 
Baldwin, 2004).  
Immunoassays for drugs can be divided into two groups: 
Heterogeneous – require an additional step to separate the bound complexes and 
free fractions of the assay before measurement of the signal 
Homogenous – do not require this step 
Immunoassays have wide applications in drug testing, and there are many 
commercially available testing kits and analysers available. They have the 
advantage of fast and convenient analysis, often without any extraction methods, 
and are applicable to many matrices.  
Some specific assays are available. They can be used to accurately quantify drugs, 
for example in therapeutic drug monitoring, immunoassay techniques are used 
routinely to quantify drugs in plasma, serum and blood. 
However, for less specific assays, where the chemistry involved looks for groups of 
drugs, e.g. opiates, rather than specific drugs, e.g. morphine, both false negative 
and false positive results can occur. The manufacturers of commercially available 
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kits will usually carry out specific tests to calculate the cross-reactivity of common 
assay “interferants”, and this information will be supplied with the kit. Obviously they 
cannot test for everything in every type of scenario so it is important for analysts 
using these assays to be aware of these assay limitations.  
For this reason, immunoassay drug screens are usually semi-quantitative, and 
should be confirmed by a secondary method such as Gas Chromatography-Mass 
Spectrometry (GC-MS) which can provide an absolute identification of which drug 
within a group caused the positive screen result, and also identify any false positive 
screening results too. For forensic work it is essential that any immunoassay results 
are confirmed by a secondary method.  
Enzyme linked immunosorbent assay or ELISA, is a heterogeneous immunoassay. 
Although, this method could appear more labour intensive than the homogeneous 
type this is not necessarily the case, although an additional step is often required to 
separate the fractions, comparatively little sample preparation is required initially, 
e.g. whole blood can be used without extraction which is uncommon in 
homogeneous methods, and also the heterogeneous assays have lower limits of 
detection, (Hand & Baldwin, 2004).  
In ELISA, the specific antibody is coupled to a solid support. Often this is to the 
plastic in micro wells on a plate. An aliquot of sample to be assayed is added to 
micro-plate wells, followed by a solution of the same antibodies coupled to an 
enzyme (horseradish peroxidase). After an incubation period, the plate is washed to 
remove any unbound material and a colourless substrate is added to the wells. 
There is another incubation period during which a coloured product is produced, 
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(refer to figure 2.1), the intensity of the colour is measured and then used to 
determine the amount of antigen present in each sample, (Hames, et al., 1997). 
 
  
 
 
 
    
 
 
 
 
Figure 2.1 Diagram to show ELISA procedure 
(Chakravarthy, 2011) 
Cloned enzyme donor immunoassay (CEDIA), is a homogeneous enzyme 
immunoassay. This technique is based on the use of an enzyme β-galactosidase, 
which has been genetically engineered into two inactive fragments; one fragment is 
conjugated to a drug and is called the enzyme donor (ED), while the other fragment 
that co-exists with the antibody is known as the enzyme acceptor (EA). Drug in the 
Antigen-coated well 
Wash 
Specific antibody 
binds to antigen 
Enzyme-linked  
antibody binds to 
specific  antibody 
Substrate is added and converted 
by enzyme into coloured product; 
the rate of colour formation is 
proportional to the amount of 
specific antibody 
Wash 
Wash 
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test sample competes with the ED for the binding site on the antibody. Any drug 
present in the sample binds to the antibody, leaving inactive enzyme fragments free 
to form active enzyme. The amount of active enzyme formed and resultant 
absorbance change are proportional to the amount of drug in the test sample. If 
there is no drug present in the sample, the antibody binds to the ED fragment 
preventing formation of active enzyme, (Henderson, et al., 1986), (Krapp, 2002). 
Within the laboratory, (where I started this study), there was a fully automated 
immunoassay analyser that used CEDIA kits for urine drugs of abuse analysis. 
However, all the assays were based on urine drug cut-off levels, (as set out by the 
Substance Abuse and Mental Health Services Administration (SAMHSA), and as 
these are so much lower than levels expected / or found in oral fluid, (see Table 
2.1), it was not possible to use this system for oral fluid analysis. 
 Urine screening 
cut-off concentrations 
Proposed oral fluid 
screening cut-off 
concentrations  
Amphetamines 500 ng/mL 50 ng/mL 
Cocaine (metabolite) 300 ng/mL 20 ng/mL 
Methadone (metabolite) 100 ng/mL 20 ng/mL 
Opiates 300 ng/mL 40 ng/mL 
Cannabinoids 50 ng/mL 4 ng/mL 
 
Table 2.1 Cut-off levels in urine versus oral fluid, (SAMHSA, 2004)  
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 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH DIODE-2.1.2
ARRAY DETECTION (HPLC-DAD) 
Chromatography can be defined as the separation of components in a mixture. 
Liquid chromatography (LC) produces separation based on the differential 
distribution of analytes between two phases. One phase is liquid, e.g. mobile phase, 
and the other is either a solid or a liquid that is firmly bound to a solid support, e.g. 
the column.  When appropriate solvent conditions are reached the drug elutes off 
the column where it can be detected by an appropriate method.  
Historically, LC was very time-consuming and it was usually only possible to analyse 
relatively few samples before the column would need to be re-packed. Complex 
separations were difficult to achieve. However, the development of high 
performance liquid chromatography (HPLC) changed all this. Once systems capable 
of quantitative analysis became commercially available, this technique became 
increasingly popular, recognised for its convenient automation, separation of a wide 
range of sample types, excellent resolution and speed. 
There are a wide range of stationary phases available, they are usually described as 
belonging to one of four mechanistic types:- 
 Adsorption chromatography – sample components are selectively adsorbed 
onto the surface of the solid stationary phase.  
 Partition chromatography – involves a liquid stationary phase that is 
immiscible with the eluent and coated on an inert support. It can be either normal 
phase where the mobile phase is less polar than the stationary phase, or reverse 
phase chromatography where the opposite is true so the mobile phase is more polar 
than the stationary phase. 
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 Ion exchange chromatography - stationary phase is an ion exchange resin 
with anionic and cationic groups on the surface which attract solutes of opposite 
charge. 
 Size exclusion chromatography –  stationary phase is a porous gel and 
separation occurs on the basis of component size  
Stationary phases in use today are “micro-particulate” column packings made up 
from uniform, porous silica particles with spherical shapes and 3 – 10 µm diameters.  
A typical HPLC system includes a pump, injector, column, detector and a recorder 
or computer, (refer to Figure 2.2). A high-pressure pump is required to move the 
mobile phase through the highly compacted column, this occurs at a constant flow 
rate e.g. 1 mL/min. Samples are injected onto the system by the auto-sampler, the 
mobile phase containing the analytes is pumped through the column and separation 
of the components occurs. Each component elutes off the column and is registered 
as a peak on the recorder.  Detection of the eluting components can be achieved by 
several methods, such as ultra-violet detector (UV), photodiode array detector (UV-
DAD), electrochemical (EC), fluorescence (FL), and mass-spectrometry (MS). For 
this study, UV-DAD was used, this consists of a large number of microdiodes, and 
each diode will record variations in the intensity of radiation from a particular section 
of the spectrum so there is a continuous monitoring of absorbance over a specified 
wavelength range, (e.g. 200-600 nm).  
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Figure 2.2 HPLC-DAD System Setup  
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Photodiode array 
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The result is that a traditional chromatogram will be generated and for this, one 
particular wavelength can be chosen to observe separation. Each “peak” relates to 
the degree of absorbance and the concentration present, i.e. a small peak indicates 
a low concentration.  
In addition to this, plotting of the absorbance at each wavelength produces a 
spectrum. This UV spectrum can be compared against UV spectra in a library of 
known compounds. This technique can be applied to any substance that has a 
suitable structure to absorb light, this usually requires a conjugated system or a 
chromophore, i.e. this is present in most drugs. The UV-spectra together with the 
retention time, provides two separate methods of identification, (Kupiec, et al., 
2004), (Holme & Peck, 1998), (Elliott, 2009), (Herzler, et al., 2003). 
 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (LC-MS) 2.1.3
Liquid Chromatography with Mass Spectrometry detection (LC-MS) can be used for 
drug screening, confirmation and quantitation. The LC system is usually an HPLC 
setup as previously described but it is linked to an MS, (see Figure 2.3). Mass 
filtration occurs in a quadrupole analyser or an ion trap. Some MS systems have 
triple quadrupoles, these are LC-MS-MS or tandem MS systems. Mass 
spectrometry (MS) is based on measurement of the mass-charge (m/z) ratio of an 
ionised compound. In LC-MS, energy is applied to compounds flowing into the MS 
from the LC system, to create an ionised compound. This is fragmented to produce 
a “full scan” mass spectrum, (Elliott, 2009). 
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Figure 2.3 LC-MS System Setup 
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It is also possible to operate LC-MS using a targeted approach. This is where 
particular transitions can be specifically looked for, and this helps to increase the 
sensitivity of the system because it is scanning a smaller range. This is known as 
multiple reaction monitoring (MRM). LC-MS has two built in methods of 
identification, e.g. retention parameter and MS fragmentation pattern. Identification 
is primarily based on the MS, and this can be compared to a library on the system. 
However, it is important to note that LC-MS libraries are not very applicable between 
different systems and tend to be both instrument and methods specific, for this 
reason they  are best built up in-house, (Elliott, 2009).   
 GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS) 2.1.4
Gas chromatography, like LC, is a separation technique; it depends upon the 
partition of a solute between two phases. The mobile phase is gaseous and 
separation is performed in a column (containing either a solid or liquid stationary 
phase) that has a continuous flow of mobile phase passing through it, (usually an 
inert carrier gas). When a mixture of compounds is injected at the inlet, each 
compound partitions between the stationary phase and the gas phase as it is swept 
(by the carrier gas) towards the detector. Some compounds have greater affinity for 
the stationary phase and so take longer to reach the detector. As described with 
HPLC, the detector produces a signal proportional to the concentration of compound 
present, and each compound that elutes from the column has a characteristic 
retention time, this can be defined as the time interval from injection to peak detector 
response. The retention time of each analyte on the column, is determined by the 
solubility and absorption, which is largely influenced by the chemical structure (e.g. 
size, polarity) and temperature. 
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Figure 2.4  GC-MS System Setup 
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A typical GC system is comprised of a gas cylinder (to provide carrier gas), a 
sample inlet port, a column oven (to maintain temperature and keep analyte in 
vapour form), a column and a detector, (see Figure 2.4). 
Unfortunately GC is not applicable to all compounds, non-volatile and polar 
compounds are not very amenable to GC. As a general rule, if a compound has 
sufficient volatility for its molecules to be in the gas phase at or below 400°C, without 
decomposing, it can probably be analysed by GC. In addition to this, small 
compounds (i.e. with low mass) do not fragment very well, this can be overcome by 
the process of derivatisation which adds more chemical groups, to produce a larger 
molecule that produces more distinctive fragmentation, resulting in a better mass 
spectrum. However, this derivatisation step complicates and lengthens sample 
preparation, and the reagents are often very toxic.     
When the detection system is an MS, the principle of mass-spectral detection is the 
same as for LC-MS, as a mass-charge (m/z) ratio of an ionised compound is 
measured. However, with GC-MS, the compounds are in a gaseous state at high 
temperature. With the most common technique of electron impact (EI), the 
compound is bombarded with electrons, compounds absorb energy which causes 
them to ionise and fragment in a characteristic and reproducible manner. The 
molecular ion can also become fragmented so the whole drug molecule is not 
usually detected intact. The ions are focused and accelerated into a mass filter that 
allows fragments of sequentially increasing mass to enter the detector. The 
abundance of each mass at a given scan time produces the mass spectrum.  
The MS detector can be operated in either full scan mode (collecting all the ions 
within a given mass range) or selected ion monitoring (SIM) mode, which collects 
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only pre-selected masses characteristic for the compound(s) under study, which 
allows for greater sensitivity. As with LC-MS, GC-MS provides two identification 
parameters, a retention time and a mass spectrum. Where scan mode is used, 
mass spectra can be compared against a library and for SIM data, the ion ratios can 
be compared to a reference standard. GC-MS libraries have the advantage that the 
data is largely applicable to all GC-MS systems, and this means that there are 
extensive points of reference to aid with identification, (Dawling, 2004), (Elliott, 
2009), (Holme & Peck, 1998). 
   GAS CHROMATOGRAPHY WITH FLAME IONISED DETECTION (GC-2.1.5
FID) 
A flame ionised detector (FID) depends upon the thermal energy of a flame causing 
some ionisation of molecules as they burn. The ions are collected by a pair of 
polarised electrodes and the current produced is amplified and recorded.   An FID 
detector responds to virtually all organic compounds, the response is dependent on 
the number of carbon atoms in the molecule but it is lowered if oxygen and nitrogen 
are also present in the molecule.  
For drug analysis it is particularly useful for ethanol and other alcohols, (as these are 
volatile carbon chain compounds) but it can also be applied to other drugs, e.g. 
valproate. Chromatographic “peaks” are observed at different retention times but 
this technique does not have a secondary method of identification, ( (Elliott, 2009), 
(Holme & Peck, 1998), (Dawling, 2004). 
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 GAS CHROMATOGRAPHY WITH NITROGEN PHOSPHORUS 2.1.6
DETECTION (GC-NPD) 
Nitrogen-phosphorus detection (NPD) or alkali flame ionisation detection (AFID), as 
it is also known, involves the introduction of alkali metal vapours (usually supplied by 
an electrically heated bead of rubidium or caesium chloride) into the flame of an FID. 
This results in an enhanced response to nitrogen- or phosphorus-containing 
compounds. This type of detector is particularly useful for drug analysis, as most 
drugs contain nitrogen, while the solvents and the bulk of the co-extracted material 
from a biological sample do not. Like with GC-FID it only has retention time for 
identification with no secondary identification parameter.  
It also has the disadvantage that the detecting element, often referred to as the 
“bead” requires a gas supply (constantly running through it), in total this means a 
supply of three gases, and the “life” of the “bead” is relatively short and will probably 
need to be replaced every few months, depending on the usage, (Dawling, 2004), 
(Elliott, 2009), (Holme & Peck, 1998).  
 ELISA SCREENING 2.1.7
 SAMPLE PREPARATION 2.1.7.1
ELISA research kits for opiates and cocaine/BZE were received from “International 
Diagnostic Systems Corporation” (IDS) supplied by Griffols.  
 EXTRACTION PROCEDURE 1 (TAKEN FROM IDS KIT INSERT 2.1.7.2
GUIDE) 
20µL blank / calibrators / controls were pipetted into the micro plate wells and 100µL 
of diluted enzyme was added to each well. After 1 hour incubation at room 
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temperature the wells were washed and 100µL of substrate was added to each well. 
After 30 minutes incubation at room temperature, 100µL of stop solution was added 
to each well. The absorbances were measuerd with a micro plate reader at 450 nm 
wavelength. 
 CEDIA SCREENING 2.1.8
CEDIA kits for amphetamine/ecstasy, cocaine, methadone metabolite (EDDP) and 
opiate assays were purchased from Microgenics Corporation. These were analysed 
on an Olympus Chemistry Immuno AU640 Analyser which is a fully automated 
system. After the instrument has been calibrated, neat urine samples can simply be 
loaded onto the system and results will be generated sometime later. 
 LIQUID CHROMATOGRAPHY FOR SCREENING 2.1.9
 SAMPLE PREPARATION  2.1.9.1
A range of calibrators were made from 1 mg/mL drug stocks purchased from LGC 
Standards (Middlesex, UK). The calibrators contained Amphetamine (AMP), 
Methamphetamine (MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxymethamphetamine (MDMA), the lowest calibrator was 10 ng/mL and 
the highest 1000 ng/mL.  
Norfenfluramine was added as an internal standard (IS), (as deuterated internal 
standards could not be used in this experiment as the extracts were going to be ran 
on HPLC-DAD), this was prepared in sodium carbonate buffer and added in place of  
the buffer, in extraction procedure 2. 
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 EXTRACTION PROCEDURE 2 – basic drugs 2.1.9.2
A basic extraction was used, where 500µL test sample were mixed with sodium 
carbonate buffer and 5 mL 1-Chlorobutane was added as the extraction solvent. The 
tubes were mechanically shaken and then centrifuged, after which the supernatant 
was removed to a clean tube and the extract was acidified with 100µL sulphuric acid 
(H2SO4 at 0.05M). The tubes were shaken and centrifuged again, then the solvent 
layer was aspirated and the remaining 100µL was transferred to a vial insert.  
 EXTRACTION PROCEDURE 3 – basic/neutral drugs 2.1.9.3
A basic/neutral extraction was used, where 500µL of test samples was mixed with 
500µL of 0.2 M sodium carbonate buffer, and 5 mL hexane:ethyl acetate (7:3) was 
added as the extraction solvent. Following mixing and centrifugation, the 
supernatant was removed to a clean tube and evaporated at dryness 50°C under 
dry nitrogen (using a sample concentrator). The extracts were reconstituted with 
100µL methanol, and vortexed, before being transferred to an appropriate vial.  
 EXTRACTION PROCEDURE 4 – acidic/neutral drugs  2.1.9.4
An acid extraction was used, where 500µL sample was mixed with 500µL of 0.2 M 
sulphuric acid , and 5 mL chloroform was added as the extraction solvent. Following 
mixing and centrifugation, the supernatant was removed to waste and the solvent 
layer was filtered into a clean tube then evaporated at dryness 50°C under dry 
nitrogen (using a sample concentrator). The extracts were reconstituted with 100µL 
methanol, and vortexed, before being transferred to an appropriate vial.  
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 HPLC-DAD SYSTEM SETUP 1 2.1.9.5
This system consisted of a Dionex liquid chromatography system with a UV-DAD 
detector. Separation was performed isocratically on a 150 x 4.6mm Phenomenex 
Synergi Fusion-RP 4 micron column. The mobile phase was acetonitrile 70% in 
triethyl ammonium phosphate buffer. Data analysis was interpreted or quantified at 
220nm.  
 LC-MS SYSTEM SETUP 2.1.9.6
The same extracts were analysed on a tandem LC-MS system, which had an 
Agilent 1200 series HPLC and a Q-TRAP, Applied Biosystems. Multiple reaction 
monitoring (MRM) was used for quantitation and two transitions were monitored for 
each amphetamine, (Table 2.2).   
 First MRM Transition Second MRM Transition 
Amphetamine 136 / 91 136 / 65 
Methamphetamine 150 / 91 150 / 119 
MDA 180 / 163 180 / 135  
MDMA 194 / 163 194 / 135 
 
Table 2.2 MRM Transitions 
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 GC-MS OPIATE CONFIRMATION 2.1.10
 SAMPLE PREPARATION 2.1.10.1
Certified stock solutions of morphine, codeine, DHC and 6-MAM were purchased 
from LGC Standards (Middlesex, UK), along with the following deuterated 
standards, morphine-d3, codeine-d3, DHC-d6 and 6-MAM-d3.  
The morphine and codeine stocks were used to prepare calibrators, and the 
deuterated stocks were used as internal standards, initial studies were carried out 
using both water and blank human saliva, Medidrug® Basis-line saliva (Medichem®, 
Steinenbronn, Germany) as a drug matrix.  
 EXTRACTION PROCEDURE 5 2.1.10.2
Solutions of 500µL calibrator/test/quality control, were extracted using 1mL 
ammonium carbonate buffer pH9 and 5 mL isopropranol:chloroform (9:1 v/v). 
Following mixing and centrifugation, the supernatant was removed to waste and the 
solvent layer evaporated at 45°C under a stream of air. Then the samples were 
derivatised with bis(Trimethylsilyl)Trifluoroacetamide (BSTFA-TMCS), heated at 
90°C for 5 minutes and then transferred to GC-MS vials. 
NB: Prior to extraction all the urine samples were hydrolysed by the addition of 
100 µL β-glucuronidase and incubated overnight at 37°C. 
 
 GC-MS SYSTEM 2.1.10.3
An Agilent GC 6890 with a 5973 mass selective detector was used for analysis. The 
inlet was maintained at 250°C and the transfer line at 280°C. 
The GC column was an Rtx 5ms of length 30m, internal diameter of 0.25mm and 
film thickness 0.25 µM, (Thames Restek UK, LTD).  
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 GC-MS PARAMETERS 1 2.1.10.4
The column temperature was initially 130°C with a hold time of 0.5 min then it was 
increased 50°C/min to 300°C, with a final hold time of 1.6 min, and a total run time 
of 5.5 min. It was run in SIM mode detecting the ions displayed in Table 2.3. 
Opiate Target Ions Qualifier Ions 
DHC / DHC-d6 373 / 379 315, 282, 236 
Codeine / Codeine-d3 178 / 181 343, 371, 234, 196  
Morphine / morphine –d3 429 / 432 236, 287, 220, 324 
6-MAM / 6-MAM-d3 399 / 402 266, 287, 340, 204 
 
Table 2.3 Opiate ions used for GC-MS analysis 
 
 EXTRACTION PROCEDURE 6 2.1.10.5
Follow Procedure 5, but after evaporation, butyl acetate was added to each tube for 
reconstitution and the extract was then transferred to GC-MS vials. 
 GC-MS PARAMETERS 2 2.1.10.6
The column temperature was initially 110°C with a hold time of 1 min then it was 
increased to 75°C/min to 300°C, with a final hold time of 2.47 min, and a total run 
time of 6 min. In scan mode codeine eluted at 8.77 min, with the predominant ions 
162, 229, and 299.  
An investigation was carried out, and the results proved that 299 and 302 were 
found to be the best target ions for codeine and codeine-d3, they were used to 
create a SIM method. 
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 GC-MS BENZOYLECGONINE CONFIRMATION 2.1.11
 SAMPLE PREPARATION 2.1.11.1
Certified 1 mg/mL stock solutions of benzoylecgonine (BZE) were purchased from 
LGC Standards (Middlesex, UK) along with the deuterated internal standards, BZE-
d3.  
The stock solutions were used to prepare calibrators, ranging from 2 ng/mL to 8000 
ng/mL, and controls were prepared from independent stock solutions at 8 ng/mL. 
They were extracted as described in extraction procedure 5.  
 GC-MS PARAMETERS 3 2.1.11.2
The same instrumentation was used as described previously, (see extraction 
procedure 5). The column temperature was initially 160°C with a hold time of 0.5 
min then it was increased 20°C/min to 300°C, with a final hold time of 0.5 min, and a 
total run time of 8 min. It was run in SIM mode detecting the ions 240, 256, 361 for 
BZE and 243, 259, 364 for BZE-d3. 
 EXTRACTION PROCEDURE 7 2.1.11.3
1 mL of calibrator was extracted using 1mL acetate buffer (2M), pH 3.8 and 5 mL 
dichloromethane:isopropanol:ammonium hydroxide (80:20:2 v/v),  
(Cone et al., 1994). Following mixing and centrifugation, the supernatant was 
removed to waste and the solvent layer evaporated at 45°C under a stream of air. 
The samples were derivatised with (BSTFA-TMCS), heated at 90°C for 5 minutes 
and then transferred to GC-MS vials. 
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 GC-MS AMPHETAMINES CONFIRMATION 2.1.12
 SAMPLE PREPARATION  2.1.12.1
Certified 1 mg/mL stock solutions of amphetamine (AMP), methamphetamine (MA), 
3,4-methylenedioxyamphetamine (MDA),  3,4-methylenedioxymethamphetamine 
(MDMA), were purchased along with deuterated standards, MA-d5 and MDMA-d5 
from LGC Standards (Middlesex, UK). These stocks were used to prepare 
calibrators that ranged from 2.5 ng/mL to 1000 ng/mL, and the deuterated stocks 
were used as internal standards.  
 EXTRACTION PROCEDURE 8 2.1.12.2
Calibrator/test/quality control solutions (400µL) were extracted with 50µL alkaline 
buffer, 200µL toluene and 25µL heptafluorobutyric acid (HFBA). Following mixing 
and centrifugation, the supernatant was removed and transferred to GC-MS vials. 
 GC-MS PARAMETERS 4 2.1.12.3
The column temperature was initially 110°C with a hold time of 1.0 min then it was 
increased 20°C/min to 250°C, with a total run time of 8 min.  
It was run in SCAN mode and the ions displayed in Table 2.4 were extracted. 
Amphetamine Target Ions Qualifier Ions 
Amphetamine  240  118, 169 
MA / d5 254 / 258 210, 218 
MDA  162  135, 136, 375 
MDMA / d5 254 / 258 162, 210 
 
Table 2.4 Amphetamine ions used for GC-MS analysis 
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      GHB SCREENING 2.1.13
 SAMPLE PREPARATION 2.1.13.1
4-Hydroxybutyrate (GHB) sodium salt was purchased from Sigma-Aldrich-Fluka. A 
20 mg/L high quality control (HQC), and a 4 mg/L low quality control (LQC) were 
spiked into plasma. GHB-d6 (100 mg/L in methanol) was purchased from LGC 
Standards. This was diluted into 0.05M H2SO4, to give a 5 mg/L working solution, 
this was used as the internal standard. 
 EXTRACTION PROCEDURE 9 2.1.13.2
100µL sample were mixed with 50µL of internal standard solution (5 mg/L GHB-D6 
in dilute acid), and 500 µL acetonitrile was added as the extraction solvent. 
Following mixing and centrifugation, the supernatant was removed to a clean tube 
and evaporated to dryness 50°C under dry nitrogen (using a sample concentrator). 
The samples were derivatised with bis(Trimethylsilyl)Trifluoroacetamide (BSTFA-
TMCS), heated at 90°C for 5 minutes and then transferred to GC-MS vials. 
The column temperature was initially 60°C with a hold time of 2 mins this was 
increased 20°C/min to 180°C, with a final ramp of 50°C/min to 230°C with a total run 
time of 9 min. The target ion used for GHB was 233 m/z, this had an expected 
retention time of ~6.78 min. 
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   BUPRENORPHINE SCREENING 2.1.14
 SAMPLE PREPARATION 2.1.14.1
Buprenorphine and norbuprenorphine stock standards (1mg/mL) were purchased 
from LGC Standards (Middlesex, UK). These were used to prepare 10 ng/mL 
combined quality control in urine. This was extracted along with the samples, as 
described in extraction procedure 5. 
 GC-MS PARAMETERS 5 2.1.14.2
They were analysed on the same GC-MS system as previously described.  
The column temperature was initially 150°C with a hold time of 0.5 min then it was 
increased 75°C/min to 300°C, with a total run time of 11 min. It was run in SIM mode 
with the target and qualifier ions, shown in Table 2.5. 
Analyte Target Ions Qualifier Ions 
Buprenorphine  450 482, 506, 539 
Norbuprenorphine 468 500, 524, 557 
 
Table 2.5 GC-MS ions for buprenorphine and metabolite norbuprenorphine 
 DRUG QUANTITATIONS 2.1.15
 HPLC MEASUREMENT OF BASIC/NEUTRAL AND ACIDIC DRUGS 2.1.15.1
The majority of drug measurements were performed using extraction procedures 2, 
3 or 4, (depending on the chemical nature of the drug, e.g. basic, neutral or acid). 
Suitable calibrators and QCs were prepared and extracted along with the test 
sample (in duplicate where possible) and in the presence of a suitable internal 
standard, (for full details refer to Appendix A).  
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 HPLC MEASUREMENT OF PARACETAMOL 2.1.15.2
2.1.15.2.1 EXTRACTION PROCEDURE 10 
In a tube 200 µL standard/QC/test was mixed with 200 µL internal standard solution, 
(2-A-P in acetonitrile, 100 mg/L). Tubes are vortex mixed and centrifuged, then 100 
µL solvent layer was transferred to HPLC vials.  
2.1.15.2.2 HPLC-DAD SYSTEM SETUP 2 
The system setup and mobile phase used, were the same as described in setup 1. 
However, separation was performed isocratically on a 150 x 4.6mm Phenomenex 
Synergi Polar-RP 4 micron column. For specific conditions refer to Appendix A. 
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 LC-MS MEASUREMENT OF MORPHINE AND GLUCURONIDES  2.1.15.3
 Solid phase extraction is performed using Varian Bond Elut C18 (6 mL, 200 mg) 
SPE columns, purchased from Agilent Technologies. 
2.1.15.3.1 SAMPLE PREPARATION  
100 mg/L morphine, 100 mg/L M3G and 100 mg/L M6G in methanol were 
supplied and purchased from LGC Standards. These were used to prepare 
calibrator standards: 5, 10, 25, 50, 100, 250 and 500 μg/L.  
These were used to prepare a 1 mg/L working internal standard solution.  
2.1.15.3.2 EXTRACTION PROCEDURE 11 
300 μL of blank/ standard/ QC/ sample was mixed with 1 mL of 0.5M ammonium 
carbonate buffer (pH 8) and 50 μL of internal standard solution (1 mg/L 
morphine-D3 and M3G-D3 in water).  
The SPE columns are conditioned with 2 mL methanol followed by 2 mL water 
and 1 mL of 0.5M ammonium carbonate buffer, then 1 mL of the prepared 
sample is loaded onto the column. It is eluted at approximately 1 mL/min.  
The SPE column is washed with 5 mL of 0.005M ammonium carbonate buffer 
and then flow dried under vacuum for 5 minutes. The extract is then eluted with 
1 mL of 70% acetonitrile: water solution. It is evaporated to dryness under dry 
nitrogen at 50oC (using sample concentrator) Reconstitute by adding 100 μL of 
4% Mobile Phase A: 96% Mobile Phase B solution. It is transferred to a vial 
insert.  
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2.1.15.3.3 LC-MS SYSTEM SETUP 
The LC-MS setup was comprised of an Agilent 1100 series liquid 
chromatography system with an auto sampler coupled to an ABSciex 2000 
QTRAP Mass-spectrometer.  
Analysis was performed on a 150 mm x 2 mm Phenomenex Synergi Polar-RP 
column protected by a 4 mm x 3 mm Phenomenex Synergi Polar-RP guard 
column. 
 GC-FID MEASUREMENT 2.1.15.4
2.1.15.4.1 VALPROATE 
2.1.15.4.1.1 SAMPLE PREPARATION 
Valproic acid (sodium salt) was purchased from Sigma-Aldrich-Fluka, and used 
to make a 200 mg/L calibrator in horse plasma (purchased from TCS 
Biosciences), this was serially diluted to give additional calibration standards of 
100, 50, 25, 12.5 mg/L. Quality control standards (QCs) were made at 30 mg/L 
and 150 mg/L also in horse plasma, (this was used as a blank matrix because it 
mimics human plasma and is commercially available). Caproic acid (hexanoic 
acid) was purchased from Sigma-Aldrich-Fluka, this was diluted into 
hydrochloric acid (1M) to give a working internal standard solution (100 mg/L). 
2.1.15.4.1.2 EXTRACTION PROCEDURE 12 
100 µL standard/QC/sample were mixed with 100 µL hexanoic acid solution (in 
HCl) and 100 µL chloroform, in a tube. The tubes were vortex mixed then 
centrifuged. The solvent layer from each tube, was removed and put into a GC 
vial insert.  
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2.1.15.4.1.3 GC-FID SYSTEM SETUP 1 
Analysis was carried out on a ZEBRON ZB-FFAP  capillary column, (15 m x 530 
µm x 1 µm), with an isothermal temperature of 135°C and run time of 3.5 
minutes. Valproate typically eluted at 2.2 min and hexanoic acid at 1.5 min. 
2.1.15.4.2 CHLORMETHIAZOLE 
2.1.15.4.2.1 SAMPLE PREPARATION AND ANALYSIS 
Chlormethiazole HCl was purchased from Sigma-Aldrich-Fluka, it was used to 
make up calibrators of 200, 100, 50, 25 and 12.5 mg/L in horse blood, 
(purchased from TCS Biosciences, this was used as a blank matrix to mimic 
human blood). QCs were made at 30 mg/L and 150 mg/L. Extraction was 
carried out as described in procedure 11, (with the same internal standard), and 
the system was setup as described in setup 1. Chlormethiazole typically eluted 
at 2.1 min. 
2.1.15.4.3 ETHYLENE GLYCOL 
2.1.15.4.3.1 SAMPLE PREPARATION AND ANALYSIS 
Ethylene Glycol was purchased from Sigma-Aldrich-Fluka, it was used to make 
a calibrator of 1000mg/L in horse blood. This was serially diluted to give 
additional calibrators of 500, 250, 125, 62.5 mg/L. A QC was made up at 400 
mg/L.  A solution of Propane-1.3-diol was prepared in acetonitrile (500 mg/L), 
this was used as the internal standard solution. 
2.1.15.4.3.2 EXTRACTION PROCEDURE 13 
Pipette 100 µL standard/QC/sample into a tube, add 200 µL of internal standard 
(propane-1.3-diol solution in acetonitrile). Then add 100 µL phenylboronic acid 
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solution in 2,2-dimethoxypropane. Vortex mix and centrifuge briefly. Transfer 
100 µL of supernatant to a GC vial.     
2.1.15.4.3.3 GC-FID SYSTEM SETUP 2 
Analysis was carried out on a RESTEK RTX-5 capillary column, (15 m x 530 µm 
x 1.5 µm), with an isothermal temperature of 120°C and run time of 4 minutes. 
Ethylene glycol typically eluted at 1.2 min and propane-1,3-diol at 2.4 min. 
 GC-NPD SREENING 2.1.15.5
2.1.15.5.1 SAMPLE PREPARATION AND ANALYSIS 
A QC standard was prepared; it contained AMP, MA, ephedrine, MDA, MDMA, 
3,4-methylenedioxyethylamphetamine (MDEA),  ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine (EDDP) and methadone (all purchased from LGC Standards, 
Middlesex, UK) in drug free urine at 5000 ng/mL.  
2.1.15.5.1.1 EXTRACTION PROCEDURE 14 
700 µL of QC / test sample were pipetted into a tube, 100 µL 5M sodium 
hydroxide and 150 µL internal standard (prazepam 10 mg/L) were also and the 
tubes were vortex mixed then centrifuged.  100 µL supernatant from each tube, 
was transferred to a GC vial. 
2.1.15.5.1.2 GC-NPD SYSTEM SETUP  
A Hewlett Packard / Agilent Technologies 6890 Series gas chromatograph 
incorporating an NPD detector, with an Agilent HP-5 15 x 0.53 x 1.5 µm column 
was used for analysis. The column temperature was initially 120 °C with a hold 
time of 0.5 min then it was increased 50°C/min to 290°C, with a total run time of 
4.9 min.  
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 CHAPTER 3: A STUDY OF ORAL 3
FLUID 
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3.1 INTRODUCTION 
 SALIVA VERSUS ORAL FLUID 3.1.1
Oral fluid can be described as all of the secretions found in the mouth, these 
include saliva (which is secreted from the salivary glands), oral mucosal 
transudate (OMT which comes from the area between the teeth and gums), 
mucoproteins, bacteria, enzymes, food, electrolytes and cells, (Niedbala, et al., 
2001), (Samyn, et al., 1999), (Höld, et al., 1996). 
Oral fluid contains secretions from the submaxillary (65%), parotid (23%) and 
sublingual (4%) glands, (Walsh, et al., 2003).  
The most important functions of human saliva, (a major component of oral fluid) 
are: - 
 To moisten the mucous membranes of the upper aerodigestive tract in order 
to facilitate speech and solubilize food to ease swallowing 
 To control the bacterial flora of the mouth, and establish defence and killing 
mechanisms 
 To supply enzymes for food digestion 
(Samyn, et al., 1999). 
In recent papers the term saliva has been replaced by oral fluid, at least with 
regard to drug testing. One explanation for this change was that as a fluid 
mixture, the term “oral fluid” seemed more appropriate than saliva or “whole 
saliva” (Gallardo & Queiroz, 2008), and probably better suited than “mixed 
saliva” which was also used at times, (Walsh, et al., 2003). 
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However, a complete explanation was given by Spieler, (2004); due to the 
mixture of fluids in the oral cavity, (as previously described) it was agreed at the 
New York Academy of Sciences meeting on saliva testing in 1993, “to use the 
word saliva for glandular secretions collected directly from the saliva glands 
(most often parotid glands), and oral fluid for fluid collected by placing 
absorbants in the oral cavity or by expectoration” (spitting). 
 TOXICOLOGICAL APPLICATIONS OF ORAL FLUID 3.1.2
It has been hypothesised that oral fluid concentrations should correlate more 
accurately with pharmacological responses than blood or urine, (Cone, et al., 
1997). The concentration of drug in oral fluid reflects the free, nonprotein-bound 
drug in plasma, and its lipophilic metabolites and these are the forms of drug 
that are able to cross the blood-brain barrier and consequently are responsible 
for pharmacological drug effects, (Spiehler, et al., 2002).  
However, when blood is used as a matrix for drug quantitation, it is the sum of 
both intracellular and extracellular bound and unbound drug that is measured, 
whereas urine provides the measurement of accumulated analytes since the last 
void of the bladder, (Schramm, et al., 1992), (Cone, et al., 1997).  
In a published codeine study, Kim et al., 2002, reported that detection times in 
oral fluid are shorter than in urine, however detection times for codeine in 
plasma compared to oral fluid were found to be similar but peak concentrations 
were found to be significantly higher in oral fluid. 
Oral fluid was recognised as an appealing matrix for drug analysis as early as 
the seventies. Due to the relative ease of collection and non-invasive technique, 
it could have a wide range of applications in both clinical and forensic toxicology.  
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With initial experiments mostly involving therapeutic drugs, it is preferred to 
blood analysis for therapeutic blood monitoring of anticonvulsants in children                                                                                                                                                                                                        
because parents can collect oral fluid themselves and send the sample to a 
laboratory, and thus the collection is painless, easier and much cheaper, 
(Gorodischer, et al., 1997).    
There is some support for its routine application with anticonvulsants and 
theophylline, and applications have also been described for carbamazepine, 
digoxin, topiramate, and methadone, (Drummer, 2006). 
For drugs of abuse monitoring, an alternative such as oral fluid could be seen as 
non-invasive in more ways than one, as the collection method is non-invasive 
and it can be collected under supervision without the potential invasion of 
privacy, (Schramm, et al., 1992). This could eliminate the possibility of the 
patient adulterating or substituting the specimen before handing it to the 
collector, (Kim, et al., 2002), and could remove the need for validity tests. 
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 MECHANISM OF DRUG TRANSFER INTO ORAL FLUID 3.1.3
Many of the drugs that can be detected in oral fluid are transferred from the 
blood by passive diffusion through the membrane lipids of the salivary glands. 
The drug has to pass through the capillary wall, the basal membrane and the 
membrane of the glandular epithelial cells, which is the rate-determining step 
(Haekel, 1996), (Höld, et al., 1996).  
The different physiochemical properties of each drug affect their diffusion into 
oral fluid. These properties include: - 
 pKa  
 Lipid solubility 
 Molecular mass  
 Spatial configuration 
The degree of plasma protein binding and the pH of each medium will also 
affect diffusion, (Samyn, et al., 1999).  
However, although passive diffusion is the main route by which drugs transfer 
into oral fluid, it is not the only route. Active transport is thought to occur for 
some drugs, where their concentration is higher in oral fluid than in plasma, for 
example this is thought to be the case for valproic acid, (Haekel, 1996), (Höld, et 
al., 1996).    
The characteristics of different membrane systems and the properties of 
different drugs, results in differences in oral fluid / plasma (OF/P) concentration 
ratios.  
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 EFFECTS OF ORAL CONTAMINATION ON INTERPRETATION OF 3.1.4
RESULTS 
Oral cavity contamination can also be a problem with oral fluid testing, when the 
drug is administered orally, intra-nasally, or by smoking, or passive smoking, 
resulting in elevated drug concentrations at early collection times. It has already 
been proven that to simply rinse the oral cavity after administration does not 
eliminate the contaminating drug, (O’Neal, et al., 1999),  (Idowu, 1982). 
However, research has shown that contamination can be overcome if a time 
delay is left between administration and collection, because this time allows for 
drug absorption. The appropriate absorption times for each drug will have to be 
determined from both literature reviews and by experimentation.  
It has been reported that following administration of codeine by one of the above 
routes, for the first 1-2 hours elevated oral fluid/plasma ratios resulted. However, 
if the oral fluid was not collected until two hours after administration, to allow for 
drug absorption, then concentrations in oral fluid and plasma were similar and 
the oral fluid/plasma ratio remained constant, (O’Neal, et al., 1999).  
Other studies have shown similar trends, whereby if a suitable delay time is 
observed prior to collection (to eliminate oral contamination), then oral fluid 
concentrations can be used to estimate plasma concentrations using the oral 
fluid/plasma ratio. 
A recent study proved that the ingestion of poppy seeds could lead to a false 
positive morphine result in oral fluid. However, this was only true for up to one 
hour after ingestion. Beyond this time the morphine was not detected above the 
SAMHSA proposed cut-off of 40 ng/mL, (Rohrig, 2003).  
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This suggests that provided the two-hour absorption time is allowed to elapse 
after administration of seeds, then this contamination should not occur. 
However, this also demonstrates that the possibility of oral contamination must 
be taken into account when opiate data is being interpreted.  
For cannabis, the main route of drug entry into the oral cavity appears to be 
direct deposition during use. Residues of 9-tetrahydrocannabinol (THC) are 
sequestered in oral tissue and appear in oral fluid, contribution of THC to oral 
fluid from blood is known to be minimal, (Niedbala, et al., 2001). This presents a 
problem with interpretation of concentrations, because the measured level of 
THC may be elevated by oral contamination. 
 EFFECTS OF pH ON INTERPRETATION OF RESULTS 3.1.5
The pH of oral fluid affects the passive diffusion of drugs, and consequently the 
OF/P ratio of drugs. The influence of salivary pH on this transport depends upon 
the pKa of the drug, the equation of Rasmussen, 1964, (Höld, et al., 1996).  
Therefore, it is important to have a good understanding of this equation, which is 
based on pH partitioning, and can be used to estimate theoretical oral 
fluid/plasma ratios (OF/P ratios), (Hold et al., 1996). 
In humans the pH of oral fluid in resting situations is 6.8, (Gallardo & Queiroz, 
2008) so it is usually more acidic than plasma (pH 7.4), so basic drugs are found 
at higher concentrations in oral fluid than in plasma. Therefore, the OF/P ratio is 
equal to or less than 1 for all acidic drugs and equal to or greater than 1 for 
basic drugs. However, if the drug is protein bound then this will only be true for 
the free fraction, when it is bound the system is in equilibrium, (Haekel, 1996). 
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The pH is crucial to getting the correct OF/P ratio, and the pH can be easily 
affected, for example stimulation to cause salivation, will alter flow rate, which 
will alter the pH. Differences therefore in experimental methods, could account 
for a difference in experimentally determined OF/P ratios to theoretical OF/P 
ratios. This theory will need to be reviewed and could be demonstrated in 
volunteer studies, e.g. stimulated oral fluid versus non-stimulated. 
 COLLECTION OF ORAL FLUID 3.1.6
Historically collection of oral fluid involved spitting into a tube and chewing 
parafilm or citric acid in order to stimulate oral fluid production but both these 
methods had problems associated with them. Parafilm has been reported to 
absorb lipophilic drugs, (Paxton, 1979), and Toennes, 2005 reports that the use 
of citric acid or sour candy to stimulate salivary flow, has the disadvantage of 
increasing pH causing lower drug concentrations and affecting drug 
detectability. This can also complicate interpretation because although the citric 
acid will naturally decrease salivary pH, its purpose is to increase salivary flow 
which is known to increase pH so it is more basic,  (Gallardo & Queiroz, 2008). 
 More recently oral fluid collection devices, (originally designed for HIV 
research), have become commercially available. They usually consist of a 
cellulose pad which goes underneath the tongue, and often contain a 
preservative buffer for storage and / or transportation.  
Analytical problems with the preservative buffer in these types of devices have 
been reported. Some of them contain detergent molecules that can strip the 
phase from LC-MS columns, reducing the life of the columns, and thus making 
them impractical for use, (Allen, et al., 2005).  
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There are several other problems associated with oral fluid collection devices. 
Although some have a volume indicator, the accuracy of this is questionable, 
and once the oral fluid has absorbed onto the pad, it needs to be extracted.  
A series of in vitro experiments using different devices found that the mean 
collection volumes between devices ranged from 0.82 – 1.86 mL, and the 
percentage of the collection volume that could be recovered varied from 18% to 
83%, (Crouch, 2005).  
 GUIDELINES  3.1.7
It is important to consider the target concentrations required for the drugs under 
investigation. This is directly affected by the application of the technique, 
whether the detection of drugs in oral fluid is intended for clinical screening or 
workplace drug testing. 
If the service is to be used for clinical cases, such as samples from drug 
rehabilitation clinics, then there are no set guidelines to follow. In this case the 
Laboratory can define cut-off levels deemed suitable for this type of sample 
analysis, and confirm presence of drugs by a secondary method, where it is 
considered necessary.  
However, if workplace testing is to be used then it is important to follow the 
guidelines proposed by SAMHSA. These state that all specimens must be 
screened using an appropriate technique, and that any positive screening 
results must be confirmed using a confirmatory analytical procedure such as 
(GC-MS) or possibly (LC-MS).  
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SAMHSA have drafted proposed screening cut-off concentrations and 
confirmatory test cut-off concentrations for common drugs of abuse in oral fluid, 
(see Table 3.1). 
Oral Fluid 
Proposed SAMHSA  
Cut-off concentration 
Cut-off concentration  
when diluted 1 in 4 with buffer  
Drug Screening Confirmation Screening Confirmation 
THC & 
metabolites 
4 ng/mL 2 ng/mL 1 ng/mL 0.5 ng/mL 
Cocaine 
metabolites 
20 ng/mL 8 ng/mL 5 ng/mL 2 ng/mL 
Opiates 40 ng/mL 40 ng/mL 10 ng/mL 10 ng/mL 
6-acetylmorphine  4 ng/mL  1 ng/mL 
Amphetamines 50 ng/mL 50 ng/mL 12.5 ng/mL 12.5 ng/mL 
 
Table 3.1 The proposed cut-off concentrations in oral fluid,  
(SAMHSA, 2004) 
3.2 METHOD VALIDATION 
It is generally accepted that it is necessary to use validated methods in a 
Toxicology Laboratory, in order to produce reliable and inter-changeable data, 
(Bramley, et al., 2004). For forensic work, a quantitative assay should be 
validated for accuracy, precision, linearity, and limit of detection (LOD), (Jones, 
2004).   
LINEARITY 
For Linear regression analysis, a calibration curve was prepared over an 
appropriate concentration range, (preferably with a minimum of 5 standards).  
This is used to calculate the regression coefficient (e.g. r2), the calculated r2 
value must be equal to or greater than 0.98.  
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LIMIT OF DETECTION (LOD) 
To determine the LOD, 10 blanks were extracted together with a calibration 
curve and suitable internal quality control standards (IQCs).  
The LOD was expressed as the equivalent concentration of the mean ‘blank’ 
value (where n = 10), plus 3 SD’s, which was determined relevant to the IQC 
response. 
REPRODUCIBILITY (WITHIN BATCH) 
To test the reproducibility of an assay, 10 replicates at a low concentration were 
extracted with 10 replicates at a high concentration. This data allowed the 
calculation of the accuracy (the mean concentration where n=10) and the 
precision (coefficient of variation, (% CV) where n=10), of the assay. 
 ELISA SCREENING 3.2.1
 OPIATE VALIDATION 3.2.1.1
In order to test the linearity and accuracy of the ELISA opiate kit (IDS),  
Morphine, codeine, 6-MAM and dihydrocodeine (DHC) curves were set upp with 
calibrators spiked separately at 0, 1, 2, 3, 5 and 6 ng/mL and internal quality 
control standards spiked at 4 ng/ml. In addition oral fluid samples with known 
codeine concentrations were also extracted, (these samples were from a 
volunteer study where the codeine concentrations had been previously 
measured by GC-MS, before being frozen for storage). All these were extracted 
using Extraction Procedure 1, (Chapter 2). 
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 RESULTS 3.2.1.2
 [Morphine] 
 in ng/mL 
[Codeine]  
in ng/mL 
[6-MAM]  
in ng/mL 
[Dihydrocodeine] 
in ng/mL 
IQC spiked 
at 4 ng/mL 
4.26 3.74 4.39 3.68 
IQC spiked 
at 4 ng/mL 
4.34 3.63 4.52 3.96 
 
Table 3.2 Results of IQCs calculated for the opiates 
 
 
Volunteer 1 Codeine concentration in ng/mL   
Time post-dose 
(in h) 
GC-MS ELISA % Difference 
0 0 0 n/a 
0.4 195 226.1 15 
1.2 89 91.9 3 
2 57 48.3 7 
3 36 39.8 10 
5 18 14.7 20 
9 0 1.9 n/a 
12 0 1.1 n/a 
 
Table 3.3 Comparison of results from one volunteer in the initial pilot 
codeine study 
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 ELISA COCAINE / BENZOYLECGONINE VALIDATION 3.2.1.3
In accordance with the kit insert, calibrators were spiked at 10, 20, 30 and 40 
ng/mL with benzoylecgonine (BZE) (1mg/mL stock purchased from LGC 
Standards). These were extracted with internal quality controls (spiked at 15, 20 
and 25 ng/mL). The extraction procedure was exactly the same as for the opiate 
assay, procedure 5.  
 RESULTS 3.2.1.4
IQC spiked at 15 ng/mL 16 ng/mL 
IQC spiked at 20 ng/mL 20 ng/mL 
IQC spiked at 20 ng/mL 22 ng/mL 
IQC spiked at 25 ng/mL 26 ng/mL 
 
Table 3.4 Results and EQCs calculated for BZE  
 
 DISCUSSION 3.2.1.5
For the opiate assay, the QC results were within an acceptable range of the 
spiked concentration (i.e. within 20%) for morphine, codeine, 6-MAM and 
dihydrocodeine, (refer to Table 3.3). As an additional validation test the codeine 
concentrations from some volunteer study samples were also calculated and 
compared to the results from a calibration curve on the GC-MS (see Table 3.4). 
The results showed good agreement between the two sets of data, with no more 
than 20% difference between the 5 values compared.  
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There was no codeine detected by the GC-MS method in the 2 final samples, 
(any codeine present must have been below the 10 ng/mL LOQ for the assay) 
so it was not possible to compare these. 
For the BZE assay, the IQC values were also accurate, i.e. within 10% of the 
spiked values.  
It should be noted that although the results appear to be accurate (as described 
above) on the Manufacture’s (IDS) Certificate of Analysis their results for a 
Typical Standard Curve are very different to those achieved in the experiments 
described previously. They quote that for the zero calibrator (0 ng/mL) the 
absorbance should be 2.87 optical density (O.D.) but in the experiments 
described only a maximum absorbance of 0.84 O.D. was achieved for the 0 
ng/mL calibrator with the morphine kit and even lower O.D.’s were found with 
the BZE kit, maximum of 0.55 O.D. It also states on the Certificate of Analysis 
that the minimum negative O.D. is 1.5 which could suggest that the results 
described previously should be rejected. However, it is acknowledged that 
ELISA should only be used as a semi-quantitation method, and the 
Manufacture’s recommend that all results should be confirmed. 
 CONCLUSION 3.2.1.6
As a screening technique ELISA has the advantage that only a tiny amount of 
sample (20 µL) is required for analysis but the disadvantages are that it is both 
costly and time-consuming.  
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 LC SCREENING VALIDATION 3.2.2
As the ELISA kits proved to be very expensive, other possible screening 
techniques were investigated for the screening of amphetamines.  
 METHOD 3.2.2.1
Combined calibrators for Amphetamine (AMP), Methamphetamine (MA), 3,4-
methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine 
(MDMA) were prepared and extracted using Extraction Procedure 2.  
These extracts were analysed on two different systems, an HPLC-DAD and a 
tandem LC-MS system. 
 RESULTS 3.2.2.2
 
Figure 3.1 Chromatography for isocratic amphetamine LC-MS method 
There was a problem with the results from the HPLC-DAD experiment as 
methamphetamine and MDA were found to co-elute. However this could be 
overcome by spiking separate standards, so that one curve would measure 
amphetamine and methamphetamine and a separate curve would be created to 
measure MDA and MDMA.  
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This is not a problem with the LC-MS-MS as the extraction of MRMs allow for 
the quantitation of each peak when co-elution occurs. For the calibration curve 
to be accepted the IQCs needed to be within 20% of the spiked value (or 80% 
accurate). This was true for the majority of the QC values but there were 2 IQC 
values for MDA that were more than 20% out, so this method of analysis for 
MDA would require additional validation, particularly for inter-assay variability, 
(see Table 3.5). However, for screening of MDA it could be considered to be 
acceptable particularly as good separation was achieved between the 
amphetamines, (see Figure 3.1). It is possible that more accurate results could 
be achieved by using deuterated standards for each drug as an internal 
standard rather than using norfenfluramine as a generic IS. 
 FURTHER METHOD DEVELOPMENT 3.2.2.3
After the amphetamine experiments proved successful, (see Figure 3.1), it was 
hypothesised that a ramp could be used for LC-MS to analyse multiple basic 
drugs, while using the same sample extract therefore conserving valuable 
specimen volume. To test this hypothesis blank oral fluid was spiked at known 
concentrations and corresponding deuterated internal standards were added, 
they were extracted as before, (Extraction Procedure 2) and analysed on the 
LC-MS. Data was collected using multiple reaction monitoring (MRM mode) for 
the transitions shown in Table 3.6. 
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Drug MRM ISTD MRM 
Spiked  
value 
Calculated 
concentration 
Accuracy 
(%) 
Amphetamine 136/91 220/220 60 55.1 92 
Amphetamine 136/65 220/220 60 57.2 95 
Amphetamine 136/91 220/220 60 68.5 88 
Amphetamine 136/65 220/220 60 74.7 80 
Amphetamine 136/91 220/220 60 56.2 94 
Amphetamine 136/65 220/220 60 55.9 93 
Methamphetamine 150/91 220/220 60 60.8 99 
Methamphetamine 150/119 220/220 60 61.2 98 
Methamphetamine 150/91 220/220 60 73.7 81 
Methamphetamine 150/119 220/220 60 73.3 82 
Methamphetamine 150/91 220/220 60 51.4 86 
Methamphetamine 150/119 220/220 60 53.5 89 
MDA 180/163 220/220 60 67.9 88 
MDA 180/135 220/220 60 74.7 80 
MDA 180/163 220/220 60 85.1 71 
MDA 180/135 220/220 60 88.6 68 
MDA 180/163 220/220 60 65.8 91 
MDA 180/135 220/220 60 70.2 85 
MDMA 194/163 220/220 60 64.7 93 
MDMA 194/135 220/220 60 63.5 94 
MDMA 194/163 220/220 60 68.8 87 
MDMA 194/135 220/220 60 72.8 82 
MDMA 194/163 220/220 60 58 97 
MDMA 194/135 220/220 60 57.2 95 
Amphetamine 136/91 220/220 300 298 99 
Amphetamine 136/65 220/220 300 289 96 
Amphetamine 136/91 220/220 300 267 89 
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Drug MRM ISTD MRM 
Spiked  
value 
Calculated 
concentration 
Accuracy 
(%) 
Amphetamine 136/65 220/220 300 283 94 
Amphetamine 136/91 220/220 300 304 99 
Amphetamine 136/65 220/220 300 290 97 
Methamphetamine 150/91 220/220 300 321 93 
Methamphetamine 150/119 220/220 300 321 93 
Methamphetamine 150/91 220/220 300 272 91 
Methamphetamine 150/119 220/220 300 277 92 
Methamphetamine 150/91 220/220 300 333 90 
Methamphetamine 150/119 220/220 300 332 90 
MDA 180/163 220/220 300 272 91 
MDA 180/135 220/220 300 279 93 
MDA 180/163 220/220 300 254 85 
MDA 180/135 220/220 300 248 83 
MDA 180/163 220/220 300 266 89 
MDA 180/135 220/220 300 282 94 
MDMA 194/163 220/220 300 284 95 
MDMA 194/135 220/220 300 286 95 
MDMA 194/163 220/220 300 263 88 
MDMA 194/135 220/220 300 256 85 
MDMA 194/163 220/220 300 299 100 
MDMA 194/135 220/220 300 288 96 
Table 3.5 LC-MS-MS IQC data for 2 different transitions for each drug 
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Drug / Metabolite Transition 
Collision Energy (CE) 
for fragmentation 
Methamphetamine-d5 155 / 91 35 
MDMA-d5 199 / 135 35 
Cocaine 
304.1 / 182 
304.1 / 150 
35 
35 
Cocaine-d3 307.1 / 185 35 
Methadone 
310.2 / 265 
310.2 / 105 
35 
35 
Methadone-d3 313.2 / 268.2 35 
Buprenorphine 
468.4 / 468.4 
468.4 / 414.2 
20 
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Buprenorphine-d4 472.4 / 472.4 20 
 
Table 3.6 Additional MRM transitions 
 
 
As good chromatography was achieved for these drugs in the combined 
standard of 10 ng/mL (see figure 3.2) the method was accepted as a possibility 
for the screening of oral fluid.  
The possibility of including EDDP and norbuprenorphine in the screen was 
explored. In addition to this deuterated internal standards for amphetamine and 
MDA were also tested using this method. Their MRMs were determined and 
then added to the LC-MS method (see Table 3.7). 
Validation experiments was set up to determine the lowest concentration that at 
which identification was possible, the limit of detection (LOD) or limit of 
quantitation (LOQ) for each of the drugs, refer to Table 3.8 for the results.   
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Drug / Metabolite Transition 
Collision Energy (CE) 
for fragmentation 
Amphetamine-d5 141 / 91 35 
MDA-d5 185.1 / 134.9 35 
EDDP 
278.2 / 233.9 
278.2 /186.2 
35 
35 
EDDP- d3 281.2 / 234.2 35 
Norbuprenorphine 
414 / 414 
414 / 101.2 
20 
 
Table 3.7 Additional MRM transitions 
 RESULTS 3.2.2.4
 
Figure 3.2 Chromatography for new ramp LC-MS Method 
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The results from the gradient ramp method showed good chromatography (see 
Figure 3.22) and demonstrated the ability to look for a wide range of drugs using 
a single extract, this helps to conserve sample volume which is precious when 
oral fluid is being analysed, due to the low volumes available. If any of the 
samples were found to be positive for amphetamine, methamphetamine, MDA 
or MDMA then it would be possible to re-inject the extract(s) and they could be 
specifically analysed isocratically.  
Analyte LOD / LOQ (ng/mL or µg/L) 
Amphetamine 3.5 
Methamphetamine 1 
MDA 3.5 
MDMA 5 
Cocaine 1 
Norbuprenorphine 2 
Buprenorphine 2 
EDDP 1 
Methadone 1 
 
Table 3.8 LC-MS new ramp LOD / LOQ Results 
 
In order to further test the LC-MS method, external quality control (EQC) oral 
fluid samples were obtained from a proficiency testing scheme, (UKNEQAS, 
Cardiff Bioanalytical Services Ltd, 16 Mount Stuart Square, Cardiff CF10 5DP). 
These were analysed alongside in-house internal quality control samples 
(IQCs), refer to Table 3.9 and 3.10 for the results.  
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ID Drug Result EQC CV (%) IQC 50 ng/mL CV (%) 
1 Methamphetamine 97.5 100.0 2.5 54.8 8.8 
2 Methadone 90.6 110.5 18.0 60.0 16.7 
3 EDDP 8.6 12.0 28.3 55.5 9.9 
4 MDMA 26.2 29.9 12.4 45.5 9.9 
 
Table 3.9 Results for external quality control oral fluid samples 
ID Drug Result EQC 
Method 
mean      
No of results 
submitted 
1 Methamphetamine 97.5 100.0 128  5 
2 Methadone 90.6 110.5 88.9 2 
3 EDDP 8.6 12.0 No Data 0 
4 MDMA 26.2 29.9 30.8 5 
 
Table 3.10 Comparison of results for external quality control scheme 
 
  
 DISCUSSION 3.2.2.5
The results from the LOD / LOQ experiment are comparable with the 
concentrations found in similar LC–MS studies (see Table 3.10). Allen et al. 
(2005) reported LC-MS cut-offs of 5 g/L for methadone and cocaine and 0.5 
g/L for EDDP and more recently iestad et al. (2007) reported the following 
LOQs: amphetamine <6.8 g/L, methamphetamine <3 g/L, MDA <3.6 g/L, 
MDMA <3.9 g/L, cocaine <0.78g/L and for methadone 4 g/L. If these 
published results are compared directly with the results displayed in Table 3.8 it 
is evident that although there is a slight variation between the concentrations 
reported in each of the studies, they are all in the same region. The LOD / LOQ 
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concentrations could also be considered to be applicable as similar values have 
been used in other studies. The SAMHSA proposed cut-offs in oral fluid could 
also be used as an indication that the LODs / LOQs are in the correct region, 
although it is not clear how these proposed cut-offs were determined.  
These LC-MS methods described here have been used as screening methods 
only but they could easily be used as quantitation methods if further validation 
work was carried out. However, drug screening rather than quantitation can be 
extremely useful in some settings, like in drug addiction clinics or prisons, where 
presence or absence of a drug would usually answer the question being asked.    
The results from the proficiency testing scheme can provide an insight into how 
the assay performed quantitatively, (Tables 3.9 and 3.10) for some analytes. All 
IQC results were within 20% of the spiked value and for the EQCs it was only 
EDDP that was greater than 20% different. The scheme collated data from the 5 
laboratories that participated, (Table 3.10) our results look comparable. As none 
of the participants reported a level for EDDP, it is difficult to comment on that 
performance but perhaps the lack of results could suggest that other 
laboratories have experienced difficulty accurately measuring this particular 
analyte.   
 CONCLUSION 3.2.2.6
The combined screen is a quick and sensitive way to analyse for amphetamine, 
methamphetamine, MDA, MDMA, cocaine, buprenorphine, norbuprenorphine, 
EDDP and Methadone. If patient samples are found to be positive for any of 
these drugs, it should be possible for further confirmatory tests to be carried out, 
as only a small amount of oral fluid sample will have been used for this test.  
83 
 CONFIRMATION OF OPIATES IN ORAL FLUID 3.2.3
 INTRODUCTION 3.2.3.1
It is important to be able to detect and accurately identify opiates in a variety of 
matrices as they are widely used in Society today. The ability to differentiate 
between prescribed opiates and illicit heroin is essential. This is possible by 
detection of the main metabolite of heroin, 6-monoacetylmorphine (6-MAM).  
 METHODS 3.2.3.2
Calibration curves were prepared morphine, codeine, DHC and 6-MAM and 
extracted as described in Chapter 2, Extraction procedure 5, they were analysed 
on the system described using GC-MS parameters 1. 
  MATRIX MATCHING  3.2.3.3
In the comparative matrix studies, water versus saliva, the morphine and 
codeine calibration curves were linear, and very similar, so it was considered 
most logical and more cost effective to use water as a drug matrix for further 
studies.   
Although the correlation between oral fluid and water was good, these 
experiments revealed a problem. It became apparent that the codeine 
calibration curve (for both oral fluid and water) did not pass through zero.  
Inspection of the GC-MS traces revealed a peak with a common ion, at the 
same retention time as codeine. In an attempt to estimate the size of the 
problem, the equation of the line was used to calculate the amount of codeine 
present in the blank, which was found to be 60 ng/mL. This was obviously going 
to be a problem when for the calculation of LOD of the assay, e.g. the 
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concentration of the background noise, as this would be above the proposed 
SAMHSA confirmatory cut-off of 40 ng/mL.  
To check that the interfering peak was not contamination and that the problem 
was reoccurring, a series of blanks were ran on the GC-MS, blank water, blank 
methanol, blank buffer (from collection device) and saliva/buffer collected from 8 
volunteers. The coefficient of variation (CV) between the blanks was calculated 
to be 9%, and the mean concentration in the blanks was calculated at 21 ng/mL. 
Although this is below the 40 ng/mL proposed SAMHSA cut-off, it still would not 
be useable with a collection device that holds a preservative buffer for 
transportation. This is because there is often 3 mL of buffer, which means that 
the detection limit required to meet the guidelines would need to be 10 ng/mL 
instead of 40 ng/mL.  
The 234 ion was considered to be a useful alternative quantitative ion, although 
its abundance was much lower than the 178 ion. However, when the validation 
study results were re-calculated with the 234 ion, the findings were similar, with 
a CV calculated at 10% and the equivalent concentration of the interfering peak 
was 16 ng/mL.  
The GC-MS was operated in scan mode in an attempt to find an alternative ion, 
for quantitation, no suitable alternative ion patterns were found. Attempts were 
made to identify the interfering peak, using the library but no matches were 
found.  
It was hypothesised that maybe the derivatisation reagent was reacting with a 
component in both the oral fluid and water as well as codeine and this was 
causing a peak on the trace, at the same retention time. 
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Therefore the extraction was tried without a derivatisation step and the results 
were found to be much better. 
 CODEINE METHOD DEVELOPMENT 3.2.3.4
Initially a 10,000 ng/mL standard in butyl acetate was run on the GC-MS, on a 
long scan (50 – 550 m/z) to test where the peak eluted and which ions were 
predominant. The same instrumentation was used as described previously, 
(GC-MS parameters 1).  
The GC-MS parameters were optimised to increase sensitivity, (GC-MS 
parameters 2) and the derivitisation step was removed from the extraction, 
(Extraction Procedure 6). 
Finally, Selective ion monitoring (SIM) was used to increase sensitivity further 
still and allow for detection at 10 ng/mL or less. The SIM looked for the following 
ions: 299, 162, 188 and 214 for codeine and 229 and 302 for codeine-d3, (see 
Fig 3.9). The 299, 162 and 229 ions were compared to identify which would be 
the best for quantitation, and the 302 and 232 to check which would be best for 
the internal standard, using the linearity of the assay and the accuracy of the 40 
ng/mL internal quality control (IQC) for assessment, (Table 3.11). 
  
86 
 RESULTS  3.2.3.5
Ions used for 
quantitation 
Equation of the 
line: 
Linearity 
(R2) 
Concentration 
IQC 40 ng/mL 
CV 
(%) 
299 for codeine 
232 for codeine-d3 
y = 0.0234x - 0.0384 R2 = 0.9936 45 12.5 
162 for codeine 
232 for codeine-d3 
y = 0.0085x + 0.046 R2 = 0.9948 46 15 
229 for codeine 
232 for codeine-d3 
y = 0.006x + 0.0896 R2 = 0.9917 79 97.5 
299 for codeine 
302 for codeine-d3 
y = 0.0064x + 
0.0214 
R2 = 0.9999 42 5 
162 for codeine 
302 for codeine-d3 
y = 0.0023x + 
0.0246 
R2 = 0.9996 44 10 
229 for codeine 
302 for codeine-d3 
y = 0.0016x + 
0.0335 
R2 = 0.9987 81 102.5 
 
Table 3.11 Comparison of codeine ions for quantitation 
 
In order to assess the various ion combinations, the CV was calculated, (Table 
3.11), generally a CV of <20% is deemed within acceptable limits.  
In this case the best target ion for codeine was found to be 299 amu and for 
codeine-d3 (IS) it was 302 amu, as together they gave the most accurate IQC 
result (CV=5%), with the best linearity, (R2 = 0.9999). 
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Figure 3.3 GC-MS Trace to show codeine retention time (5.17) and 
typical ion fragmentation pattern when ran in SIM mode 
 
 
 
 
Figure 3.4 GC-MS Trace to show DHC retention time (4.91) and typical 
ion fragmentation pattern when ran in SIM mode 
 
Codeine 
Codeine-d3 
DHC 
DHC-d6 
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Figure 3.5 GC-MS Trace to show morphine retention time (5.18) and 
typical ion fragmentation pattern when ran in SIM mode 
 
 
 
 
Figure 3.6 GC-MS Trace to show 6-MAM retention time (5.43) and typical 
ion fragmentation pattern when ran in SIM mode 
Morphine 
Morphine-d3 
6-MAM 
6-MAM-d3 
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Drug 
Linearity 
ng/mL 
LOD 
ng/mL 
LOQ 
ng/mL 
Accuracy ng/Ml 
n= 10 
Precision % n= 
10 
Morphine 1000 8 10 
40 = 36 
400 = 398 
40 = 2.5 
400 = 2.6 
DHC 1000 1 10 
40 = 39 
400 = 408 
40 = 2.5 
400 = 3.7 
6-mam 1000 3 5 
10 = 9 
100 = 102 
10 = 6.4 
100 = 3.7 
Codeine * 8000 6 10 
40 = 38 
400 = 402 
40 = 3.2 
400 = 2.8 
* Results obtained from extraction procedure 2 
Table 3.12 Summary of Opiate Validation Results 
 
 DISCUSSION 3.2.3.6
Despite the small volume of sample used, the results of the validation studies 
proved acceptable for all the opiates studied: morphine, dihydrocodeine, 6-MAM 
and codeine (Table 3.12). All the curves had an R2 value of at least 0.99 and the 
quality control values calculated within 10% of the spiked concentration so were 
deemed acceptable. In addition the assays all proved to be reproducible with 
precision values all well below 10% and accuracy within 10% of the spiked 
concentration. The limit of detection values are all below 10 ng/mL, which was 
the target value (SAMHSA cut-off  being 40, and corrected to account for 3 mL 
buffer, found in some brands of collection device). The limit of quantitation was 
taken as the first calibrator above the LOD, where a peak was detectable at the 
correct retention time and the ion fragmentation pattern matched sufficiently. 
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 CONFIRMATION OF BENZOYLECGONINE IN ORAL FLUID 3.2.4
 INTRODUCTION 3.2.4.1
The aim of this study was to develop and validate a method for detection and 
measurement of cocaine and / or its metabolites in oral fluid, by GC-MS. Studies 
have proved that parent cocaine, Benzoylecgonine (BZE) and ecgonine methyl 
ester (EME) can all be detected in oral fluid following cocaine use. However, 
cocaine has a pKa of 8.6 resulting in highly pH dependent concentrations being 
detected. In contrast the metabolites BZE and EME have pKa constants of less 
than 5.5 so oral fluid concentrations are less pH dependent and more consistent 
(Kato, et al., 1993). 
It has been estimated that an oral fluid pH change from 6.5 from 7.6 could 
decrease the amount of cocaine detected by a factor of 12 (Jufer, et al., 2000). 
Therefore due to changes in oral fluid pH and the effect of different collection 
methods it can be concluded that that the metabolites are going to give more 
reliable and reproducible results when measured.  BZE was found to have the 
longest detection time in both oral fluid and plasma when compared to other 
cocaine metabolites (Jufer, et al., 2000).  
BZE is the cocaine metabolite that is included in the SAMSHA proposed 
guidelines monitoring illicit drug use by analysing with a proposed cut-off for 
confirmatory techniques of 8 ng/mL.  
 METHODS 3.2.4.2
A calibration curve was prepared in duplicate, for BZE and two different 
extractions were used for each, as described in Chapter 2, Extraction procedure 
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1 and Extraction procedure 7, (Cone, et al., 1994), they were analysed on the 
system previously described, using GC-MS parameters 3. 
 RESULTS 3.2.4.3
The two extraction procedures were compared and the BZE peak height 
abundance was much greater for Extraction procedure 1 compared to Extraction 
procedure 3.  
However, there were problems with both the accuracy and sensitivity at low 
levels, so the decision was made to increase the extraction volume from 500 µL 
to 1mL.  
The results showed that even when the larger sample volume of 1 mL was used 
for the extraction, the very low calibrators, 2 and 5 ng/mL caused problems. 
Although peaks were detected at these low levels the corrected results did not fit 
with the linear part of the line derived from the other calibrators, and the ion 
patterns were not consistent. 
 
 
Figure 3.7 GC-MS Trace to show BZE retention time of 6.45 and ion 
fragmentation pattern 
BZE 
BZE-d3 
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Drug 
Linearity 
ng/mL 
LOD 
ng/mL 
LOQ 
ng/mL 
Accuracy 
ng/mL n = 10 
Precision 
% n = 10 
Benzoylecgonine 
4000 
R2= 0.9997 
13 15 
32 = 33.2 
320 = 315.2 
15 = 14.4 
32 = 7.5 
320 = 1.4 
15 = 8.9 
 
Table 3.13 A Summary of the method validation results 
 DISCUSSION 3.2.4.4
Initially it was the aim of this project to be able to reproducibly detect BZE 
concentrations at 2 ng/mL and quantify at a minimum of 8 ng/mL, using only 500 
µL of sample. Despite different approaches to this problem, including increasing 
sample volume to improve sensitivity and trying a different extraction method 
altogether, this has not proved to be possible with the in-house laboratory 
resources.  
A possible solution to this problem could be to use solid-phase extraction to 
concentrate the drug before derivatisation (Kolbrich, et al., 2003), (Schramm, et 
al., 1993), (Cone, et al., 1997), (Kato, et al., 1993), (Jufer, et al., 2000), (Jenkins, 
et al., 1995). However, this method would prove expensive and may not turn out 
to be cost-effective for routine use.  
Consequently, validation studies were carried out using 1 mL sample, and the 
limits of detection and quantitation using extraction procedure 5, were 
determined, (Table 3.13).  
Although these cut-offs do not lie within the proposed Work-place limits, there is 
no reason why this validated assay could not be used for clinical analysis.  
Most clinical cases involve working with samples from addiction clinics and 
these have much higher drug concentrations than those proposed by SAMHSA, 
due to routine drug use.  
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A few studies have been carried out which could give an indication of expected 
BZE levels.  
In a study described by Jenkins et al. (1995) a single 44.8 mg intravenous dose 
of cocaine was administered, peak concentrations ranged from 428 to 1927 
ng/mL. In another study with chronic cocaine users, involving large multiple 
doses, Jufer et al, (2000) reported that the mean Cmax for benzoylecgonine in 
oral fluid was 2980 ng/mL.  
However these figures alone are difficult to interpret, since there seems to be a 
lack of data published in this area.  
 CONCLUSION 3.2.4.5
In conclusion, the validation parameters achieved seem acceptable for cocaine 
detection in clinical cases. Further studies involving patient samples from drug 
clinics will prove if this is true, and if this assay performance is satisfactory for 
that need.   
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 CONFIRMATION OF AMPHETAMINES IN ORAL FLUID 3.2.5
 INTRODUCTION 3.2.5.1
The following amphetamines have been included in the SAMHSA proposed 
guidelines for oral fluid testing: AMP, MA, MDA, MDMA and MDEA.  
The proposed test cut-off concentration has been set at 50 ng/mL for both 
screening and confirmation testing for all the above amphetamines, (SAMHSA, 
2004). 
Within the Laboratory a urine GC-MS method was recently developed and 
based on the extraction method described by (Kankaanpää, et al., 2004). 
Problems were encountered with the measurement of MDEA. The curve was 
not linear and the internal quality control standards (IQCs) were not calculated 
to be within 10% of the spiked value. Based on these findings, the decision was 
made to validate the amphetamine method without MDEA, as its metabolite 
MDA was been measured anyway and its use in the UK is quite rare today. 
Therefore the measurement of MDEA in oral fluid will not be attempted in this 
study as if the higher concentration cut-offs in urine could not be detected in 
urine then the lower oral fluid cut-off concentrations would prove impossible. 
 METHODS 3.2.5.2
Calibration curves were prepared for AMP, MA, MDA and MDMA and extracted 
as described in Chapter 2, Extraction procedure 8 (Øiestad, et al., 2007), they 
were analysed on the system described using GC-MS parameters 4. 
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 METHOD DEVELOPMENT 3.2.5.3
The results from this initial extraction showed that sensitivity was not good at 
low concentrations. The limit of quantitation was 50 ng/mL, and the lower 
concentrations were not detected at all. The possibility of reducing the amount 
of extraction solvent was investigated, in an attempt to improve sensitivity. 
Results proved that 150µL toluene gave the most abundant peaks so it was 
concluded that this would be used for future work. 
In a subsequent run, problems were still encountered, and the linearity was not 
consistent and the quality control samples were not calculated to the correct 
spiked values.  
The GC-MS method was converted into a selective ion monitoring (SIM) 
method, in order to try to increase sensitivity. The ions displayed in Table 2.3, 
(Chapter 2), were added to the GC-MS method, and calibrators were extracted 
again. However, this change did not solve any of the problems. 
Although on comparison of the results from the last two experiments, a common 
trend was evident; the results showed that the linearity for MDMA and MA was 
far better (higher) and the IQCs were closer to the spiked value than for MDA 
and amphetamine. It was hypothesised that this could be due to the internal 
standards used as MDMA and MA had corresponding deuterated standards but 
for amphetamine MA-d5 was used and for MDA then MDMA-d5 was used.  
Valtier and Cody, 1995, had observed linearity problems with amphetamine-d3, 
so this was not considered as an option to use. However, Valentine and 
Middleton, 2000, used amphetamine-d5 with HFBA derivatisation successfully 
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so the decision was made to try that as the IS for amphetamine, along with 
MDA-d5 as the IS for MDA. 
When the deuterated amphetamine and MDA were received (amphetamine-d5 
and MDA-d5) two standards at 100 ng/mL and two at 1000 ng/mL were 
extracted, each contained different amounts of internal standard to investigate 
the amount required to give a suitable response. A standard curve was 
extracted that contained standards from 10 ng/mL to 1000 ng/mL to investigate 
the linearity of the assay and a series of blanks to calculate the limit of detection 
of the assay. The target ion used to quantify amphetamine-d5 was 244 and for 
MDA-d5, the target ion 167 was used, these were added to the SIM program on 
the GC-MS prior to analysis. 
 RESULTS 3.2.5.4
Drug 
Linearity 
ng/mL 
LOD 
ng/mL 
LOQ 
ng/mL 
Accuracy 
ng/mL  
n=10 
Precision % 
n = 10 
Amp 1000 1 10 
160 = 161.8 
500 = 513.3 
160 = 1.36 
500 = 2.34 
MA 1000 1 10 
160 = 161.5 
500 = 500.1 
160 = 2.7 
500 = 4.1 
MDMA 1000 12 15 
160 = 159.3 
500 = 493.7 
160 = 2.6 
500 = 2.3 
MDA 1000 3 10 
160 = 163.7 
500 = 518.9 
160 = 3.4 
500 = 3.2 
 
Table 3.14 A Summary of the method validation results 
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 DISCUSSION 3.2.5.5
The validation parameters achieved seem acceptable for detection of AMP, MA, 
MDA and MDMA in clinical cases. As is the case with the cocaine validation, 
further studies involving patient samples from drug clinics will prove if this is 
true, and if this assay performance is satisfactory for that required. 
3.3 APPLICATION OF VALIDATED METHODS 
 AN INVESTIGATION OF THE DISTRIBUTION OF CODEINE IN ORAL 3.3.1
FLUID FOLLOWING A SINGLE DOSE 
  PILOT STUDY 3.3.1.1
An initial pilot codeine study was set up with 4 volunteers, (they all completed 
consent forms); their demographics are given in Table 3.15. Each volunteer 
provided an oral fluid sample (pre-dose), before taking a single oral dose of 20 
mg codeine phosphate (as Propain®) and then followed the sample collection 
regime below (Table 3.16)  
The pre-dose sample was analysed for the presence of codeine, to ensure that 
no other codeine preparations were taken prior to the dose in the study.  
Samples were collected at the proposed sampling times, using Quantisal™ 
collection devices (purchased, from Agriyork 400 Ltd, (Pocklington, UK).  
 After the 1mL volume adequacy indicator had turned blue, then the Volunteers 
placed their saturated cellulose pad in the preservative buffer, in the storage 
tube. These storage tubes were labelled and kept together, in a refrigerator 
which was maintained between 2 and 8 °C, until they were analysed. 
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All of the samples were extracted to test for codeine and morphine, as a 
metabolite, extraction procedure 5 and extraction procedure 6 (Chapter 2). 
 
 Gender Age range weight in kg dose mg/kg mg/70kg 
Vol 1 M 20 - 29 86 0.23 16.28 
Vol 2 M 20 - 29 84 0.24 16.67 
Vol 3 F 20 - 29 54 0.37 25.93 
Vol 4 F 20 - 29 63 0.32 22.22 
Mean   72 0.29 20.28 
 
Table 3.15 Demographics of volunteers involved in pilot study 
 
Sampling time (h) 
following initial dose 
Actual sampling time Day of study 
Pre-dose (blank) 8.30 1 
0 9.00 1 
0.66 9.40 1 
1.33 10.20 1 
2.0 11.00 1 
3.0 12.00 1 
5.0 14.00 1 
7.0 16.00 1 
9.0 18.00 1 
12.0 21.00 1 
 
Table 3.16 The collection times and times post-dose for specimen 
collection, following a single oral dose of codeine phosphate (20mg) 
 
99 
3.3.1.1.1 RESULTS 
Time post-dose in h 
Codeine concentration in ng/ml 
Vol 1 Vol 2 Vol 3 Vol 4 
0 0 0 0 0 
0.66 148 171 142 22 
1.33 188 292 95 26 
2 81 123 96 26 
3 20 105 106 27 
5 9 27 n/a* 8 
7 0 0 0 6 
9 0 0 0 2 
12 0 0 0 0 
*(Data missing for Volunteer 3 after 5h post-dose due to sample not being collected).  
 
Table 3.17 Concentration at sampling times for 4 volunteers.  
 
 
Figure 3.8 Concentration time profile for 4 volunteers following 
administration of 20 mg codeine phosphate 
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The results of the pilot codeine study showed that beyond the 7h sampling time, 
codeine was not detectable in any of the volunteers. These data were used to 
determine that the sampling time for the second larger study should also be 12h. 
Morphine was not detected in any of the specimens, this was also been found to 
be the case in a previously reported study, (Kim, et al., 2002).  
 ENLARGED CODEINE STUDY  3.3.1.2
To test whether the trends found in the pilot study were representative; a larger 
study was subsequently set up, using the same dose and similar sample 
regime, (same as Table 3.16, except for the 7pm sample was omitted).  
The larger study was designed to include the same 4 individuals that 
participated in the Pilot Study, (volunteers 1 – 4), as well as an additional 6 
volunteers. For the demographics of the 10 volunteers, see Table 3.18. 
The design of the study was intended to test whether the trends found in the 
Pilot study were typical and / or reproducible between 2 groups of individuals, 
but it also allowed for comparison of trends between the same individuals in 2 
separate studies.  
Each volunteer completed a consent form, and samples were collected, 
labelled, stored and extracted, as described in the Pilot Study.  
As described in the Pilot study, all of the samples were extracted to test for 
codeine and morphine, (as a metabolite), extraction procedure 5 and extraction 
procedure 6 (Chapter 2). 
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 Gender Age range weight in kg dose mg/kg mg/70kg 
Vol 1 M 20 - 29 86 0.23 16.28 
Vol 2 M 20 - 29 84 0.24 16.67 
Vol 3 F 20 - 29 54 0.37 25.93 
Vol 4 F 20 - 29 63 0.32 22.22 
Vol 5 F 30 - 39 65 0.31 21.54 
Vol 6 M 20 - 29 70 0.29 20.00 
Vol 7 F 20 - 29 97 0.21 14.43 
Vol 8 F 20 - 29 65 0.31 21.54 
Vol 9 M 40 - 49 67 0.30 20.90 
Vol 10 M 40 - 49 90 0.22 15.56 
Mean   82 0.28 19.51 
 
Table 3.18 Demographics of the 10 volunteers that participated in the 
enlarged codeine study 
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3.3.1.2.1 RESULTS 
Time 
post-
dose in h 
Codeine Concentration in ng/mL 
Vol 1 Vol 2 Vol 3 Vol 4 Vol 5 Vol 6 Vol 7 Vol 8 Vol 9 Vol 10 
0 0 0 0 0 0 0 0 0 0 0 
0.66 195 319 372 0 0 265 0 90 95 85 
1.33 89 172 304 64 0 194 41 97 94 294 
2 57 139 187 58 41 158 126 72 77 317 
3 36 107 146 53 53 104 87 53 73 212 
5 18 32 48 25 45 62 57 43 40 102 
9 0 15 24 12 28 42 36 40 38 45 
12 0 8 11 13 16 22 21 41 30 37 
Table 3.19 Concentration at sampling times for 10 volunteers 
Results from the larger codeine study, (see Figure 3.99) showed that codeine 
was detectable from 0.66h to 12h; with codeine being detected in 10 volunteers 
at the final sampling time of 12h, above the 10 ng/mL LOQ. However if the 
proposed SAMHSA cut-off of 40 ng/mL was used to differentiate recent use, 
then codeine would only be detected in one volunteer at 12h, and the mean 
detection time would be reduced to 5.8 hours.  
The samples were also analysed for morphine but it was not detected in any of 
the specimens, these results support those found in the pilot study where no 
morphine was detected either. 
103 
 
Figure 3.9 Concentration time profile for 10 volunteers following 
administration of 20 mg codeine phosphate  
 
In a previously reported study involving 19 volunteers, administered a 
60mg/70kg oral dose, codeine could only be detected in oral fluid for 7h when 
the 40 ng/mL cut-off concentration was applied (Kim, et al., 2002). 
Using the Subject demographics, (see Table 3.18) it is possible to calculate the 
mean codeine dose per 70kg, (a weight generally considered to be average). 
For this study it was found to be 20 mg/70 kg, which was the actual dose given 
to each individual anyway. The demographic data was also used to compare 
male and female trends. The standard error and mean codeine concentrations 
were calculated at each time point for both the sexes (refer to Figure 3.10 and 
3.11). 
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Figure 3.10 Mean +/- SE codeine concentration in oral fluid for Female 
Volunteers administered 20 mg codeine orally 
 
Figure 3.11 Mean +/- SE codeine concentration in oral fluid for Male 
Volunteers administered 20 mg codeine orally 
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The results have also been calculated as dose per kg for each individual, (see 
Table 3.18 and Figure 3.122).   
Time 
post-
dose 
in h 
Codeine Concentration in ng/mL per mg/kg 
Vol 1 Vol 2 Vol 3 Vol 4 Vol 5 Vol 6 Vol 7 Vol 8 Vol 9 Vol 10 
0 0 0 0 0 0 0 0 0 0 0 
0.66 848 0 1005 1029 1104 0 0 290 317 386 
1.33 387 221 822 555 808 0 195 313 313 1336 
2 248 200 505 448 658 128 600 232 257 1441 
3 157 183 395 345 433 166 414 171 243 964 
5 78 86 130 103 258 141 271 139 133 464 
9 0 41 65 48 175 88 171 129 127 205 
12 0 45 30 26 92 50 100 132 100 168 
 
Table 3.20 Codeine concentration for 10 volunteers in ng/mL per mg/kg 
 
Figure 3.12 Codeine concentration for 10 volunteers in ng/mL per mg/kg 
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3.3.1.2.2 STATISTICAL ANALYSIS OF RESULTS 
Microsoft Excel has built-in pharmacokinetic (PK) functions, (Usansky, et al., 
1999), these were used to calculate the following PK parameters: Cmax which 
can be defined as the maximum concentration within the range, Tmax which can 
be defined as the time point of the maximum concentration, k which is the 
elimination rate constant, the half-life (t½) which can be described as the time 
taken for the concentration to reach half its original value and the area under the 
concentration-time curve (AUC), which has been calculated from time zero to 
the last quantifiable point (AUCt-0) and also from time zero to time infinity  
(AUCt-inf), both these functions were calculated by use of the linear trapezoidal 
rule, (Usansky, et al., 1999). 
 
Pk 
Parameter 
Vol 1 Vol 2 Vol 3 Vol 4 Vol 5 Vol 6 Vol 7 Vol 8 Vol 9 Vol 10 
Cmax  
(µg/L) 
195 265 372 53 319 64 126 97 95 317 
Tmax (h) 0.66 0.66 0.66 3.00 0.66 1.33 2.00 1.33 0.66 2.00 
k (h-1) 0.83 0.22 0.46 0.08 0.42 0.11 0.26 0.10 0.12 0.27 
t 1/2 (h) 0.84 3.22 1.51 8.46 1.64 6.20 2.69 6.89 5.80 2.53 
AUCt-0 244 944 995 247 617 176 437 544 308 1323 
AUCt-inf 312 1140 1100 794 870 649 657 944 920 1487 
 
Table 3.21 PK Parameters for 10 volunteers based on Table 3.20 and 
Figure 3.122 codeine concentration in ng/mL 
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 Mean Range SD SEM 
Cmax  (µg/L) 190 53 – 372 119 38 
Tmax (h) 1.3 0.66 – 3.0 0.81 0.26 
k (h-1) 0.23 0.07 – 0.51 0.13 0.04 
t 1/2 (h) 4.16 1.37 – 9.46 2.42 0.77 
AUCt-0 584 176 – 1323 386 122 
AUCt-inf 887 312 - 1487 320 101 
 
Table 3.22 Table to show mean results for PK parameters 
 
The results obtained for dose per kg for each individual were used to calculate 
an additional set of PK parameters, this allowed for further investigation into the 
handling of the drug by the individuals studied, (see Table 3.24).   
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Pk 
Parameter 
Vol 1 Vol 2 Vol 3 Vol 4 Vol 5 Vol 6 Vol 7 Vol 8 Vol 9 Vol 10 
Cmax  
(µg/L) 
848 1104 1005 166 1029 221 600 313 317 1441 
Tmax (h) 0.66 0.66 0.66 3.00 0.66 1.33 2.00 1.33 0.66 2.00 
k (h-1) 0.51 0.20 0.31 0.11 0.31 0.17 0.12 0.07 0.10 0.16 
t 1/2 (h) 1.35 3.40 2.25 6.58 2.21 4.07 5.91 9.32 6.60 4.21 
AUCt-0 1500 4001 2894 1159 2466 1060 2818 1919 1993 6160 
AUCt-inf 
1611 4212 3049 1566 2811 1371 3292 2495 2724 6442 
 
Table 3.23 PK Parameters for 10 volunteers based on Table 3.20 and 
Figure 3.12, codeine concentration in ng/mL per mg/kg  
 
 Mean Range SD SEM 
Cmax  (µg/L) 704 221 - 1441 140 442 
Tmax (h) 1.3 0.66 – 3.0 0.81 0.26 
k (h-1) 0.21 0.07 – 0.51 0.14 0.04 
t 1/2 (h) 4.59 1.35 – 9.32 2.49 0.79 
AUCt-0 2597 1060 – 6160 1538 487 
AUCt-inf 2957 1371 - 6442 1505 476 
 
Table 3.24 Table to show mean results for PK parameters 
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 RESULTS 3.3.1.3
For the second enlarged codeine study, the 10 volunteers included 4 volunteers 
from the pilot study. This allowed for the comparison of values between the 
same individuals in the two separate studies. The results were found to alter 
significantly between the studies even though the dose was the same and the 
sampling regime was very similar, (see Table 3.26).  
This could be due to the impact of the many factors that affect the absorption of 
drugs and their subsequent passage into oral fluid.  
PK values 
Pilot Codeine Study Enlarged Codeine Study 
Cmax Tmax k T ½ Cmax Tmax k T ½ 
Vol 1 188 1.33 0.92 0.76 195 0.66 0.51 1.37 
Vol 2 292 1.33 0.48 1.44 265 0.66 0.2 3.41 
Vol 3 142 0.66 0.1 6.92 372 0.66 0.31 2.23 
Vol 4 26 1.33 0.15 4.6 53 3 0.13 5.22 
 
Table 3.25 Summary of the mean PK parameters for the 4 volunteers 
involved in both codeine studies 
 
 DISCUSSION 3.3.1.4
In both the pilot study and the larger second study, the results varied 
considerably between individuals, and this trend has been found in other similar 
studies (Kim, et al., 2002), (O’Neal, et al., 1999), (O’Neal, et al., 2000). Different 
people metabolise drugs at different rates and this is determined by individual 
phenotype. Gender, age, weight, health, environmental factors and genetic 
makeup all affect responses to drugs. Cytochrome P450 enzymes are involved 
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in drug metabolism and they exhibit genetic variability (polymorphism) that affect 
an individual’s response to drugs. As a result, there are “fast” metabolisers that 
produce a short half-life or higher metabolites and “slow” metabolisers that 
produce a longer half-life and can accumulate parent drug or metabolites, 
(Lynch, 2007), (Daly, 2010), (Elliott, 2009).   
In the enlarged study, there was such a huge variation between individuals that 
the concentration data was also calculated so that the individual differences in 
weight were taken into consideration, so concentrations were expressed as 
ng/mL per mg/kg. From the observation of the data and curves (see Tables 
3.19, 3.20, 3.21 and 3.22), it is evident that there has been a shift between 
volunteers 2, 3 and 5, (Figure 3.99 compared to Figure 3.122) but apart from 
this the trends appear very similar.  
Comparison of male versus female means (see Figure 3.100 and Figure 3.111) 
showed that although the females have a higher Cmax and shorter times, the 
overall elimination profiles are quite comparable. This similarity can be verified 
by comparing the area under the curves, which is calculated at 606 ng-h/mL for 
the males, compared to 571 ng-h/mL for the females. 
The codeine concentrations in general were found to be much lower than in 
other reported studies. In a comparable study O’Neal et al. (1999), have 
reported that where 30 mg liquid codeine was administered to volunteers, it was 
found that enhanced concentrations were present for the initial samples. It was 
later acknowledged that this was probably due to oral contamination. However 
the results in this current study show no obvious evidence of oral contamination 
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and after 40 minutes the concentrations are only around 20% of those reported 
by O’Neal et al. (1999).   
This could suggest that by using codeine caplets, rather than codeine linctus, 
the problem of oral contamination could either be overcome or at least reduced. 
The results of the codeine studies reported here, show longer half life’s and 
lower elimination rate constants than those reported in other studies indicating 
that clearance is reduced in the individuals included here. Looking at T1/2 
values the mean for males was 3.74h and for females 3.66h compared to 2.9h 
for males and 2.4h for females in a similar study (Kim, et al., 2002). However 
this may be partly explained by the fact that the volunteers participating in these 
studies were naïve users e.g. had seldom or never used codeine before. 
Whereas in the study reported by Kim et al. (2002), the volunteers were regular 
opiate users and abusers, thereby introducing possible metabolic and 
pharmacokinetic differences.  
By studying the same 4 volunteers (numbered 1 to 4) in both codeine studies, 
(refer to Figure 3.14 and 3.15) it can be seen that the concentrations not only 
vary between individuals but can also vary in one individual from day to day. For 
example in the pilot study the highest Cmax was from volunteer 2 and yet in the 
larger study it was from volunteer 3, even though the same dosing and similar 
sampling regimes were followed. Similar evidence for intra and inter-subject 
variability has been seen before (Kim, et al., 2002) (Skopp, et al., 2001). 
However, the opposite scenario was also demonstrated as in both studies the 
results for volunteer 4 were similar and showed very little codeine absorption 
when compared to the other volunteers. It is possible that volunteer 4 did not 
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take the required tablets but as they volunteered and consented to both studies, 
this would be unlikely. It is possible that they were in a poor state of health for 
both studies but as they were well enough to attend work and as the first study 
was carried out in January and the second in April this also seems unlikely. The 
differences in absorption between volunteers 4 and 5 (with low absorption), 
compared to volunteers 2 and 3 (with relatively high absorption) could have 
been due to the presence of two different phenotypes and if this was the case, 
this would demonstrate a very good example of polymorphism within a small 
population, (n=10). 
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 AN INVESTIGATION OF THE DISTRIBUTION OF DIHYDROCODEINE 3.3.2
(DHC) IN ORAL FLUID FOLLOWING A SINGLE DOSE 
 INTRODUCTION 3.3.2.1
Although there seem to be quite a few published articles involving codeine, 
there does not seem to be as much involving DHC. In addition to this DHC has 
some physiochemical similarities to cocaine, such as low protein binding and a 
pKa value of 8.6, (same as cocaine), (Skopp, et al., 2001). Therefore as it is 
available over-the counter, a pilot volunteer study was designed. 
The study proposed that a single oral dose of 10 mg DHC (2 tablets containing 
4.98 mg dihydrocodeine per tablet, Paramol®) was to be taken at time 0, with 
the same sampling collection times as used for the codeine pilot study, (see 
Table 3.16). There were four volunteers included in this study, and they had all 
participated in the enlarged codeine study. As in the previous studies, each 
volunteer needed to provide a blank oral fluid sample before taking the DHC 
dose, (pre-dose blank). This was analysed for the presence of DHC, to ensure 
that it was indeed blank and did not contain any DHC or assay interferents.  
For this proposed study, commercially available collection devices were 
provided by Grifols® Uk Ltd (Cambridge, UK).  
Four volunteers participated in the study, (see Table 3.27 for demographics), as 
they also took part in the codeine studies, for continuity and for ease when 
comparing the studies, they have kept the same volunteer number as allocated 
previously. 
The samples were collected, labelled, stored and extracted, as described in the 
Codeine Pilot Study.  
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 Gender Age range weight in kg dose mg/kg mg/70kg 
Vol 2 M 20 - 29 84 0.24 16.67 
Vol 3 F 20 - 29 54 0.37 25.93 
Vol 8 F 20 - 29 65 0.31 21.54 
Vol 10 M 40 - 49 90 0.22 15.56 
Mean   73 0.29 19.93 
 
Table 3.26 Demographics of the 4 volunteers that participated in the DHC 
Study 
 RESULTS 3.3.2.2
Time post- 
dose in h 
DHC Concentration in ng/mL 
Vol 2 Vol 3 Vol 8 Vol 10 
0 0 0 0 0 
0.66 241 211 110 297 
1.33 235 174 153 234 
2 253 95 103 250 
3 112 118 36 172 
5 73 67 14 151 
7 26 26 0 65 
9 na 18 0 78 
12 na 0 0 0 
na= There is no data for Volunteer 2 at the last 2 sampling times as oral fluid was not collected. 
 
Table 3.27 DHC Concentration at sampling times for 4 volunteers 
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Figure 3.13  Concentration time profile for 4 volunteers following the 
administration of 10 mg dihydrocodeine tartrate 
 
Microsoft Excel was used to calculate the following pharmacokinetic 
parameters: the maximum concentration within the range (Cmax), the time point 
of the maximum concentration (Tmax ), the elimination rate constant (k), the 
half-life t ½, and the area under the curve (AUC), (see Table 3.29). 
 
PK values Cmax Tmax k T ½ AUC AUCt-inf 
Vol 2 253 2 0.36 1.9 870 890 
Vol 3 211 0.66 0.29 2.38 648 710 
Vol 8 153 1.33 0.56 1.23 292 317 
Vol 10 297 0.66 0.18 3.89 1234 1671 
Mean 229 1.16 0.35 2.35 761 897 
 
Table 3.28 Pharmacokinetic parameters for DHC volunteer study 
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Due to the lack of available published studies regarding DHC in oral fluid, these 
PK parameters could only be compared to the PK parameters found in the 
codeine study for the same volunteers, following a similar sampling regime, (see 
Table 3.16). 
PK values Cmax Tmax k T ½ AUCt-0 AUCt-inf 
Vol 2 265 0.66 0.22 3.22 944 1140 
Vol 3 372 0.66 0.47 1.51 995 1100 
Vol 8 97 1.33 0.10 6.89 544 944 
Vol 10 317 2 0.27 2.53 1323 1487 
Mean 263 1.16 0.27 3.54 952 1168 
 
Table 3.29 Pharmacokinetic parameters for Codeine volunteer study 
 
The mean parameters can be seen not to vary greatly between the two types of 
opiates, with Cmax and Tmax being similar for both drugs. However, the results 
do show a marked variation between the individuals studied.  
 DISCUSSION 3.3.2.3
Very few DHC studies in oral fluid have been published and so there is very little 
data with which to compare with the findings reported here. Skopp et al. (2001) 
described a DHC volunteer study involving a single 60 mg dose, but this study 
used a much lower dose (10 mg). They found that the maximum concentrations 
were reached 2 – 4 hours post-dose, whereas the mean Tmax in this study was 
only 1.16h. They also reported a mean T1/2 of 8h compared to a mean T1/2 of 
3.5h in this study but this could be explained by the difference in dose as it 
would generally be expected to take longer to eliminate more of the drug.  
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The results in this study could show some biphasic and triphasic distribution, 
(see Figure 3.133) for some of the volunteers but not all of them. The same 
observation has not been noted by Skopp et al., (2001) after a 60 mg dose.  
Further studies will need to be carried out to fully evaluate this area of research. 
A study on a larger scale incorporating several matrices would be regarded to 
give a better insight into the individual handling of the drug, perhaps comparing 
saliva, blood and urine levels. 
 CONCLUSION 3.3.2.4
In conclusion, due to the variations observed both within and between the 
studies described, and the combined effects of flow rate, pH and collection 
method, further opiate studies need to be carried out before firm conclusions 
can be reached regarding the effectiveness of oral fluid as a means of 
monitoring opiate abuse.  
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 AN INVESTIGATION OF THE DISTRIBUTION OF CODEINE IN 3.3.2.5
ORAL FLUID COMPARED TO URINE FOLLOWING A SINGLE 
DOSE 
 INTRODUCTION 3.3.2.6
A codeine study was designed, to include the collection of both urine and oral 
fluid at designated sampling times, to allow for the comparison of the codeine 
time profile in these 2 different biological matrices. The design was similar to the 
previous codeine studies with a proposed single oral dose of 20 mg codeine 
phosphate (as Propain®), and proposed sampling collection times, post-dose, 
(see Table 3.31 and 3.32). As before each volunteer needed to provide an oral 
fluid sample and in addition to a urine sample before taking the codeine dose, 
(pre-dose blank). These were also analysed for the presence of codeine, to 
ensure that they have not taken any other codeine preparations prior to the dose 
in the study. There were 4 volunteers included in the study, and they all signed 
consent forms before taking part in the study. The urine was collected in plain 
plastic universals and the oral fluid was collected using the Quantisal™ 
collection devices as described previously, (purchased, from Agriyork 400 Ltd, 
Pocklington, UK).  
All of the samples were extracted to test for codeine (extraction procedure 6) 
and morphine, as a metabolite, (see extraction procedure 5). 
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Sampling time (h) 
following initial dose 
Actual sampling time Day of study 
Pre-dose 8.30 1 
0 9.00 1 
0.66 9.40 1 
1.33 10.20 1 
2.0 11.00 1 
3.0 12.00 1 
5.0 14.00 1 
7.0 16.00 1 
9.0 18.00 1 
12.0 21.00 1 
 
Table 3.30 The collection times and times post-dose for oral fluid 
collection, following a single oral dose of codeine phosphate (20mg)  
Sampling time (h) 
following initial dose 
Actual sampling time Day of study 
Pre-dose 8.30 1 
0 9.00 1 
0.5 9.30 1 
2.0 11.00 1 
4.0 13.00 1 
6.0 15.00 1 
9.0 18.00 1 
12.0 21.00 1 
24.0 9.00 2 
30.0 15.00 2 
 
Table 3.31 The collection times and times post-dose for urine collection, 
following a single oral dose of codeine phosphate (20mg)  
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 RESULTS 3.3.2.7
Urine Codeine    
Time after dose Vol 2 Vol 8 Vol 6 Vol 10 
0 0 0 0 0 
0.5 70 28 13 1284 
2 1325 1400 1246 2425 
4 1040 1118 1653 2439 
6 519 1200 949 2490 
9 401 725 754 1495 
12 143 49 797 908 
24 0 3 244 51 
30 0 0 24 7 
 
Table 3.32 Urine concentration at sampling times for 4 volunteers 
 
Figure 3.14  Urine codeine concentration time profile for 4 volunteers following 
the administration of 20 mg codeine phosphate 
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Urine Morphine 
Time after dose Vol 2 Vol 8 Vol 6 Vol 10 
0 53 0 0 0 
0.5 0 17 37 194 
2 72 697 403 485 
4 73 671 799 888 
6 34 1131 340 1113 
9 57 541 490 614 
12 6 65 553 535 
24 0 82 727 154 
30 0 67 260 145 
 
Table 3.33 Urine Morphine concentration at sampling times for 4    
volunteers 
 
 
Figure 3.15 Urine morphine concentration time profile for 4 volunteers 
following the administration of 20 mg codeine phosphate  
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Oral Fluid Codeine    
Time after dose Vol 2 Vol 8 Vol 6 Vol 10 
0 0 0 0 0 
0.66 51 32 0 233 
1.33 114 38 52 90 
2 21 11 32 92 
3 30 0 0 107 
5 14 0 0 27 
7 0 0 0 0 
9 0 0 0 0 
12 0 0 0 0 
 
Table 3.34 Oral Fluid concentration at sampling times for 4 volunteers 
 
 
Figure 3.16 Oral fluid concentration time profile for 4 volunteers following 
the administration of 20 mg codeine phosphate  
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ORAL FLUID VERSUS URINE  
The urine codeine concentrations were much higher than the oral fluid 
concentrations, as expected. To facilitate comparison of the 2 different matrices, 
the results were calculated as a percentage of the maximum concentration for 
each matrix, in each volunteer (see Figures 3.17 and 3.18). It should be noted 
that a problem with this type of urine analysis is that there will always be 
concentration differences between individuals due to fluid intake and bladder 
voiding differences.     
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Figure 3.17 Codeine Profiles for Volunteer 2 
 
Figure 3.18 Codeine Profiles for Volunteer 8 
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Figure 3.19 Codeine Profiles for Volunteer 6 
 
 
 
Figure 3.20 Codeine Profile for Volunteer 10 
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 DISCUSSION 3.3.2.8
Codeine is metabolised by glucuronidation to codeine-6-glucuronide, N-
demethylation to norcodeine and O-demethylation to morphine in humans,  
(Kim, et al., 2002). In this study only free codeine and morphine were analysed.  
The urine drug concentration profiles demonstrated some biphasic distribution 
for both codeine and the metabolite morphine, in another study the elimination 
of codeine was also found to be biphasic, (Vree & Verwey-van Wissen, 1992). 
Whereas for oral fluid, the time concentration profiles only showed biphasic 
distribution in 2 out of the 4 volunteers. This is likely related to the differences in 
elimination profiles of the two matrices. 
The results show a common trend between volunteers, they show that codeine 
is detected for a shorter time window in oral fluid compared to urine, and this is 
well documented and was to be expected. This means that the appropriate drug 
matrix (i.e. oral fluid or urine) can be selected in accordance to the question 
being asked, e.g. if its required to know whether someone has taken codeine in 
the past 2 – 7 hours then oral fluid could be used for analysis. However, if the 
query is whether any codeine has been taken in the past 24 hours then urine 
would need to be collected and analysed. It should be noted that the codeine 
dose used in this study (20 mg) was available to purchase over the counter and 
as such was a very low dose. If larger codeine doses (e.g. 60 mg) were used 
then the results would be expected to provide different time windows. 
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 AN INVESTIGATION OF THE PRESENCE / ABSENCE OF SOME 3.3.3
DRUGS OF ABUSE IN A SMALL POPULATION OF INDIVIDUALS 
SEEKING HELP FOR DRUG ADDICTION 
 INTRODUCTION 3.3.3.1
A drug-users treatment clinic agreed to participate in a small investigation to 
help with the completion of the oral fluid method validation and allow 
comparison of a relatively new drug matrix (oral fluid) to the traditional matrix for 
drugs of abuse (urine).  
The samples were to be tested for: opiates (OPI), cocaine (COC), 
amphetamines (AMPS), methadone (METH) and buprenorphine (BUP).  
The clinic agreed to collect approximately 20 oral fluid specimens, with 
corresponding urine samples, (where possible) and send them to the laboratory 
for analysis.  
In total 17 oral specimens were sent in to the laboratory with 17 corresponding 
urine specimens. In addition to this 1 oral fluid sample, (3004) was received 
without a corresponding urine specimen. All the specimens were allocated 
Laboratory numbers when they were received. 
 ANALYTICAL METHODS 3.3.3.2
Oral fluid screening: 
ELISA kits were used to screen for OPI and COC / benzoylecgonine (BZE).  
LC-MS was used to screen for amphetamine (AMP), methamphetamine (MA), 
MDA, MDMA, COC, BUP, norbuprenorphine (NBUP), METH and  
2-ethylidene- 1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). 
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GC-MS was used to screen for AMP, MA, MDA and MDMA. 
Oral fluid confirmation: 
If the ELISA opiate screen was positive then GC-MS was used to identify 
whether morphine (MORPH), dihydrocodeine (DHC), codeine (COD) and / or 6-
monoacetylmorphine (6-MAM) were present. 
If the COC screen was positive by ELISA but negative by LC-MS then  
GC-MS was still used to test specifically for BZE.  
 On the urine specimens the following analytical methods were performed: 
Urine screenng: 
CEDIA screen for AMPS, OPI, EDDP, and BZE. In addition to these tests the 
urine samples were also tested for benzodiazepines, cannabinoids and 
creatinine, as these were already included in the service provision for urine 
screening, it seemed important to include them in the project.  
GC-MS used to screen for BUP and NBUP. 
Urine confirmation: 
If the CEDIA opiate screen was positive then GC-MS was used to identify 
whether MORPH, DHC, COD and / or 6-MAM were present. 
If the CEDIA AMPS screen was positive then GC-NPD was used to identify 
whether AMP, MA, MDA and / or MDMA were present. 
If the CEDIA EDDP screen was positive then GC-NPD was used to test if METH 
(parent drug) was also present. 
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 RESULTS 3.3.3.3
Laboratory Number COC / BZE OPI 
3002 Negative Negative 
3004 POSITIVE POSITIVE 
3005 Negative Negative 
3007 Negative Negative 
3009 Negative Negative 
3011 Negative Negative 
3013 POSITIVE Negative 
3015 POSITIVE POSITIVE 
3017 POSITIVE Negative 
3019 POSITIVE POSITIVE 
3021 Negative Negative 
3023 Negative Negative 
3025 Negative Negative 
3027 POSITIVE Negative 
3029 Negative Negative 
3031 POSITIVE Negative 
3033 Negative Negative 
3035 Negative Negative 
 
Table 3.35 ELISA Screening Results on the oral fluid specimens 
ELISA BZE / COC results >20 ng/mL = Positive 
ELISA OPI results >40 ng/mL = Positive 
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Laboratory No 
AMPS 
(Amp, MA, MDA, MDMA) 
COC BUP METH 
3002 Negative Negative Negative POSITIVE 
3004 Negative POSITIVE Negative POSITIVE 
3005 Negative Negative Negative Negative 
3007 Negative Negative Negative POSITIVE 
3009 Negative Negative Negative POSITIVE 
3011 Negative Negative Negative Negative 
3013 Negative Negative Negative Negative 
3015 Negative POSITIVE Negative Negative 
3017 Negative POSITIVE POSITIVE Negative 
3019 Negative Negative Negative POSITIVE 
3021 Negative Negative Negative POSITIVE 
3023 Negative Negative Negative Negative 
3025 Negative Negative Negative POSITIVE 
3027 Negative Negative Negative Negative 
3029 Negative Negative Negative POSITIVE 
3031 Negative POSITIVE Negative POSITIVE 
3033 Negative Negative Negative POSITIVE 
3035 Negative Negative POSITIVE Negative 
 
Table 3.36 LC-MS Screening Results on the oral fluid specimens 
 
LC-MS LOD for MA, COC and METH = 1 ng/mL, LOD for Bup = 2 ng/mL 
LC-MS LOD for Amp and MDA = 3.5 ng/mL, LOD for MDMA = 5 ng/mL 
 
The LC-MS also screened for the methadone metabolite (EDDP) and the 
buprenorphine metabolite (norbuprenorphine) but these results are not 
131 
displayed in the table as neither of these metabolites were detected in any of the 
oral fluid samples. 
Laboratory Number BZE OPI 
3004 + POSITIVE + 
MORPH, COD, 
6-MAM 
3013 + Negative - NA 
3015 + POSITIVE + 
MORPH, COD, 
6-MAM 
3017 - POSITIVE - NA 
3019 + Negative + 
MORPH, COD, 
6-MAM 
3027 + Negative - NA 
3031 + POSITIVE - NA 
 
The + / - symbol refers to the ELISA screening results (see Table 3.38). 
 
Table 3.37 GC-MS Conformation results on the oral fluid specimens 
 
GC-MS was also used to screen for the amphetamines (Amp, MA, MDA and 
MDMA) in the oral fluid samples and they were all found to be negative by this 
method too.  
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Laboratory Number AMPS BZE EDDP OPI 
3003 Negative Negative POSITIVE POSITIVE 
3006 Negative Negative POSITIVE Negative 
3008 Negative Negative POSITIVE Negative 
3010 Negative Negative POSITIVE Negative 
3012 Negative Negative Negative Negative 
3014 Negative Negative Negative Negative 
3016 Negative POSITIVE Negative POSITIVE 
3018 Negative POSITIVE Negative Negative 
3020 Negative POSITIVE POSITIVE POSITIVE 
3022 Negative Negative POSITIVE Negative 
3024 Negative Negative Negative Negative 
3026 Negative Negative POSITIVE Negative 
3028 Negative POSITIVE Negative POSITIVE 
3030 Negative Negative POSITIVE Negative 
3032 Negative POSITIVE POSITIVE POSITIVE 
3034 Negative Negative POSITIVE Negative 
3036 Negative Negative Negative Negative 
 
Table 3.38 CEDIA Screening Results on the urine specimens 
 
CEDIA cut-offs are as follows: AMPS = 500 ng/mL,  
BZE = 300 ng/mL, EDDP = 100ng/mL and OPI = 300 ng/mL  
Every urine sample that screened positive for EDDP also tested positive for 
methadone on the GC-NPD.  
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Laboratory Number BUP NBUP 
3003 Negative Negative 
3006 Negative Negative 
3008 Negative Negative 
3010 Negative Negative 
3012 Negative Negative 
3014 Negative Negative 
3016 Negative Negative 
3018 POSITIVE POSITIVE 
3020 Negative Negative 
3022 Negative Negative 
3024 Negative Negative 
3026 Negative Negative 
3028 Negative Negative 
3030 Negative Negative 
3032 Negative Negative 
3034 Negative Negative 
3036 POSITIVE POSITIVE 
LOD BUP/NBUP = 2 ng/mL 
 
Table 3.39 GC-MS Screening Results on the urine specimens 
Laboratory Number Opiate Result 
3003 MORPH 
3016 MORPH, COD, 6-MAM 
3020 MORPH, COD, 6-MAM 
3028 MORPH 
3032 MORPH, COD 
GC-MS LOD MORPH, COD, DHC = 50 ng/mL and 6-MAM = 5 ng/mL  
 
Table 3.40 GC-MS Confirmation Results on the opiate positive urine     
specimens 
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 AMPS BZE BUP METH MORPH COD 6-MAM 
Oral Fluid 0 3 2 10 2 2 2 
Urine 0 5 2 10 5 3 2 
Difference 0 2 0 0 3 1 0 
(Above data refers to n=17, as a corresponding urine was not submitted with one of the oral fluid 
samples). 
 
Table 3.41 The amount of positive results in oral fluid compared to urine 
 
Sample  
 
(Lab no) 
Elisa 
BZE / 
COC 
Cut-off = 
20 ng/ml 
GC-MS 
BZE LOD 
= 13 ng/ml 
LC-MS 
COC 
LOD = 
1 ng/ml 
Sample  
 
(Lab no) 
CEDIA 
Cut-off = 
300 ng/ml 
GC-MS 
BZE 
LOD = 50 
ng/ml 
Oral fluid 
(3019) 
POSITIVE Negative Negative 
Urine 
(3020) 
POSITIVE POSITIVE 
Oral fluid 
(3027) 
POSITIVE Negative Negative 
Urine 
(3028) 
POSITIVE POSITIVE 
 
Table 3.42 Cocaine / BZE Discrepancies 
 
The CEDIA screens for BZE in the above samples were positive, they were also 
analysed on the GC-MS to allow comparison with the oral fluid samples at a 
lower LOD. 
Sample 
(Lab No) 
ELISA OPI 
Cut-off = 40 
ng/mL 
GC-MS OPI 
LOD = 10 
ng/mL 
Sample 
(Lab No) 
CEDIA 
Cut-off = 
300 ng/mL 
GC-MS OPI 
LOD = 50 
ng/mL 
Oral Fluid 
(3002) 
Negative Negative 
Urine 
(3003) 
POSITIVE MORPH 
Oral Fluid 
(3027) 
Negative Negative 
Urine 
(3028) 
POSITIVE MORPH 
Oral Fluid 
(3031) 
Negative Negative Urine (3032) POSITIVE 
MORPH 
COD 
 
Table 3.43 The Opiate Discrepancies 
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Although the ELISA screens for OPI were negative the above samples were 
also analysed on the GC-MS to allow comparison with the urine samples at a 
lower LOD. 
 
 DISCUSSION 3.3.3.4
When the oral fluid results are compared to the urine results (see Table 3.41), it 
becomes apparent that many of the results support each other. All the samples 
found to be positive for a drug in the oral fluid proved to be positive for at least 
the same drug in the corresponding urine, although sometimes analysed 
positive for additional drugs in the urine. This means that as the same amount of 
samples were found to be positive for MET, BUP or 6-MAM in both matrices 
then the same results would have been found whether the oral fluid or urine had 
been collected (or selected) for analysis.  
However, the same results were not shown in both matrices for BZE, MORPH or 
COD, as more positive results were found in the urine samples. It is important to 
focus on these samples that had different results for each matrix (see Table 
3.43 and 3.44). 
In Table 3.43, both oral fluid samples screened positive for COC/BZE by ELISA 
but on confirmation they were found to be negative for both COC and BZE so 
the ELISA result was a false-positive result. These can be common with this 
type of screening technique which is why confirmation of the results is 
recommended. However the corresponding urine specimens were found to be 
positive for BZE. The reason for the different results is due to the difference in 
time detection windows between the matrices. BZE in urine is normally 
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detectable for at least 24 hours after ingestion whereas BZE / COC in oral fluid 
may only be detectable for a few hours after ingestion. The difference in the OPI 
results displayed in Table 3.44 can also be explained by the different time 
detection windows. The results suggest that when the oral fluid was collected 
OPI could not be detected as it had been more than several hours since the 
ingestion, however it could not have been more than 24 hours after ingestion as 
it was still possible to detect morphine and codeine in the urine. 
The difference between the periods of time that drugs can be detected in each 
matrix is very important, and this must be considered when deciding which 
matrix is best to use. There are times when oral fluid may be the best matrix to 
analyse but there are also times when only urine can provide the answer to the 
question being asked. If both urine and oral fluid are collected and analysed, a 
better insight can be given to the drug-use of the individual being tested. 
A significant observation is that although the clinic submitted 17 oral fluid 
samples with corresponding urines, for one individual only an oral fluid sample 
was submitted and for some reason there was noticeably less than 4 mL in total, 
the expected volume, (1 mL oral fluid plus 3 mL buffer). This raised several 
questions, firstly, would there be enough sample volume to perform all 
necessary confirmations, secondly had something gone wrong during collection, 
(to account for the short sample?), and thirdly, was it possible that the individual 
had deliberately sent a short sample with no urine perhaps in the hope that 
there would not be enough sample to confirm drug use?  
However, when the screening and confirmation techniques were applied, there 
was sufficient sample volume to screen for amphetamines, opiates, cocaine, 
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methadone and buprenorphine and confirm their presence, where necessary but 
very little sample volume remained. The clinic had queried cannabis use on the 
“request form” but without a urine sample, it was not possible to test for this.  
If validation work had been completed successfully for benzodiazepines and 
cannabinoids in oral fluid, then as the panel of drugs would have been larger, 
then it is unlikely that in this case at least, that there would have been sufficient 
sample to carry out all confirmations. 
 CONCLUSION 3.3.3.5
This final study has helped to show that the methods developed for oral fluid 
analysis are applicable to samples collected from drug-users in a treatment 
setting.  
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 CHAPTER 4: A STUDY OF 4
POST-MORTEM TOXICOLOGY 
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4.1 INTRODUCTION 
A post-mortem examination is carried out by a pathologist, to determine the 
cause of death. They are usually ordered by a coroner if the cause of death is 
unknown, sudden or unexpected, or at the request of a family member to 
provide information about illness and cause of death, (Department of Health, 
2009). 
The traditional matrices analysed in post-mortem (PM) toxicology are blood and 
urine. However, in some circumstances these are not available so other 
specimens such as stomach contents, vitreous humor, bile, liver and other 
tissues are submitted. In these cases it can be difficult to analyse and interpret 
results as these matrices are not routinely used and therefore there is often 
limited published data to refer to. 
Typical cases where blood and/or urine are not available include; decomposed 
bodies, fire deaths, drownings, road traffic incidents and aircraft crashes. 
However, in cases where blood/urine is available in addition to forensic tissue 
and other fluids, the analysis of all the biological specimens could provide the 
data, to evaluate the potential interpretative usefulness of such alternative 
matrices.  
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 ALTERNATIVE MATRICES 4.1.1
Historically, urine, stomach contents, bile and liver have all been routinely used 
for PM screening for drugs, as they are known to have the highest drug 
concentrations and therefore offer the greatest chance for detection.  
In decomposed cases it is often only stomach contents and liver specimens that 
are available for analysis. However, in these cases interpretation of analytical 
results can be complicated, due to endogenously produced substances and 
destruction of drugs from the putrefactive process, (Paterson, 1993). 
 STOMACH CONTENTS 4.1.1.1
Stomach contents analysis actually notionally detects if any drugs have been 
taken close to the time of death, if a drug is present in the stomach it is there 
because it either has not yet been absorbed or completely absorbed, and would 
therefore not necessarily be detected in any other specimens collected from the 
body. Sometimes whole tablets are present in the stomach contents that have 
not been absorbed at all and it can be possible to use their shape and colour to 
identify them, (along with a database such as TICTAC (TicTac Communications 
Ltd), (Jones, 2008). The presence of whole tablets can be very useful for 
interpretation purposes, they could indicate “intent” in suicide situations where 
an alternative method of death has been used, e.g. in a hanging.  
There are a few important points to consider, when analysing and interpreting 
stomach contents results; as metabolism does not occur in the stomach, it is 
only usually the parent drugs that need to be detected, and after an overdose, 
drug concentrations in the stomach may be quite high even after the majority of 
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the drug has passed into the small intestine which can make drug detection a lot 
easier in stomach contents compared to corresponding blood, where extensive 
distribution in the body could have occurred. Therefore, a low amount of drug in 
the stomach cannot rule out a possibility of overdose. In addition to this, the 
presence of a drug in the stomach contents does not necessarily mean that it 
has been ingested orally as passive diffusion from the blood into the stomach 
contents is known to occur, (Jones, 2008), (Skopp, 2004). 
Unlike the other alternative matrices, with stomach contents there is not usually 
a low sample volume so this is not usually an issue, a portion of approximately 
10 mL, is typically submitted. This creates a problem in itself though, as a 
portion rather than the whole stomach contents is submitted. This makes 
estimation of a drug dose difficult because the sampled portion could have a 
high concentration, for example if a 10mg tablet is taken then if the entire 
stomach contents was 1 L then the overall concentration would be 10 mg/L, but 
if only a 10mL portion was submitted and analysed this could give a high false 
concentration of 1 mg/mL (which is the equivalent of 1000 mg/L). Therefore, it is 
generally accepted that the concentration of a substance in the stomach is 
virtually meaningless by itself. However, if drugs are measured in stomach 
contents then they should only be reported as the amount of drug present in the 
volume or mass of stomach contents received, (Jones, 2008). 
There are other problems associated with stomach contents analysis. The 
composition is very varied and ranges from a very thin “soup-like” consistency to 
a thick mass of chewed-up food, largely depending on how long before death 
the individual last eat. The fact that the stomach contents are rarely 
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homogenous is another contributory factor into why drug concentrations cannot 
be accurate, unless the contents are homogenised. Soon after a dose is 
ingested the stomach contents concentration may be very high even if the total 
amount taken is not. The absence of a large amount of drug in the stomach 
contents does not necessarily rule out an oral overdose because it could take 
several hours to die from an drug overdose during which time the drug could 
have been absorbed and metabolised. However, consumption of an oral 
overdose of medicine can result in the formation of a “bezoar” (medicine mass) 
in the stomach, which can take several hours or more to dissipate, (Jones, 
2008). 
Whether or not stomach contents analysis will prove useful can be largely 
dependent on the type of case involved. In general it can be useful in cases 
where there is an alternative cause of death, for example many tablets in the 
stomach contents after a hanging could show suicidal intent, e.g. if an individual 
could take an overdose of tablets in an attempt to take their own life but then 
death took longer to occur then they expected, they might try an alternative 
suicide technique, such as hanging. In other cases however, stomach contents 
analysis will not be very relevant, e.g. if the deceased was a passenger in a 
road traffic collision, whether or not they ingested a lot of drugs before their 
death is probably incidental as these drugs would not have been fully absorbed 
and therefore are unlikely to have produced any effect or contributed to the 
death. 
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 VITREOUS HUMOUR 4.1.1.2
Vitreous Humour is the clear gel that fills the posterior cavity of the eye, 
(Chronister, et al., 2008), (see Figure 4.1). It is usually obtained by needle 
puncture of the eyeball, at the sclera, (see Figure 4.1), generally this yields 2-3 
mL, (Forrest, 1993).  
The blood-ocular barrier restricts the entrance of drugs to the eye so that only 
lipophilic or very small hydrophilic substance can pass through it. The 
distribution equilibrium between blood and vitreous humour is determined by 
plasma-protein binding. During survival time, it is thought that vitreous humour 
levels should follow blood concentrations with a certain time delay, determined 
by this binding. Lipophilic drugs are eliminated quickly by diffusion through the 
membranes whereas hydrophilic drugs are eliminated more slowly, (Pragst, et 
al., 1999).  
It is the preferred specimen for post-mortem ethanol measurement as post-
mortem formation of ethanol does not occur in this matrix, (yet it has been 
shown to in blood and other tissues). This is because the interior of the eye is a 
sterile medium until the most advanced stages of decomposition, (Jones, 2008).  
It has also been reported as very useful for the measurement of digoxin, as 
concentrations increased markedly in post-mortem blood (which could lead to a 
false diagnosis of digoxin toxicity) but conversely, were below ante mortem 
values in vitreous, (Vorpahl & Coe, 1978).      
Vitreous humour has also been shown to be of benefit in instances where 
unstable drugs such as 6-monoacetylmorphine (6-MAM) and cocaine are 
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involved. Conversion to morphine and benzoylecgonine, respectively, is 
hydrolytic and is rapid in the presence of esterase enzymes. As such, the 
conversion readily occurs in blood. As the vitreous humour is within the sterile 
and compartmentalised eye environment, the relative lack of enzymes reduces 
this effect and the compounds are more stable (Pragst, et al., 1999, Jones, 
2008). Opiate distribution in vitreous humour specimens has also been studied, 
the results showed that vitreous could be used to differentiate death due to 
codeine overdose from heroin (morphine) abuse, (Lin, et al., 1997). Cocaine and 
metabolites have been compared in blood and vitreous. Results showed that 
although cocaine levels were higher in vitreous the metabolites were a lot lower 
and so although vitreous could be used to quantitate cocaine and its metabolites 
it was not found to be as reliable as blood, (Mackey-Bojack, et al., 2000).  
There are disadvantages associated with the use of vitreous humour for drug 
analysis, firstly its relatively small sample volume means that analysis is limited, 
this can mean that choices have to be made between screening, confirmation 
and quantitation tests, rather than being able to cover the whole sprectrum. As 
very few studies have been published on drug blood concentrations compared 
to vitreous humour, interpretation of results can prove difficult. It is possible that 
this lack of published data could be due to the limited sample volume.  
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Figure 4.1 The chambers of the eye 
The ciliary body and lens divide the interior of the eye into a large posterior 
cavity, also called the vireous chamber, and a smaller anyerior cavity.  
The vitreous body helps to stabilise the shape of the eye and gives additional 
physical support to the retina. It also contains specialised cells that produce 
collagen fibres and proteoglycans, these are responsible for the gelatinous 
consistency of the mass, (Martini, 1998). 
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 BILE 4.1.1.3
Historically, bile was considered valuable in post-mortem toxicology because it 
contains high concentrations of drug conjugates, which meant that detection 
was easier than in blood, with concentrations as great as 1000 times higher. 
However, as the instrumentation for drug detection has developed and more 
sensitive methods are now available, bile has been used less and less. It has 
been reported that the correlation between blood and bile concentrations is 
generally poor, (Jones, 2008).  
Bile can be useful for establishing drug use, in the last few days prior to death, 
this can be useful in cases where drug history is unclear.  
 LIVER 4.1.1.4
Liver can be considered important in post-mortem toxicology because there is a 
large amount of tissue available, and it is relatively easy to collect and prepare 
compared to other tissues. Concentrations of drugs in the liver are usually 
higher than in the blood which makes detection easier, and they are relatively 
stable which is very important for the analysis of drugs that undergo post-
mortem redistribution. For this reason, the liver can be more reliable than blood 
for measurement of drugs that are known to undergo post-mortem redistribution, 
e.g. tricyclic antidepressants, dextropropoxyphene and phenothiazines, (Jones, 
2008). The major disadvantage with liver is that it tends to be fatty and putrefy 
faster than blood. It is possible to get unequal drug distribution due to diffusion 
of drugs from intestinal contents or from incomplete circulation and distribution 
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within the liver. It has also been demonstrated that post-mortem diffusion of 
drugs from the stomach can occur, (Jones, 2004). 
  INTERPRETATION 4.1.2
It used to be assumed that post-mortem blood concentrations of drugs were 
more or less uniform throughout the body and that concentrations measured in 
blood obtained at a post-mortem reflected the situation at the time of death. 
Therefore, interpretation of results could be based on comparison with 
“therapeutic” plasma concentration data. However, interpretation of post-mortem 
toxicology results is much more complex, and many factors need to be taken 
into account. These include the clinical pharmacology of the agents in question, 
and the circumstances under which death occurred, nature of specimens sent,  
changes that occur in composition after death, stability of analytes and suitability 
of analytical techniques, (Flanagan, 2011). It is also important to consider in 
cases where more than one drug has been ingested, the presence of other 
drugs and / or alcohol can have an impact on the overall toxic effect.    
    POST-MORTEM REDISTRIBUTION 4.1.2.1
One of the most important factors in sample selection and collection is the 
potential influence of post-mortem redistribution. The time period between death 
and post-mortem is very important, as this depicts how long drugs have to 
redistribute around the body.  
It was noted back in the 1960s that different barbiturate concentrations were 
found in blood taken from central body cavities compared to that obtained from 
femoral vessels, (Curry & Sunshine, 1960). Later, a similar phenomenon was 
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seen in a study of digoxin where the concentration of blood collected at autopsy 
from various sites was higher than the concentration predicted at the time of 
death. This bought about the conclusion that post-mortem changes in drug 
concentration could occur, (Vorpahl & Coe, 1978 ).  
In life when drugs are taken they are transported around the body in the blood to 
their point of action. They can also be retained or stored within larger organs, 
such as heart, lung or liver. However, these processes require energy and once 
death takes place, the supply of energy from metabolic processes is 
dramatically reduced. As changes in cellular biochemistry and autolysis 
proceed, drugs and other poisons may be released from their binding sites in 
the tissues and major organs. The diffusion of drugs from an area of high 
concentration to an area of low concentration can be expected as a natural 
physical process. This modification of the equilibrium between blood and tissues 
means that drugs can move into the surrounding blood, and this can result in an 
elevated concentration close to these sites, (Elliott, 2009), (Forrest, 1993), 
(Ferner, 2008), (Jones & Pounder, 1987). 
Another consideration is that unabsorbed drug can diffuse from the bladder or 
the stomach. In one particular case, death was thought to occur after a long 
comatose period during which a large volume of urine containing drugs at high 
concentrations may have accumulated in the bladder. It is thought that diffusion 
from the bladder caused elevated drug levels of diphenhydramine and 
dihydrocodeine in femoral venous blood, (Moriya & Hashimoto, 2001).  
Pounder et al., 1995, assessed post-mortem drug diffusion from the stomach in 
a human cadaver model. They found that diffusion from the stomach showed 
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marked case to case variability but at worst produced significant levels in both 
tissues and fluid samples. In order to overcome this problem they suggested 
that “blood be sampled from a peripheral vessel, skeletal muscle from a limb, 
liver from deep within the left lobe and lung from the apex rather than the base.”      
Typically specimens taken from “central” sites, e.g. heart, tend to give relatively 
“high” values for most analytes. The “peripheral” site least affected is thought to 
be the femoral vein for interpretation, (see Figure 4.2), but it still does not 
necessarily represent the concentration at the time of death, (Elliott, 2009). 
This complicated interpretation of drug concentrations can be further 
complicated, e.g. in deaths where repeated physical CPR attempts have taken 
place, this could artificially redistribute the blood around the body and this could 
also affect the femoral vein, (Elliott, 2009).  
Vitreous humour samples are thought to be least affected by post-mortem re-
distribution. This is probably due to its location, it is embedded in the eye, (in the 
vitreous chamber), (see figure 4.1), where it is relatively isolated from blood, 
organs and other body fluids (Chronister, et al., 2008). 
 
 
150 
 
Figure 4.2  Common veins in the body. 
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There have been numerous studies published that prove this phenomenon, 
where blood samples have been collected from different veins and arteries, and 
drug concentrations have been measured to allow for direct comparisons.  
In one such case, Pounder and Jones, 1990, found blood concentrations of 
doxepin that ranged from 3.6 to 12.5 mg/L and its metabolite (desmethyl-
doxepin) from 1.2 to 7.5 mg/L, depending on where it was sampled from. The 
highest levels were found in the pulmonary vein, and the results suggest that the 
elevated levels could easily be from diffusion of drugs from the liver or lung, 
where drug concentrations were found to be very high. They also quantified the 
vitreous humour from the same case, and found 2.9 mg/L doxepin and 1.0 mg/L 
desmethyl-doxepin respectively, although generally vitreous levels are thought 
to be lower than in blood, these figures do not seem drastically lower than the 
lower blood ranges. Presumably this was due to lack of post-mortem 
redistribution influence of vitreous humour.  
However, it has been proven that redistribution of drugs, does not affect all 
drugs. Jones and Pounder, 1987, compared levels of imipramine, 
acetaminophen (paracetamol), codeine and diphenhydramine from 10 blood 
sites, 24 tissue samples, cerebrospinal fluid, vitreous humour and bile. They 
found that imipramine and metabolite (desipramine) had the widest site-
dependent concentration range and was also most highly concentrated in the 
organ tissues, particularly the lungs and liver. In contrast the paracetamol was 
relatively evenly distributed throughout the blood and the lungs with only a 
slightly higher concentration in the liver. Whereas the uniformity of blood levels 
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for diphenhydramine and codeine fell somewhere in between those of 
imipramine and paracetamol. 
Another important aspect to take into consideration is contamination of blood 
during collection, e.g. stomach contents, particularly if the body has suffered 
internal trauma, this could also produce falsely elevated concentrations. 
    ETHICAL AND LEGAL ISSUES 4.1.3
There are extensive ethical and legal issues that need to be considered and / or 
adhered to when working with post-mortem specimens. A deceased person has 
rights which are exercised through the local legal framework that exists within 
each jurisdiction. This is usually through the coroner, who determines the type of 
investigation and what tests are appropriate. This does not usually include 
research unless prior permission is sought, (Drummer, 2007). 
 HUMAN TISSUE ACT 2004 4.1.3.1
The Human Tissue Act (HT Act), 2004 covers primarily England, Wales and 
Northern Ireland, it replaced the Human Tissue Act 1961 and came into effect 
on 1st September, 2006. The HT Act, 2004 established the Human Tissue 
Authority (HTA), to regulate activities that concern the removal, storage, use and 
disposal of human bodies, organs and tissue. It is a legal requirement that any 
premises, involved with these processes holds a valid licence, issued by the 
HTA, (Department of Health, 2009).  
At our laboratory we hold a licence that authorises the storage of a deceased 
person or relevant material which has come from a human body for use for 
listed scheduled purposes. These include: determining the cause of death, to 
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establish how effective a drug or treatment has been after death, to conduct 
research in connection with disorders or the functioning of the human body. 
Apart from this, the schedule does not include any scope for research. In order 
to comply with the schedule, after a case has been reported, further analysis 
should only be carried out with consent from the family of the deceased. 
4.2  MATERIALS AND METHODS  
Before any analysis could take place, each case had to be examined thoroughly 
and an analytical plan had to be developed. This involved careful consideration 
of case circumstances and background, combined with assessment of the 
volume of each sample, to ensure that the correct testing was performed. It also 
confirmed that all analysis undertaken would comply with the Human Tissue Act. 
Qualitative screening for basic, neutral and acidic drugs was performed on 
alternative specimens, alongside blood where possible and appropriate.  
If there was sufficient sample volume, quantitation of analytes was carried out 
on vitreous humour and bile, in order to compare drug levels to those found in 
the corresponding blood. Specialist analyses, (e.g. valproate and GHB 
measurement) were performed as required for the case.   
 SCREENING AND QUANTITATION 4.2.1
The extraction procedures for basic, neutrals and acids are detailed in 
Extraction Procedure 2, 3 and 4, (Chapter 2). The same procedures were used 
for quantitations too, except that extractions were carried out in the presence of 
a suitable internal standard with an appropriate range of calibrators and QCs, 
(for further details see Appendix A). 
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4.3 RESULTS 
From January 2008 to March 2010, the receipt of alternative matrices as 
submissions for toxicological analysis was monitored, in total 476 cases were 
included in this study. The types of case varied dramatically with no obvious 
trend, except with the possible exception of “sudden infant death syndrome” 
(SIDS) cases because then the stomach contents is always submitted and 
analysed as a matter of course. Other types of cases received included: 
hangings, road traffic collisions, drownings or bodies found in water, fire deaths, 
hospital deaths, train deaths, aircraft deaths and shotgun deaths.  
Results showed the following trends: 10% of cases received included the 
submission of alternative matrices, (Figure 4.3). Most of these cases included 
blood and urine but were of low volume, high viscosity and general poor state. 
The majority (87%) of alternative matrices submitted were stomach contents but 
vitreous humour was sometimes available, while bile and other matrices, e.g. 
liver, brain, muscle were sent occasionally, ( 
Figure 4.4). 
Analysis of the alternative matrices revealed that stomach contents had the 
largest proportion of negative findings (64% of cases), with drugs detected in 
71% of vitreous humour cases and 67% of bile, compared to 47% of other 
matrices.  
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Figure 4.3 Proportion of toxicology cases where alternative matrices 
were submitted for analysis 
 
 
 
 
 
 
Figure 4.4 The types and proportions of alternative matrices that were 
submitted for analysis (some cases involve multiple specimen types) 
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 DRUG SCREENING  4.3.1
 STOMACH CONTENTS 4.3.1.1
It is not routine practice at our laboratory to request the entire stomach contents 
for analysis, and drugs are not quantified in this matrix. Instead, we ask for an 
aliquot of up to 20 mL, this can then be used to give an indication of any recent 
drug ingestion, prior to death. This collection procedure needed to be 
maintained throughout this project, (in order to comply with the Human Tissue 
Act), therefore all stomach contents results fall into the drug screening category.  
Analysis of the alternative matrices revealed that stomach contents was the 
most common submission, received in 87% of cases (that is 416 out of a 
possible 476). Out of these 36% were found to be positive for at least one drug, 
and in some cases for several drugs, which meant that in 64% of cases no 
drugs were detected. This was the largest proportion of negative findings; 
however, it is important to remember that a “negative” stomach contents result, 
does not necessarily rule out “overdose”, as a cause of death, (refer to section 
4.1.1.1, for explanation). With this in mind, all the cases with negative stomach 
contents results were reviewed to see if there were any case examples to 
demonstrate this, e.g. where blood levels indicate an overdose but in the 
stomach contents no drugs were detected. Morphine and metabolites were 
detected in 35 cases where no drugs were found in the stomach, see Table 4.1). 
In addition to these, two other cases were found where interpretation of the 
blood drug concentration would be consistent with an overdose but the drug 
responsible was not found in the stomach contents, (refer to Table 4.2).  
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Drug Blood Cause of death Case number 
morphine y (147 ug/L) heroin death 260 
morphine y (19 ug/L) not morphine related 495 
morphine y (41 ug/L) not morphine related 500 
morphine y (95 ug/L) heroin death 660 
morphine y (21 ug/L) not morphine related 777 
morphine y (726 ug/L) heroin death 1215 
morphine y (213 ug/L) heroin death 1445 
morphine y (316 ug/L) heroin death 1970 
morphine y (142 ug/L) heroin death 1971 
morphine y (96 ug/L heroin death 1972 
morphine y (32 ug/L) not morphine related 2034 
morphine y (140 ug/L) heroin death 2101 
morphine y (945 ug/L) possible opiate/opioid toxicity? 2167 
morphine y (126 ug/L) heroin death 2208 
morphine y (298 ug/L) heroin death 2261 
morphine y (1889 ug/L) heroin death 2433 
morphine y (71 ug/L) heroin death 2555 
morphine y (105 ug/L) heroin death 2682 
morphine y (1346 ug/L) heroin death 2868 
morphine y (874 ug/L) heroin death 3162 
morphine y (316 ug/L) heroin death 3195 
morphine y (1378 ug/L) heroin death 3220 
morphine y (42 ug/L) heroin death 3247 
morphine y (663 ug/L) heroin death 3279 
morphine y (40 ug/L) heroin death 3310 
morphine y (1167 ug/L) heroin death 3363 
morphine y (56 ug/L) heroin death 3474 
morphine y (227 ug/L) heroin death 3515 
morphine y (63 ug/L) Home - px morphine given wrong dose? 3516 
morphine y (142 ug/L) heroin death 3662 
morphine y (126 ug/L) heroin death 3724 
morphine y (163 ug/L) heroin death 3837 
morphine y (162 ug/L) heroin death 3846 
morphine y (99 ug/L) heroin death 3903 
morphine y (1554 ug/L) possible opiate/opioid toxicity? px morphine 4033 
Table 4.1 Morphine positive results, in cases where no drugs were 
detected in the stomach contents 
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Analyte Blood Urine 
Stomach 
Contents 
Case 
Number 
Amphetamine y (4.8 mg/L) y nd 3810 
Citalopram y (6.47 mg/L) y y 4751 
citalopram metabolite 
(Desmethylcitalapram) 
y (0.37 mg/L) y nd 4751 
Codeine y (6.29 mg/L) y nd ? 4751 
codeine metabolite (norcodeine) y y nd 4751 
Metoclopramide nd y nd 4751 
paracetamol y (203 mg/L) y y 4751 
Zopiclone y y nd 4751 
Key:  nd=no drugs detected, o=not received or not analysed, y=detected 
 
Table 4.2 Comparison of negative stomach contents results to blood and urine 
 
Analytes in blood 
Analyte(s) 
responsible for 
overdose 
Analytes in stomach 
contents 
Case 
number 
ODV, Risperidone, 
Imipramine, Desipramine 
Imipramine Imipramine 143 
Venlafaxine, Lamotrigine, 
Flecainide, DHC, 
Propranolol, Amlodipine, 
Paracetamol, Salicylate 
Flecanide, 
Venlafaxine 
Flecanide, 
Venlafaxine, 
Lamotrigine, 
Propranolol 
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Promazine And 
Metabolites 
Promazine Promazine 1091 
Zopiclone, Valproate Zopiclone, Valproate 
Zopiclone, Valproate 
 
1233 
Amplodipine And Metab, 
Atenolol, Dosulepin And 
Metabs, Chlortalidone, 
Diazepam 
Atenolol, Dosulepin 
Atenolol, Dosulepin, 
Chlortalidone 
1251 
Citalopram And Metab, 
Amitriptyline And Metab 
Codeine, Paracetamol, 
Diazepam, Salicylate 
Codeine, Paracetamol 
Codeine, Paracetamol, 
Citalopram, 
Amitriptyline 
1382 
Paracetamol, 
Dextropropoxyphene And 
Metab, Diazepam + 
Metab 
Dextropropoxyphene, 
Paracetamol 
Dextropropoxyphene, 
Paracetamol 
1447 
Key:  ODV=o-desmethylvenlafaxine, DHC=dihydrocodeine, metab=metabolite 
Table 4.3 Comparison of blood and stomach contents results in drug overdose 
cases 
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There were seven other cases where blood drug concentrations indicated 
overdoses, and stomach contents were received. In all of these cases the drugs 
responsible for the overdose were detected in the stomach contents, (see Table 
4.3). 
There were some cases where certain drugs and metabolites were found in the 
stomach contents but were not detected in blood and / or urine, (see Table 4.4).  
These results could be important as they could help to assess how effective 
stomach contents would be as an alternative matrix compared to traditional 
matrices, e.g. if stomach contents was the only matrix received for analysis, how 
would this effect interpretation. It is clear that where drugs have not been 
detected in the blood that despite their presence in the stomach contents, an 
oral overdose has not occurred and this would need to be emphasised and 
reflected in the interpretation of any future cases where stomach contents was 
the only matrix analysed.  
Any “obvious tablets or capsules” found in the stomach contents at post-
mortem, are usually extracted and submitted for analysis in a separate tube. 
However, tablets submitted separately or within an aliquot of stomach contents, 
were not commonly found, (only seen in 1.4% of stomach contents analysed), 
(Table 4.5).  
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Drug or metabolite Blood Urine Stomach contents Case No. 
Citalopram nd o y 841 
Diazepam nd (AM serum) o y 1868 
Diazepam nd o y 3361 
Diclofenac nd o y 497 
Diclofenac nd o y 2260 
Diclofenac nd nd y 3106 
Ibuprofen nd o y 2545 
Ibuprofen metabolites nd o y 3228 
Ibuprofen metabolites nd nd y 3260 
Lansoprazole nd o y 2622 
Lansoprazole nd nd y 4558 
Nitrazepam nd nd y 3533 
Omeprazole nd o y 3136 
Omeprazole nd o y 3516 
Omeprazole nd o y 4009 
Zolpidem nd o y 841 
Zolpidem nd o y 3136 
Key:  nd=no drugs detected, o=not received or not analysed, y=detected 
 
Table 4.4 Comparison of positive stomach contents results to blood and urine 
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Case and circumstances Tablets from stomach contents Interpretation 
Case 472 –  
found dead on sofa 
Carbamazepine, oxycodone  
Blood levels do not 
indicate OD 
Case 2005 - Psychiatric ward 
- found dead in bed 
oxycodone  
OD - indicated 
from blood levels 
Case 2774 –  
found dead on kitchen floor 
codeine, fluoxetine, Paracetamol, 
tolterodine, zopiclone 
Blood levels do not 
indicate OD 
Case 3566 – 
found dead at home 
Venlafaxine    
OD - indicated 
from blood levels 
Case 3685 –  
found dead in chair 
oxycodone  
OD - indicated 
from blood levels 
Case 4732 –  
found dead in bed 
oxycodone, warfarin 
Possible excessive 
ingestion 
 
Table 4.5 Results of tablet analysis, isolated from stomach contents 
 
Although metabolites are not usually present in the stomach contents, 18 
different metabolites were found and some of these were present in more than 
one case so this gave a total of 31 occurrences, (see Table 4.6). 
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Metabolite Blood Urine Number of cases Case No. 
amitriptyline metabolite (nortriptyline) y y 3 2423, 3449, 4656 
Carbamazepine metabolite y o 1 3823 
chlordiazepoxide metabolite (demoxepam) y y 1 1709 
chlormethiazole metabolite y y 1 3997 
citalopram metabolite (desmethylcitalapram) y (2/2) y (2/2) 2 3775, 4255 
clobazam metabolite (norclobazam) y (2/2) y (1/2) 2 1571, 2422 
clozapine metabolite (norclozapine) y (2/2) y (2/2) 2 2807, 3143 
diazepam metabolite (nordiazepam) y (7/8) y (3/8) 8 1155, 1215, 1709, 2101, 2188, 2367, 3195, 4423 
diltiazem metabolite (deacetyldiltiazem) y o 1 2859 
dosulepin metabolites y y 1 3366 
nitrazepam metabolite y nd 1 3533 
O-desmethyltramadol (ODT) y y 1 2862 
O-desmethylvenlafaxine (ODV) y y 1 2040 
omeprazole metabolite y o 1 2422 
oxycodone metabolites nd y 1 3533 
promazine metabolies y y 1 4423 
propranolol metabolites y (2/2) y (2/2) 2 4255, 4448 
sertraline metabolite (norsertraline) y y 1 2545 
Key: y=detected, o=not analysed, nd=no drugs detected 
Table 4.6 Metabolites detected in the stomach contents 
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Although, the reason for not routinely measuring drug levels in the stomach 
contents has been discussed at length, an exception was made in one particular 
case, (2473). The customer specifically requested ethylene glycol analysis on 
both samples submitted, these were blood and stomach contents. This is a 
specialist assay carried out on the GC-FID, (refer to section 2.9.3.3, extraction 
procedure 13). In the blood no ethylene glycol was detected above 50 mg/L (the 
limit of detection for this assay), in the stomach contents 205 mg/L was 
detected.  
In another case (3194), circumstances revealed that an empty bottle of “Gamma 
Butyrolactone” was found in the room of the deceased. As it is known that 
gamma butyrolactone (GBL) is converted to gamma-hydroxybutyrate (GHB) in 
the body then it was necessary to do specific GC-MS analysis for GHB, (refer to 
section 2.7.1, extraction procedure 9). Both blood and stomach contents were 
analysed, the measured blood level was >1250 mg/L and it was also found to be 
present in the stomach contents.  
164 
VITREOUS HUMOUR 
In total there were 134 analytes detected in vitreous humour but there were a 
further 62 analytes that were detected in other matrices that were not detected 
in vitreous humour. 
If the screening results are compared for blood and vitreous, there were 43 
analytes that were detected in blood that were not found in the corresponding 
vitreous humour, (see Table 4.7).   
However, if the reverse scenario is looked at, positive results in vitreous that 
have not been detected in the blood, there are 9 examples, (see table 4.8).  
If the vitreous and urine results are compared, there are 27 positive results in 
urine that have not been detected in the vitreous humour, (comprised of 16 
parent compounds and 11 metabolites (or associates), (see table 4.10).    
If vitreous positive results are compared to those not detected in urine, there are 
7 examples, and 5 of these are metabolites, (see table 4.9). 
If the results from blood and urine are looked at in conjunction, there are only 2 
compounds that have been detected in vitreous humour that have not been 
found in either blood or urine, (see table 4.8 and 4.9), these results have been 
highlighted).    
There was one case received (2584), where vitreous humour was the only 
matrix sent in for analysis. Case circumstances stated that the deceased had 
been hit by an oncoming train, and the prescription history stated that she had 
been prescribed antidepressants. The results showed that citalopram and 
metabolite were detected.   
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Analyte 
Number of 
cases 
Case No. 
Amlodipine 3 609, 2164, 2192 
Clomipramine and metabolite (norclomipramine) 1 668 
Omeprazole metabolite 1 2422 
Cyclizine 2 775. 2290 
Cyclizine metabolite (norcyclizine) 1 2165 
Diazepam 4 
775, 1510, 2164, 
2366 
Diazepam metabolite (nordiazepam) 4 
775, 1510, 2164, 
2366 
Duloxetine related 1 2165 
Fluoxetine 1 1040 
Fluoxetine metabolite (norfluoxetine) 1 939 
Lansoprazole metabolite 1 1661 
Levomeprazine 1 668 
Lignocaine 1 1040 
M3G 1 277 
Methadone 1 939 
Methadone metabolite (EDDP) 1 939 
Mirtazepine 2 1, 668 
Omeprazole 1 2290 
Oxazepam 1 1650 
Papaverine 1 260 
Paracetamol 3 1688, 2491, 3086 
Promethazine 1 2165 
Risperidone 1 3086 
Sertraline 2 3086, 2170 
Sertraline metabolite (norsertraline) 1 2170 
Temazepam 2 1, 1650 
Zuclopenthixol 1 277 
Key: y=detected, o=not analysed, nd=no drugs detected 
 
Table 4.7 Analytes detected in blood but not detected in vitreous humour  
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Analyte Blood Urine Vitreous Humour Case No. 
6-MAM nd o y 260 
amisulpride metabolite nd y y 3 
chloroquine associates nd nd y 775 
Codeine nd y y 2291 
Ibuprofen metabolites nd nd y 2298 
Laudanosine nd y y 1 
Levamisole nd y y 959 
Lignocaine nd y y 1 
omeprazole metabolite nd y y 3 
Key: y=detected, o=not analysed, nd=no drugs detected 
 
Table 4.8 Analytes detected in vitreous humour that were not found in blood  
 
 
Key: y=detected, o=not analysed, nd=no drugs detected 
Table 4.9 Analytes detected in vitreous humour that were not found in urine 
 
 
 
  
Analyte Blood Urine 
Vitreous 
humour 
Case 
Number 
Chloroquine associates o nd y 348 
Chloroquine associates nd nd y 775 
Ibuprofen metabolites nd nd y 2298 
Mirtazapine metabolites y nd y 1650 
Noscapine y nd y 277 
Paracetamol y nd y 2143 
Pethidine metabolite (norpethidine) y nd y 3066 
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Analyte Number of cases Case No. 
6-MAM 1 1441 
Amlodipine 1 609 
Amlodipine metabolite 2 609, 2165 
Ciprofloxacin 1 3086 
Cocaine 2 939, 959 
Cocaine metabolite 1 959 
Cyclizine 1 775 
Cyclizine metabolite (norcyclizine) 2 775, 2165 
Duloxetine related 1 2165 
Fluoxetine metabolite (norfluoxetine) 1 939 
Lansoprazole metabolite 1 3066 
Methadone 1 939 
Methadone metabolite (EDDP) 1 939 
Mirtazepine 1 1 
Paracetamol 2 2298, 3086 
Promethazine 1 2165 
Quinine 1 609 
Ranitidine 1 939 
Risperidone 1 3086 
Sertraline 2 3086, 2170 
Sertraline metabolite (norsertraline) 1 2170 
Temazepam 1 1650 
Key: y=detected, o=not analysed, nd=no drugs detected 
Table 4.10 Analytes detected in urine that were not found in vitreous humour  
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 BILE 4.3.1.2
It was only possible to screen the bile for 12 cases; this was partly due to the 
low number of submissions received. However, in addition to this, problems 
were encountered with extraction, following the addition of solvent to the 
sample, mixing and centrifugation, sometimes the fluid would solidify to form a 
“jelly-like” consistency, once this had occurred it was not possible to continue 
with the extraction. As bile shows drug use in the past few days, and this is also 
true for urine it would make sense to compare the screening results obtained for 
these matrices. Unfortunately, this is only possible for 4 cases, as urine was not 
submitted for analysis, with the other cases.  
If the bile results are compared to the both blood and urine results, 5 more 
analytes were found in the bile, (no urine was submitted for 4 of these cases), 
but in the case where urine was received (case 2753), the results show that no 
cyclizine was detected in the urine or blood, although it was found to be present 
in the bile, (see table 4.11). 
There were 7 analytes that were not detected in bile that were detected in blood 
and / or urine, (see Table 4.11). All 7 were detected in urine and out of these an 
additional 2 analytes were also detected in blood, these were codeine and the 
venlafaxine metabolite, O-desmethylvenlafaxine. 
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Key: y=detected, o=not analysed, nd=no drugs detected 
Table 4.11 Analytes detected in bile that were not found in blood or urine  
 LIVER AND OTHER MATRICES 4.3.1.3
There were 10 cases submitted where in the absence of more suitable matrices, 
it was deemed appropriate to analyse a different matrix to any already 
described, these were: liver, liver fluid, bowel, brain, lung, muscle or fluid from 
the pleural cavity, (see Table 4.12). For some of these cases blood and or urine 
were also submitted but for the majority only alternative matrices were available 
for analysis, so comparison of results was limited. Case circumstances have 
been included as it is generally due to reasons given here, that only limited 
specimens were available for analysis, e.g. if the body was found very 
decomposed (or found in water which can speed up decomposition). 
Analyte Blood Urine Bile Case Number 
Amlodipine metabolite nd o y 2192 
Cyclizine nd nd y 2753 
Doxazosin nd o y 2192 
Doxazosin related nd o y 2192 
Valproate nd o y 807 
6-mam nd y nd 3310 
Bisoprolol nd y nd 2753 
Codeine y y nd 3310 
Haloperidol nd y nd 2753 
Midazolam nd y nd 2753 
O-desmethylvenlafaxine (ODV) y y nd 3310 
Trazadone nd y nd 563 
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 ALTERNATIVE MATRICES ONLY 4.3.1.4
There was one case received (2498), where only vitreous humour and stomach 
contents were submitted for analysis. The case circumstances stated that the 
deceased was a known epileptic found unresponsive in the bath, she had been 
prescribed carbamazepine. The results showed that carbamazepine was 
detected in the vitreous at 1.53 mg/L and was also present in the stomach 
contents.    
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Case number and 
circumstances 
Matrices 
received 
Drugs detected 
1235 
suspected solvent abuse 
blood 
fluoxetine at 2.647 mg/L and 
norfluoxetine at 2.02 mg/L, butane 
and propane 
urine fluoxetine and norfluoxetine 
Stomach contents Fluoxetine (trace amount) 
brain and lung butane and propane 
2270 
suspected overdose 
blood 
 
diazepam and metabolite, 
venlafaxine (13.8mg/L), o-
desmethylvenlafaxine (5 mg/L), 
phenytoin (24 mg/L), propranolol, 
Temazepam, zopiclone and 
metabolite 
Urine 
venlafaxine and ODV, propranolol 
zopiclone and metabolite 
bowel contents 
venlafaxine and ODV, phenytoin, 
propranolol 
812 
recovered from river 
Liver Citalopram 
1032 
found hanging, decomposed 
Liver Fluoxetine 
2937- found dead in bed Liver Codeine 
2879 found hanging, 
decomposed 
liver and muscle venlafaxine and ODV 
3504 
found dead, decomposed, 
drug user - syringe in arm 
Liver 
morphine and M3G, noscapine, 
papaverine 
stomach contents no drugs detected 
2672 
died at home 
liver fluid 
citalopram and metabolite, 
omeprazole, paracetamol, 
zopiclone 
vitreous humour 
citalopram and metabolite, 
omeprazole, paracetamol 
3873 
recovered from stream 
liver fluid citalopram and metabolite 
stomach contents no drugs detected 
1003 
found hanging, decomposed 
pleural cavity 
 
amitriptyline and metabolite, 
diazepam and metabolite, 
temazepam and metabolite, 
quetiapine metabolite, tramadol 
(33.3 mg/L) and ODT (6.83 mg/L) 
stomach contents Tramadol 
Bile 
amitriptyline and metabolite, 
diazepam, temazepam and 
metabolite, quetiapine metabolite, 
tramadol and ODT 
Key: ODV=o-desmethylvenlafaxine, ODT= o-desmethyltramadol 
Table 4.12 Results from cases where “different” matrices were analysed 
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 DRUG QUANTITATION  4.3.2
Due to a low number of suitable submissions, limited sample of vitreous and 
lipid content of bile (interfering with extraction) performing drug measurements 
proved challenging. It was only possible to quantify drugs in vitreous (30 Cases) 
and/or bile (6 Cases) in relatively few cases. 
 VITREOUS HUMOUR 4.3.2.1
In the majority of cases analysed drug levels were found to be much lower in 
vitreous than in the corresponding blood, however there were a few exceptions, 
(Table 4.13).  
In one Case, there was slightly more tramadol and metabolite, (O-
desmethyltramadol) found in vitreous than in the blood, and in another case 
more pethidine and metabolite (norpethidine) were detected, (Table 4.13).  
The results for the benzodiazepines all demonstrated lower levels in vitreous 
compared to blood, (Table 4.13). 
During this study, 41 cases were found to be positive for tricyclic 
antidepressants in blood, these included amitriptyline, clomipramine, 
desipramine and / or dosulepin (dothiepin), but of these cases, only 2 submitted 
vitreous for analysis. For each of these cases, detailed analytical plans were 
developed and adhered to. 
In Case 668, (see Table 4.14) the blood and stomach contents were screened 
for basic, neutral and acidic drugs. The results showed, clomipramine (+ 
metabolites), levomepromazine (+ metabolites), zopiclone (+ metabolites), 
mirtazapine (+ metabolite), diazepam (+ metabolite) and propranolol were 
detected in blood, with no drugs detected in the stomach, (Table 4.14). The 
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screening results allowed for the comparison of drug responses and 
clomipramine, levomepromazine, zopiclone, mirtazapine and diazepam were 
seen to be present at a low concentration that would be consistent with 
therapeutic use, so a measurement was not necessary. Propranolol was the 
most significant and so this was measured in both the blood and the vitreous. It 
was found to be 1.11 mg/L in the blood compared to 0.62 mg/L in vitreous, 
another example of a lower concentration in vitreous. The vitreous extract was 
screened for basic drugs, and levomepromazine, zopiclone (+ metabolites), and 
mirtazapine metabolite were all detected, but clomipramine and / or metabolite 
were not.  
In Case 2591 the blood was screened for basic, neutral and acidic drugs and 
codeine, quinine, amitriptyline, bisoprolol and citalopram were detected, all the 
levels seen in the screen were low and so no measurements were required. The 
vitreous was screened for basic drugs and the results fully supported the blood, 
with the same drugs being detected.  
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Drug Blood Vitreous Vitreous:Blood ratio
Benzodiazepines mg/L mg/L
chlordiazepoxide 0.76 0.1 0.1316
demoxepam 2.61 0.75 0.2874
clobazam   0.41 0.1 0.2439
clobazam   0.225 0.091 0.4044
norclobazam 4.94 1.98 0.4008
diazepam 0.23 0.0715 0.3109
nordiazepam 0.6 0.0205 0.0342
temazepam    3.27 0.85 0.2599
oxazepam   0.5 0.21 0.4200
Anticonvulsants / Antiepileptics
Carbamazepine o 1.53 n/a
lamotrigine   1.039 0.875 0.8422
lamotrigine 1.6 o n/a
phenytoin 9.06 < 1 n/a
phenytoin  17.32 2.67 0.1542
Valproate nd o n/a
Antidepressants
duloxetine  0.47 <0.05 n/a
Opioids
methadone 0.46 0.1 0.2174
methadone   1.2 0.36 0.3000
methadone   0.211 0.035 0.1659
methadone    1.46 0.72 0.4932
Pethidine    9.7 10.5 1.0825
norpethidine 2.5 2.7 1.0800
tramadol 1.36 1.41 1.0368
O-desmethyltramadol (ODT)    0.32 0.33 1.0313
Opiates ug/L ug/L
Morphine 147 18 0.1224
Morphine 783 103 0.1315
NSAIDS mg/L mg/L
ibuprofen 210.2 13.7 0.0652
salicylate  56 9 0.1607
B-blockers
propranolol  1.11 0.62 0.5586
Antipsychotic
olanzapine  0.0295 0.049 1.6610
Stimulant
Amphetamine 4.8 o n/a
Caffeine    4.28 3.93 0.9182  
Table 4.13 blood vs vitreous - measured concentrations 
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Drug Blood 
Stomach 
contents 
Vitreous 
Clomipramine (+ metabolite) Y (Y) nd Nd (nd) 
Zopiclone (+metabolite) Y (Y) nd Y (Y) 
Levomepromazine (+ 
metabolite) 
Y (Y) nd Y (nd) 
Mirtazepine (+ metabolite) Y (Y) nd Y (Y) 
Diazepam (+ metabolite) Y (Y) nd O 
Propranolol Y (1.11 mg/L) nd Y (0.62 mg/L) 
 
Table 4.14 Results for Case 668 
 BILE 4.3.2.2
Analyte Blood (mg/L) Bile (mg/L) Blood:Bile ratio 
Amphetamine 4.8 29 6.04 
clobazam 0.225 0.499 2.22 
clobazam metabolite (norclobazam) 4.943 9.99 2.02 
lamotrigine 1.6 9 5.63 
Lorazepam 0.19 0.36 1.89 
olanzapine 0.0295 0.2725 9.24 
Valproate nd 35 Na 
 
Table 4.15 blood vs bile, measured concentrations 
 
The bile levels were found to be much greater than those determined in blood, 
which was expected, as it is known to contain high concentrations of drugs, and 
many drugs have been shown to accumulate in the bile, (Skopp, 2004), (Jones, 
2004).  
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The blood:bile ratios were calculated to see if any specific trends were evident,  
(Table 4.15). it is interesting that clobazam (a benzodiazepine derivative) and its 
metabolite norclobazam are found to both be present at the same ratio, which is 
twice as much in bile compared to blood, and lorazepam (a similar type of drug, 
benzodiazepine), comes very close to this with a ratio of 1.89. The other ratios 
determined were much greater, with amphetamine and lamotrigine nearly 6 
times greater in bile than blood and olanzapine 10 times greater.  
 DRUG STUDIES 4.3.3
 MORPHINE AND HEROIN RELATED COMPOUNDS 4.3.3.1
The solid phase extraction method allowed for the detection and measurement 
of morphine and morphine metabolites, M3G and M6G, (this allowed for the 
calculation of free:total morphine ratio), as well as the detection of codeine, 
codeine-glucuronide and the specific heroin metabolite, 6-MAM in post-mortem 
blood, (refer to Figure 4.5 Metabolic pathways of morphine and analogues,).  
However, as heroin is rapidly absorbed, it is not always possible to detect 6-
MAM in blood and so additional heroin markers, noscapine and papaverine are 
also included in the analysis, (refer to Figure 4.6). These are components of the 
opium poppy that have come through the production process, their presence 
confirms heroin use rather than diamorphine or morphine, (Elliott, 2009).   
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Figure 4.5 Metabolic pathways of morphine and analogues,  
Redrawn from Jones, (2008) 
 
 
Figure 4.6 Structures of noscapine (left) and papaverine (right) 
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Blood versus vitreous 
It is well documented that 6-MAM is unstable and therefore not always 
detectable in the blood, however as vitreous humour has a very sterile 
environment, it has been suggested that it could be a better matrix for analysis 
of this metabolite. An interesting part of this study was going to test this theory.  
However in reality, of all the cases where morphine analysis was required, there 
were only three cases that included vitreous as a submission and these were 
analysed specifically for morphine, (see Table 4.16). 
In terms of morphine concentrations, levels were found to be a lot lower in 
vitreous than in blood, and the metabolites M3G and M6G were not detected in 
vitreous in Case 260 or 277, (above the 10 ug/L LOD for the assay). In Case 
1441, the calculated concentrations for the duplicate samples were not within 
20%, ordinarily this would mean the analysis would need to be repeated but this 
was not possible due to insufficient sample volume. 
6-MAM was detected in 1/3 cases in blood and in 2/3 cases in vitreous, the 
opposite was found to be true for papaverine, detected in 2/3 in blood compared 
to 1/3 in vitreous, while noscapine was found to be present in both matrices in 
all 3 cases. 
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Case 260 Case 277 Case 1441
Morphine 147 ug/L 783 ug/L 39 ug/L
M3G nd (< 10 ug/L) 75 ug/L 388
M6G nd (< 10 ug/L) nd (< 10 ug/L) 43
6-MAM nd y nd
Noscapine y y y
Papaverine y y nd
Morphine 18 ug/L 103ug/L y
M3G nd (< 10 ug/L) nd (< 10 ug/L) y
M6G nd (< 10 ug/L) nd (< 10 ug/L) y
6-MAM y y nd
Noscapine y y y
Papaverine nd y nd
vitreous:blood ratio 0.12 0.13 n/a
Vitreous Humour
  
Key:   y = detected, nd=not detected, n/a= not applicable 
 
Table 4.16 Morphine - blood versus vitreous 
Analyte Blood Urine Stomach contents Total 
Morphine Y Y Y 
6 Cases M3G Y Y O 
M6G Y Y O 
Noscapine Y Y Y 3 Cases 
6-MAM Y Y Y 1 Case 
Key:  y=detected, o=none received or not analysed 
 
Table 4.17 Morphine - blood versus stomach contents 
 
 CODEINE 4.3.3.2
Codeine was detected in 67 of the cases included in this study, blood and urine 
were submitted for the majority, stomach contents was received in 63 of these 
cases, bile in 2, vitreous in 3 and there was one case where only liver and 
stomach contents were available (2937).  
180 
Of the 63 stomach contents samples analysed, codeine was only detected in 4 
of them, and in each of these cases it was detected with a minimum of at least 3 
other drugs, Table 4.18. 
Codeine was detected in all 3 vitreous submissions but in one of the cases there 
was no codeine detected in the blood which was an unexpected result, Table 
4.19. On investigation of the timings, it became apparent that the cases with the 
unexpected result had been subjected to a long time delay between date of 
death and collection of samples, Table 4.20. 
In the case where only liver and stomach contents were submitted, the case 
information states that the deceased was an alcoholic, found dead in bed. In this 
type of case, the date found is recorded as the date of death; estimations of time 
of death are not routinely disclosed to the laboratory. The results showed 
codeine and putrefactants in the liver, and putrefactants in the stomach, 
(quantitation or estimation of the codeine concentration in the liver was not 
performed).  
Case Blood Stomach Contents 
Case 
1382 
Amitriptyline, Citalopram, Codeine, 
Diazepam, Paracetamol, Salicylate 
Amitriptyline, Citalopram, 
Codeine, Paracetamol 
Case 
2034 
Atenolol, Codeine, Diazepam, 
Ibuprofen, Morphine, M3G, M6G, 
Oxazepam, Salicylate, Temazepam, 
Trazadone, Zopiclone 
Atenolol, Codeine, Diazepam, 
Ibuprofen,  Salicylate, 
Temazepam, Trazadone, 
Zopiclone 
Case 
2774 
Codeine, DHC, Fluoxetine, 
Orphenadrine, Paracetamol, 
Risperidone, Tolterodine, Zopiclone 
Codeine, Fluoxetine,  
Paracetamol, Tolterodine, 
Zopiclone 
Case 
2859 
Codeine, Diltiazem, Paracetamol, 
Temazepam, Warfarin 
Codeine, Diltiazem, 
Paracetamol, Temazepam, 
Warfarin 
 
Table 4.18 Results for codeine positive stomach contents   
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 Blood Urine Vitreous 
Case 1441 Y Y Y 
Case 2291 Nd Y Y 
Case 2591 Y Y Y 
 
Table 4.19 Codeine results – blood versus vitreous 
 
Days elapsed Case 1441 Case 2291 Case 2591 
Death to collection 6 - 7 0 – 2 0 
Collected to receipt 0 23 5 
Receipt to analysis 0 0 1 
Further Analysis vitreous 7 vitreous 4 vitreous 6 
Total days since death 13 - 14 27 – 29 12 
 
Table 4.20 Results of timings of samples in codeine - blood versus 
vitreous cases 
 
 DIAZEPAM 4.3.3.3
Diazepam was one of the most commonly detected drugs, (found in 83 cases) 
along with its main metabolite nordiazepam (desmethyldiazepam), (refer to 
figure 4.9). Out of the positive cases, 72 submissions included stomach contents 
and 8 included vitreous. Diazepam was detected in 21 stomach contents and 
nordiazepam was detected in 8 cases. Diazepam was detected in 4 of the 
vitreous cases and nordiazepam was detected in the same 4 cases, plus an 
additional one. As nordiazepam is a metabolite of several different compounds, 
(not just diazepam) e.g chlordiazepoxide and chloazepate, this explains its 
presence in one of the vitreous cases and one of the stomach contents cases, 
as chlodiazepoxide was also detected.    
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Figure 4.7 Metabolism of diazepam 
Redrawn from Baselt, (2011, p. 472). 
 
 
 COCAINE 4.3.3.4
Cocaine was detected in 14 cases; blood and urine were submitted for every 
case, stomach contents was submitted for 13 of them and vitreous was sent in 
for 2 of them, (unfortunately bile was not submitted in any of these cases). 
Results showed that urine tested positive in every case, blood tested positive for 
5 of them, and it was found in the stomach contents of one case and was not 
detected in either of the vitreous submissions.  
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Drug Blood Urine Stomach contents Vitreous humour 
Case 
number 
cocaine y (6.9 mg/L) y y o 491 
cocaine y y nd o 698 
cocaine nd y nd nd 939 
cocaine nd y o nd 959 
cocaine nd y nd o 1215 
cocaine y y nd o 1258 
cocaine nd y nd o 2261 
cocaine y y nd o 2367 
cocaine nd y nd o 2682 
cocaine y y nd o 2767 
cocaine nd y nd o 3363 
cocaine nd y nd o 3422 
cocaine nd y nd o 3837 
cocaine  nd y nd o 4255 
Key: nd=no drugs detected, y=present, o=none received 
Table 4.21 Results where urine tested positive for cocaine  
 
 AMPHETAMINE 4.3.3.5
A case where amphetamine overdose was the most likely cause of death, 
(3810) has already been considered, but it is interesting that in 3 other cases, 
(1971, 3290 and 4023) amphetamine was detected in the blood and / or urine 
but was again, not found in the stomach contents. 
 METHADONE 4.3.3.6
Methadone was detected in the blood of 39 cases, and the main metabolite 
EDDP, was detected in 12 of the same cases. 35 of these cases submitted 
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stomach contents for analysis and 5 submitted vitreous (4 of these were 
measured and have already been discussed) but only 1 submitted both. The 
stomach contents results showed that methadone was detected in 12 cases but 
the metabolite EDDP, was not detected at all. 
4.4       DISCUSSION 
 DRUG SCREENING  4.4.1
 STOMACH CONTENTS 4.4.1.1
Regarding the 35 cases where no drugs were found in the stomach but 
morphine was detected in the blood, four of these cases had low levels of 
morphine <50 ug/L, and as fatal opiate poisonings are usually associated with 
free morphine concentrations greater than this, (although deaths have been 
recorded at lower concentrations in individuals with little or no tolerance to this 
group of drugs), it is unlikely that in these cases, a morphine overdose was the 
cause of death. 
In 28 of these cases either a specific heroin metabolie (6-MAM) was present or 
marker compound(s) were detected that confirmed heroin use, e.g. noscapine or 
papaverine,  prior to death and in the absence of any other cause of death been 
found, it is most likely that the individuals in these cases died from fatal opiate 
toxicity. As heroin is usually smoked, injected or snorted if it’s in its pure form, 
morphine was not necessarily expected to be detected in the stomach contents 
for these cases, (although it is not impossible for analytes to be detected in the 
stomach following routes of administration other than oral ingestion). The three 
remaining cases are somewhat more complicated, there is no evidence of 
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heroin use so it is unclear whether the morphine detected has come from heroin 
or morphine use, but in one case the deceased was a known heroin user 
prescribed methadone and the most likely cause of death was opiate or opioid 
toxicity so you would not necessarily expect to see morphine in the stomach 
contents of this case. However, in the 2 remaining cases morphine was 
prescribed in tablet form so the absence of morphine in the stomach contents of 
these cases indicates that morphine was not orally, close to the time of death.   
Besides the morphine cases described, only two other cases had blood drug 
levels that would be regarded as consistent with an overdose, (see Table 4.2). 
For case 3810, amphetamine was detected at a significant level in the blood to 
be consistent with an overdose and it was also detected in the urine and the 
bile, yet it was found to be absent in the stomach contents. As previously 
described with heroin, this could be due to the route of administration as it can 
be snorted or rubbed onto the gums, ingested orally or injected, so it is possible 
that it could have avoided exposure to the gastric system and would therefore 
not necessarily be detectable in the stomach contents.  
A possible scenario could be that a range of tablets were taken as an attempt at 
suicide and perhaps when there was no immediate effect, more tablets were 
taken “to speed things up”, these could have been the citalopram and 
propranolol, then the individual died before these extra tablets had chance to be 
fully absorbed. 
In case, 4751, blood levels suggest an overdose of both citalopram and codeine 
and paracetamol (available in combined preparations). In the stomach contents 
citalopram and paracetamol are detected but it is not clear if any codeine is 
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present. Paracetamol and codeine elute at very similar retention times on the 
HPLC-DAD system used, and as the paracetamol in the stomach was present at 
such a high level it was not possible to detect any codeine but that does not 
mean that there was none present. In addition to this the interpretation of this 
case is further complicated because the blood was not collected from the 
femoral vein (the recommended site of collection) but instead the vena cava, 
which is a site close to the heart. As a result of this the measured concentrations 
of drugs, (see Table 4.2), could be artificially elevated and therefore not reflect 
the concentrations that were exerting an effect.  
The results that showed drugs and / or metabolites detected in the stomach 
contents but absent in the blood and / or urine, (see Table 4.3), could have 
important implications. Drugs in the stomach that are absent in the blood, and or 
urine, suggest very recent ingestion of these drugs prior to death, e.g. they have 
been ingested but not absoerbed. In the case of suicide, sometimes drugs are 
taken as a “back-up” plan in case the intended plan does not work or they 
cannot go through with it, e.g. if they planned to take their own life by hanging or 
shooting. Another possible scenario could be that a range of tablets were taken 
as an attempt at suicide and perhaps when there was no immediate effect, more 
tablets were taken “to speed things up”, then the individual died before these 
extra tablets had chance to be fully absorbed and would therefore not be 
detected in other matrices. 
The results show that ibuprofen metabolites have been detected in the stomach 
contents of two cases (where they have not been detected in the blood or urine).  
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It is unusual to see metabolites in the stomach contents, you would normally 
expect to see only parent drugs. In total, ibuprofen metabolites have been 
detected in stomach contents of 5 cases all of which also have ibuprofen 
present (in parent form), it is therefore possible that they are not “true” 
metabolites that are present in the stomach but possible break-down products 
from the parent compound. However, it is equally possible that the metabolites 
are present due to back diffusion from the bile after death. Although it is not 
possible to decipher exactly how these compounds came to be present in the 
stomach, the very acidic nature of the stomach contents would provide a 
favourable environment for these compounds, and the fact that they were 
detected in several different cases seems to support this.    
A review of positive stomach contents results showed that in addition to the 
ibuprofen results, metabolites were detected on 31 other occasions, (see Table 
4.6), this does not mean in 31 cases because some of these cases have more 
than one metabolite present. Perhaps the presence of more than one metabolite 
suggests that they have most likely got into the stomach via back diffusion 
rather than simultaneous breakdown of different compounds.  
With reference to the results in Table 4.5, in case 2774, codeine, fluoxetine, 
paracetamol, tolterodine, zopiclone were detected on analysis of the tablets, but 
it is probable that some of the drugs were present due to contamination from the 
stomach contents. The results from this case also showed a discrepancy with 
the blood and urine as fluoxetine was only present in the stomach contents, this 
would indicate very recent ingestion of fluoxetine prior to death. 
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In Case 4732, the stomach contents were submitted for analysis in addition to 
the tablets that had been isolated from the stomach. These results showed up a 
discrepancy as the warfarin detected in the tablet was not detected in the 
stomach contents but it was detected in the blood. However, despite this result it 
is still most likely that the tablets were contaminated with warfarin from the 
stomach contents as these drugs are not available in combined preparations, 
and it is unlikely that they were contaminated before ingestion. This could 
highlight a potential problem with stomach contents analysis for drugs because 
it is possible that due to its varied composition and lack of homogeneity, the 
results could be different depending where the sample or aliquot was collected 
from i.e. proximity to where the tablet was removed from. Perhaps if more than 
one sample of stomach contents had been collected and analysed, warfarin 
would have been detected.  
For case 2473, where the ethylene glycol was measured in the stomach 
contents, it is important to note that only an aliquot (not the entire stomach 
contents from the body) was received so the measurement itself is somewhat 
meaningless. However, the result does indicate that ethylene glycol must have 
been ingested sometime recently prior to death; this is information that would 
have been missed if the blood alone had been analysed. 
For case 3194, where specific GHB analysis was carried out, although it is 
known that GHB exists as an endogenous compound in mammalian tissue and 
can be found in almost all post-mortem biological fluid, a level of >1250 mg/L is 
much higher than endogenous levels and consistent with recent ingestion of 
GBL/GHB and this is supported by the presence of GHB in the stomach.         
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 VITREOUS HUMOUR 4.4.1.2
A total of 44 more analytes were found in blood compared to vitreous humour, 
this means that if only vitreous had been sent for analysis, none of these 
analytes would have been detected.  
When the results were reviewed, no clear overdose cases would have been 
missed by vitreous analysis alone, but there was one case of possible excessive 
ingestion that would not have been picked up. This was case 939, where blood 
levels indicate excessive ingestion of fluoxetine (1.41 mg/L) and possibly 
excessive ingestion or chronic therapeutic use of methadone (0.42 mg/L), the 
toxicological significance of opiate/opioid drug levels are difficult to interpret, as 
they vary greatly from case to case, and largely depend on the deceased’s dose 
regime and their degree of tolerance.  Although fluoxetine was detected in the 
vitreous, methadone was not. The case circumstances state that the individual 
allegedly drank a bottle of methadone before jumping from a 14th floor flat, 
maybe the time-scale and very recent ingestion of methadone prior to death 
could explain its absence in the vitreous. Although if this was the explanation it 
would be likely that methadone would be detected in the stomach contents but it 
was not, so there is no real evidence to support this theory. 
It is only fair to compare positive results in vitreous that are negative in blood, 
and there are 8 examples that demonstrate this, had the blood alone been 
analysed then some analytes would have been missed. However, in the cases 
where urine was also sent most (all but 3) of these analytes would have been 
detected. One exception was case 260, where urine was not submitted for 
analysis, in this case the presence of 6-MAM in the vitreous humour is very 
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significant as it indicates heroin use prior to death, (for further details refer to 
section 4.3.3.1 and 4.4.3.1). 
There were 2 analytes: chloroquine associates and ibuprofen metabolites that 
were detected in vitreous that were not detected in either blood or urine, (see 
Table 4.8 and 4.9). As they are both metabolites, their presence in the vitreous 
would indicate previous use prior to death but this is unlikely to help determine 
the cause of death so overall for case interpretation these results are not very 
significant.   
There were 5 other analytes that were detected in vitreous but not in urine, (see 
Table 4.9), but for 4 of these cases the analytes in question were present in the 
corresponding blood. In case 348 where no blood was submitted for analysis, 
chloroquine associates were detected in the vitreous but not in the urine.  
More positive results were found in urine than in vitreous, this was expected as 
drug concentrations are known to be higher in urine than vitreous, and would 
therefore be easier to detect.  
In terms of case 2584, the presence of citalopram in the vitreous humour  
indicates the ingestion of this antidepressant drug at some point prior to death 
but as this was the only matrix received for analysis, it is difficult to determine 
whether therapeutic or excessive ingestion had occurred. 
 BILE 4.4.1.3
Comparison of bile and urine results, show that there was only one compound 
that was present in the bile that was not detected in the urine (or blood) and this 
was cyclizine, (in case 2753). 
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For case 807, the circumstances revealed that an epileptic was found dead, he 
had been prescribed sodium valproate. Blood and bile were submitted for 
analysis, it was not detected in the blood above the 12.5 mg/L cut-off, and this 
result alone could have implied that the individual had not been taking his 
medication and was therefore non-compliant. However the presence of the drug 
in the bile suggests that he had taken his medication at some time before death, 
even though it is not possible to determine when or how much was taken. 
The results showed that 2 analytes were detected in the bile that were absent in 
the blood and urine, this information could prove useful on occasion, in a similar 
way, as described previously for the valproate case. 
 LIVER AND OTHER MATRICES 4.4.1.4
For case 1235, blood, brain and lung were submitted for analysis as 
circumstances suggested solvent abuse and these are the best matrices for 
detecting solvents, as due to their volatile nature they quickly leave the blood 
and accumulate in the organs. Butane and propane were detected in the blood, 
brain and lung which confirmed the suspicions. However, fluoxetine was also 
detected in blood, urine and stomach contents. The fluoxetine blood levels are 
high and could suggest an overdose but the solvents are more likely to be cause 
of death. A possible scenario for these findings is that the deceased took an 
overdose of fluoxetine and when they didn’t die very quickly - the solvents were 
used. This would explain the elevated fluoxetine blood levels and trace amount 
in the stomach. 
Case 2270, was a suspected overdose case and in the absence of stomach 
contents the bowel was analysed to check for recent drug ingestion. Blood 
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results suggested that an overdose of venlafaxine had been taken prior to 
death, and this was was supported by the detection of this in the bowel.  
The liver was the only matrix submitted for analysis in cases 812, 1032 and 
2937, one drug was detected in each case, citalopram, fluoxetine and codeine, 
respectively. The presence of these drugs in the liver indicates that they were 
used at some time prior to death but with no other matrices to analyse it is not 
possible to determine the nature of the ingestion, e.g. whether it was recent, 
therapeutic or excessive. Similarly in case 2879, the detection of venlafaxine 
and the metabolite, o-desmethylvenlafaxine (ODV) in the liver and muscle 
indicates  that it was taken sometime prior to death but based on these results 
alone, again it is not possible to determine the nature of the ingestion.   
In terms of case 3504, due to the case circumstances, where the deceased was 
found with a syringe in their arm, specific morphine analysis was performed. 
This allowed for the detection of morphine, M3G, noscapine and papaverine in 
the liver which clearly indicated that heroin had been used prior to death and the 
presence of no drugs in the stomach contents seems to be consistent with other 
heroin deaths. However based on these results, it is not possible to determine 
whether such heroin use was recent or excessive prior to death. 
For case 2672, the case circumstances state that the deceased died at home, 
and was found the same day so it is not clear why only liver fluid and vitreous 
humour were submitted for analysis. The results show that citalopram and 
metabolite, desmethylcitalopram, omperazole and paracetamol were detected in 
both matrices, in addition zopiclone was detected in the liver but not in the 
vitreous humour. The reason for this, could be due to timing and so these 
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results indicate previous rather than recent ingestion. However, it could be 
hypothesised that as zopiclone is known to act in a similar way to 
benzodiazepines, and be both lipophilic in nature and quite highly protein bound, 
that it is not often seen in vitreous. Conversely though, a review of results from 
this study showed that this is the only case where zopiclone has not been 
detected in vitreous when it has been detected in other matrices, it was found in 
2 other cases in both blood and vitreous, and in another study it was detected in 
8 cases in vitreous compared to 10 in urine, (Pelander, et al., 2010).  
In case 3873, the presence of citalopram and metabolite in the liver fluid and 
detection of no drugs in the stomach contents only indicates that the drug was 
used at some time prior to death but probably not recently before death. 
However, it is impossible to determine if this drug was used excessively prior to 
death and therefore, overdose cannot be ruled out. 
In case 1003, by the time the body was found, decomposition was quite 
advanced, it was not possible to collect blood from the femoral vein, so instead 
fluid was collected from the pleural cavity; bile and stomach contents were also 
collected. It is interesting that the comparison of the pleural cavity and bile 
screening results are very similar, only one metabolite was detected in the 
pleural cavity that was not present in the bile, and this was the diazepam 
metabolite, (nordiazepam). Tramadol and metabolite, o-desmethyltramadol 
(ODT) were measured in the fluid and when compared to femoral blood levels 
they would be consistent with an overdose prior to death, the presence of 
tramadol in the stomach indicated recent ingestion prior to death. However, as 
the blood was not collected from the recommended site (the femoral vein), the 
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measured concentrations of the cavity blood could have been elevated due to 
post-mortem redistribution resulting in the relative concentrations mimicking the 
more “concentrated” bile fluid content.  
 ALTERNATIVE MATRICES ONLY 4.4.1.5
In case 2498, the presence of carbamazepine in both vitreous humour and the 
stomach contents, suggests recent use prior to death. However, it is difficult to 
comment on the significance of the measured concentration, (1.53 mg/L) as this 
was the only case in this study where it was possible to measure 
carbamazepine in this matrix, so there are no other cases where blood was also 
measured, to compare it to. No published data was found to help with this 
interpretation. 
 DRUG QUANTITATION  4.4.2
 VITREOUS HUMOUR 4.4.2.1
It has been reported that while the blood:vitreous ratio for some drugs is close to 
unity, this is not true for all drugs, (Jones, 2004) and the results from this study 
were rarely an exception to this, (Table 4.13).  
However there were 2 cases where the measured concentrations were slightly 
higher in vitreous than blood, one with tramadol and ODT, and the other 
pethidine and norpethidine but the differences are so slight, that the significance 
is questionable, and they could actually be considered to be quite close to unity 
which would again support the literature. If the results are significant then 
perhaps tramadol and pethidine are exceptions to the rule, although without 
other similar results it is not possible to say. Another possible scenario is that 
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the difference in drug concentrations could be due to timing. Samples were 
collected 4 days after death, and received in the laboratory 12 days later. They 
were refrigerated on receipt and analysed 14 days later. So there were 30 days 
between death and analysis could this have impacted on the results. Is it 
possible that tramadol could have been lost from the blood but preserved in the 
vitreous.   
For the pethidine case, the timings were reviewed: specimens collected 
collected 4 days after death, and received in the laboratory 9 days later. They 
were refrigerated on receipt and analysed 7 days later. So during the 20 days 
between death and analysis is it possible that pethidine could have been lost 
from the blood but preserved in the vitreous.   
As tramadol and pethidine are both opioids notionally this may provide a 
structural reason to explain why there were higher concentrations in vitreous 
compared to blood. However, this seems unlikely as methadone (another 
opioid) was measured in 4 cases and found to be considerably lower in vitreous 
than in blood. The vitreous:blood ratios were very varied with the greatest 
difference reading 6 times lower in vitreous than in blood but in another case the 
concentration in vitreous was half that in blood. It is possible that the differences 
in the methadone results could be due to differences between individuals and 
their metabolism of methadone, as described for the codeine volunteer studies 
(see section 3.3.1.4). However, it might be considered that comparison of 
vitreous:blood ratios, rather than individual concentrations, should take these 
differences into account. 
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The observed concentrations for the benzodiazepines, lower levels in vitreous 
compared to blood, Table 4.13, supports the literature. A similar trend was 
reported in a study where diazepam, nordiazepam and temazepam blood levels 
were compared to vitreous in 17 cases, although the mean levels were found to 
be close to unity, the range of results were found to be quite varied, but in all 
cases the highest and mean concentrations in vitreous were lower than in blood 
(Scott & Oliver, 2001), this could be due to the highly lipid-soluble nature of 
benzodiazepines (Jones, 2004). 
For highly protein bound drugs, such as tricyclic antidepressants, similar 
findings have also been reported, where concentrations in vitreous were again, 
found to be a lot lower than in blood, (Jones, 2004). 
Although in case 668, (refer to Table 4.14) it was not analytically necessary to 
quantify the clomipramine (a tricyclic antidepressant), it seems feasible that 
screening result alone could support the literature as the drug was detected in 
the blood but not in the vireous. In terms of timing, the case information states 
that the deceased was found dead at home on 21/05/12, last seen on 19/05/12, 
with a note in a diary indicating that she planned to take her own life. All 
samples were collected on 27/05/08 and received on 30/05/08, the blood was 
screened on 02/06/08 and propranolol was quantified in both blood and vitreous 
on 06/06/08 and the vitreous was also screened on this date. 
In another case, (case 2591), amitriptyline (another tricyclic antidepressant) was 
detected in the blood and the vitreous but as the levels appeared very low on 
the screen, no quantitations were toxicologically necessary. Without 
concentrations, it is difficult to comment on the significance of this result. As far 
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as timings go, date of death was 21/05/09, all samples were collected and 
received at the laboratory on 26/05/09, analysis was carried out on the blood on 
27/05/09 and on the vitreous on 02/06/09. Comparison of the timings of this 
case with the previous, (Table 4.22), shows that analysis was carried out at 
least 7 days more quickly in this instance, if stability of the tricyclic 
antidepressants in vitreous is an issue then this time difference could account 
for the detection of amitriptyline in the one case, compared with the absence of 
clomipramine in the other. 
 
 
Case 668 Case 2591 
Date 
Days 
elapsed 
Date 
Days 
elapsed 
Found Dead 21/05/08 (0 – 2?) 21/05/09 0 
Samples collected 27/05/08 6 26/05/09 5 
Samples received 30/05/08 3 27/05/09 1 
Samples Analysed 
02/06/08 (bl) and 
06/06/08 (vit) 
3 (bl) 
And 7 (vit) 
02/06/09 6 
Total days since 
death 
 
12 – 14 (bl) 
19 – 21 (vit) 
 12 
Key: bl = blood, vit = vitreous humour 
 
Table 4.22 Results of timings of samples in TCA in blood versus vitreous 
cases 
 
 
 BILE 4.4.2.2
The similarities observed between the blood:bile ratios for clobazam and 
lorazepam could be attributed to them both been benzodiazepines with 
similarities in structure, properties and mechanisms of action, (refer to figure 
4.8). However, this is not a likely scenario given that similar blood:bile ratios are 
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also seen between amphetamine and lamotrigine which are known to be very 
different drugs, with very different structures, (refer to figure 4.9). 
 
Figure 4.8 Structures of lorazepam (left) and clobazam (right) 
 
Figure 4.9 Structures of lamotrigine (left) and amphetamine (right) 
 
It is therefore, more likely that the similarities in blood:bile ratios are due to the 
timing of events rather than any structural similarities. In the valproate case, as it 
was not detected in the blood above the limit of detection for the assay (12.5 
mg/L), it was not possible to calculate a blood:bile ratio but it has still been 
included in the results table (4.15), as the bile measurement proved very useful 
in this particular case as previously described. 
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 DRUG STUDIES 4.4.3
 MORPHINE AND HEROIN RELATED COMPOUNDS 4.4.3.1
VITREOUS HUMOUR 
One possible scenario for the difference in the results between cases could be 
due to timing, i.e. collection time compared to time of analysis, particularly if 
stability is an issue. Once received in the laboratory all samples are stored in the 
fridge at 2-5°C, prior to analysis then stored in the freezer at -20°C, when all 
analysis is complete.  
For Case 260, (refer to Table 4.16) the samples were received 11 days after 
collection, during this time the storage conditions were unknown. The blood was 
analysed 27 days later, and the vitreous 31 days later. Despite this delay, 6-
MAM was still detectable in the vitreous and papaverine in the blood. For Case 
277 the samples were received 8 days after collection, during this time the 
storage conditions were unknown. The blood was analysed 25 days later, and 
the vitreous 29 days later. After this delay, 6-MAM, noscapine and papaverine 
were all detectable in both matrices. This is an important result as it proves that 
it is possible to detect all 3 analytes in vitreous and therefore acts as a positive 
control which suggests that there is not a physical or structural reason why they 
could not be detected in this matrix. For Case 1441 all samples were submitted 
to the laboratory on the day of collection, both blood and vitreous were analysed 
13 days after this, and noscapine alone, was detected in both matrices. The 
different findings in these results suggest that it is not a delay between collection 
and analysis that is responsible for the different results. 
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Although 6-MAM was detected in vitreous, in more cases than the 
corresponding blood, there is not enough data (n=3), to prove or disprove the 
theory. However, the results do demonstrate that in the cases compared, if only 
vitreous had been submitted for analysis, heroin use would have been detected. 
In another study, 25 samples of both blood and vitreous humour were analysed 
for 6-MAM. All the samples were from heroin deaths and 6-MAM was found in 
13 of the blood samples and all of the vitreous samples, (Wyman & Bultman, 
2004).    
In this study, the vitreous to blood ratio is quite comparable between the 2 cases 
(260 and 277) but without any other data it is difficult to comment. It has been 
found previously that no correlation existed between 6-MAM levels in blood and 
vitreous humour, (Scott & Oliver, 1999).  
STOMACH CONTENTS 
Although specific morphine analysis was not carried out on the stomach 
contents, the HPLC screen used, was able to detect morphine, 6-MAM, 
papaverine and noscapine.  
Morphine was detected in the stomach contents of 6 Cases, all of them had 
morphine, M3G and M6G present in the blood, with nothing to indicate heroin 
use, i.e. 6-MAM, papaverine or noscapine, (see Table 4.17). There was no 
codeine detected in the urine of any of these cases either, this can sometimes 
indicate heroin use as acetylcodeine is a manufacturing impurity (1-15%) of 
heroin, and this is readily deacetylated to produce codeine, which is 
subsequently metabolised to morphine, (O'Neal & Poklis, 1998), (Staub, et al., 
2001). 
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Noscapine was detected in the stomach contents of 3 Cases, (all of which also 
had noscapine present in blood and urine) and 6-MAM was detected in the 
stomach contents in one case, (where it was also present in the blood and 
urine).  
For the six cases where morphine was detected in the stomach contents, blood 
and urine it could be assumed that morphine had been ingested orally, recently 
prior to death. 
However, for the other 4 cases, where there is evidence of diamorphine (heroin) 
use, the interpretation could be more complicated. As heroin is not usually orally 
ingested it would be easy to assume that it would not be detected in the 
stomach contents, however there is published data that contradicts this 
prediction. In one publication, Duflou et al., 2009, give details of 29 heroin 
overdoses, (where there was death scene evidence of intravenous use) and 
morphine was detected in the stomach contents of all cases. This is thought to 
be due to the reflux of morphine from the duodenum into the stomach, which 
appears to be normal after death (Duflou, et al., 2009). In another report, 
Kerrigan et al., 2004, found morphine in the stomach contents of a single case 
of a pancreatic cancer patient who was fitted with an intravenous catheter. This 
raises some questions about the results seen in this study: if morphine can be 
found in the stomach contents then is it possible that the noscapine and 6-MAM 
detected could have also got there via the same route? It is also necessary to 
question if the stomach contents collected could have been contaminated in any 
way i.e. during collection and is it definitely “true stomach contents” that was 
collected. 
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Although 6-MAM was only detected in the stomach contents in one case in this 
study, there is a report which obtained similar findings, where 23 samples of 
gastric contents were analysed for drugs and poisons and in one case 6-MAM 
was found in the blood by GC-MS and in the stomach by HPLC, (Politi et al., 
2004). It is possible that the 6-MAM seen in the stomach contents is a 
breakdown product of diamorphine formed by hydrolysis. However, if this was 
the case then morphine would also be expected to be detected, (refer to fig ??), 
but it was not found in either of the case examples, e.g. this study or the study 
reported by Politi et al., 2004. 
LIVER 
In Case 3504, (refer to Table 4.12) a body was found in a very decomposed 
state, only liver and stomach contents were available for analysis. It was clear 
from the circumstances that heroin use was suspected so the analytical plan 
was to analyse the liver fluid for morphine by solid phase extraction and screen 
the stomach contents for the presence of any basic, neutral or acidic drugs and 
screen the liver for any basic drugs. . 
The results showed that the screening methods detected no drugs or 
metabolites, but the morphine analysis detected morphine, M3G, noscapine and 
papaverine in the liver. This confirmed morphine and/or heroin use, at some 
time prior to death and this is an example where an alternative matrix (liver), 
proved to be useful, even without blood or urine submissions. However, it was 
not possible to determine from the liver specimen alone, (i.e. without a blood 
specimen) whether such heroin use was recent or excessive prior to death. In 
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addition to this, if only the stomach contents had been submitted for this case, 
no drugs would have been detected.     
 CODEINE 4.4.3.2
The presence of codeine (and other drugs) in the stomach contents, indicate 
recent ingestion prior to death, and all 4 cases are suspected multi-drug 
overdoses, Table 4.18. Although based on few findings, this scenario was found 
to be common in supporting literature where it states, in most fatalities involving 
codeine other drugs, and or alcohol is present, (Moffat, et al., 2004, p. 847). 
In 3 out of the 4 cases paracetamol was also detected which could indicate that 
a combined preparation of codeine and paracetamol had been used. 
For the blood versus vitreous results, it is necessary to consider that the time-
scale could have had an impact on the unexpected result, (refer to Tables 4.19 
and 4.20). It is possible that from the time of death until collection (delay of 23 
days) that the codeine was lost from the blood but preserved in the more stable 
vitreous humour matrix. 
LIVER 
In case 2937, (refer to Table 4.12), the results indicated ingestion of the codeine 
some time prior to death but could not give any indication of whether the level 
ingested was significant or excessive. The presence of putrefactants suggest 
that the deceased may have been dead for some time before the body was 
found, and may have been in a decomposed state. This could explain why blood 
and urine were not submitted for analysis. It is likely that had blood been 
available, results would have proved more useful and that this is an example of 
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the limited use of alternative matrices (liver and stomach contents) when 
submitted without the traditional blood and urine matrices.  
 DIAZEPAM 4.4.3.3
The presence of nordiazepam in the stomach contents of 8 separate cases was 
an unexpected result. In 4 of these cases both diazepam and nordiazepam were 
detected in the stomach contents, in 2 of the cases diazepam was detected in 
the blood and in another nordiazepam was found in the blood. A possible 
scenario could be that that diazepam has broken down in the stomach contents 
to produce nordiazepam. However, an N-desmethylation process (removal of a 
methyl group, refer to Figure 4.7)  is not likely to occur in the stomach because 
the enzymes required for the process are not present here, they are in the liver. 
Therefore it seems more likely that the metabolite is present in the stomach due 
to back diffusiuon after death.  
 COCAINE 4.4.3.4
Cocaine was detected in the urine of 14 cases but was only detected in 5 of the 
corresponding blood samples, (see Table 4.21). This is most likely because 
cocaine is known to be unstable in blood, and although some types of preserved 
container can help with stability, it can still be detected in urine for longer. 
Vitreous humour was received in 2 of the urine positive cases, (939 and 959) 
but cocaine was not detected in the vitreous of either case. However, in case 
959, levamisole was detected in both the urine and the vitreous, and although 
this drug is used to treat roundworm infections; it is also commonly encountered 
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as a contaminant in some batches of cocaine. Therefore, its presence in this 
particular case, could help to confirm cocaine use. 
The cocaine detected in the stomach contents (case 491) was an unusual result 
as due to the usual routes of administration i.e. Injection, inhalation or smoking, 
you would not necessarily expect to find it there. However, as discussed for 
morphine, a drug or metabolite in the stomach does not necessarily mean that it 
was taken orally; gastric juice (formed from extracellular fluid) is constantly 
being secreted into the stomach, this may contain some drugs or metabolites 
circulating in the blood, (Jones, 2004). In addition to this it is possible for 
diffusion to occur after death. Active processes stop after death and the 
permeability of the gut wall has been known to increase, e.g. ethanol which is 
absorbed from the small intestine in life, can diffuse across the stomach wall 
after death into adjacent tissues and blood vessels, (Ferner, 2008). For this 
reason, vitreous humour is commonly used for ethanol measurement as this is 
thought to be unaffected by post-mortem re-distribution.   
In this particular case the blood cocaine level was very high (6.9 mg/L typically 
>2mg/L is fatal) and benzocaine was also detected in both the stomach and 
blood. Benzocaine is a local anaesthetic but it is also commonly used as a 
contaminant or “bulking agent” in some batches of cocaine. 
 AMPHETAMINE 4.4.3.5
The lack of amphetamine in the stomach contents could be due to the route of 
administration, as previously described. In all 3 cases where amphetamine was 
detected the individuals were known drug users, (so most likely not adverse to 
snorting) and case 4023, was found n possession of a white powder, although 
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this was not submitted for analysis, so whether it was actually amphetamine 
remains unconfirmed. Vitreous humour was not submitted for analysis for any of 
these cases, it would have been interesting to see whether amphetamine, with 
its lipophilic nature, would have been detected in the vitreous, as one might 
expect.  
 METHADONE 4.4.3.6
The presence of methadone in the stomach contents of 12 cases is an 
indication that it was taken recently prior to death and the absence of the main 
metabolite would be expected, as metabolism does not usually occur in the 
stomach. Although the presence of a drug in the stomach does not necessarily 
confirm or rule out an overdose, as a point of interest, with other drugs the 
measured blood levels have been used to indicate if a drug, (most likely) 
responsible for an overdose was detected in the stomach. However, it is difficult 
to draw any such conclusions with methadone as the toxicological significance 
of the blood methadone concentration depends upon the degree of tolerance 
possessed by the deceased, e.g. in non-addicted subjects plasma concentration 
of >2 mg/L could be lethal but in 13 methadone maintenance patients who died 
of accidental methadone overdose, the post-mortem blood concentrations 
ranged from 0.18-4 mg/L, (Baselt, 2011, p. 1021-1024), (Moffat, et al., 2004, p. 
1231-1232).  
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The validated methods for oral fluid analysis and their application to the studies 
carried out, suggests that for drugs of abuse testing, oral fluid could be a 
suitable matrix. However, it is important to be aware of the limitations, and 
remember that when using oral fluid for drug detection, it will only reflect drug 
use in the previous 2 to 3 hours before sample collection. If a more detailed 
insight is required, e.g. a reflection of drug use in the past 12-24 hours then a 
more suitable matrix will need to be used for analysis. A good example of this 
was shown in the Clinic study, when results of oral fluid testing were compared 
to urine, results revealed that two cocaine positive and three morphine positive 
results would have been missed if only the oral fluid had been tested, rather 
than both matrices.  
In addition to this, the relatively low volume of oral fluid specimens could 
continue to be a problem for this matrix. For example, after drug screening there 
might not be enough sample remaining to complete all the necessary 
confirmation and / or quantitation tests required. In the studies conducted, 
approximately 1 mL oral fluid was collected and this was added to a 
preservative buffer, to give a total of 4 mL sample so although this gave greater 
sample volume, the collection process introduced another problem, which was 
dilution of analytes by a factor of 4, when the levels detected in oral fluid are 
already considered to be relatively low. This resulted in problems with analysis 
as it proved difficult to validate methods with such low levels of detection and 
quantitation required, (refer to Table 3.1).  
One of the possible outcomes from this study was to replace an existing urine 
drug screening provision with oral fluid. The existing service offered urine testing 
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for amphetamines, opiates, cocaine metabolite, methadone metabolite, 
benzodiazepines, cannabis as well as a validity test for urine (creatinine) and 
buprenorphine testing when required. Ideally, methods would have been 
developed and validated for all these analytes but unfortunately due to the 
difficulties encountered reaching the required limit of detection and the time 
spent on method development, this was not achieved. Unfortunately, the 
development of screening methods which should have been relatively straight 
forward, proved very difficult and time-consuming. Initially it was planned for 
screening to be carried out in much the same way as it was done for urine 
samples that was to use CEDIA immunoassay reagents, on an automated 
analyser that was already in the laboratory. However, the oral fluid kits were still 
in the “early in-house research” stages when they were required for this study 
and so it was not possible to obtain any kits, even for research purposes. It was 
for this reason that ELISA screening was investigated but as this was a new 
technique to our laboratory, this involved the purchase of new equipment which 
involved a long time-delay. The overall result was that to fill-in the time delay 
(required to purchase an ELISA plate-reader), the confirmation methods for 
opiates and benzoylecgonine were validated and in-house volunteer studies 
were completed, before the ELISA screening could be investigated.  
The methods were validated in order of priority, (from a rehabilitation clinics 
point of view, at least). When validation of the most important drugs was 
completed a rehabilitation clinic was contacted with the idea of the study and 
this was set up. However, due to the length of time taken to validate the other 
analytes, for both screening and confirmation methods, work on 
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benzodiazepines and cannabis in oral fluid, never really got started. However, if 
these assays had been validated, the small sample volume could have been an 
issue and a choice would have had to be made in which confirmation tests were 
carried out, i.e. some kind of priority order would have needed to be established. 
For this reason, for the clinic study conducted, both benzodiazepines and 
cannabis were screened for in the corresponding urine. This means that until 
further work has been carried out, the oral fluid protocols put forward in this 
study, could not replace the existing urine service offered. 
In order for oral fluid to be considered for workplace drug testing, the SAMHSA 
proposed cut-off levels needed to be achieved, (see Table 3.1). The results 
showed that although the cut-off levels were achieved for some drugs it was not 
possible for others, the amphetamines (except for MDMA) and the opiates, 
(except for 6-MAM) were successfully validated at the low levels but 
benzoylecgonine and 6-MAM were not, (see Table 4.23). This meant that further 
work would need to be undertaken, (to achieve the outstanding cut-off levels) 
before oral fluid could be included in a work place drug testing service. 
However, this would not necessarily be a difficult task as since the oral fluid 
work was carried out (2004 – 2007), more sensitive techniques have become 
available, such as tandem GC-MS which would easily detect down to the 
required levels. In addition to this CEDIA immunoassay kits for oral fluid analysis 
are now also commercially available and have been running successfully on 
automated analysers for over 2 years in several laboratories. This would be a lot 
less time-consuming than the ELISA screening techniques investigated in this 
study and would probably use less sample volume and be more versatile than 
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the LC-MS screening technique that was validated but would obviously require 
further confirmation of positive results, (which is not required following the LC-
MS screen).   
Oral Fluid 
(ng/mL) 
Proposed 
SAMHSA 
cut-off 
concentration 
Cut-off 
concentration when 
diluted 1 in 4 with 
buffer 
LOQ / LOD for 
validated methods 
Analyte Screen Conf Screen Conf Screen Conf 
Cocaine 
metabolite 
20 8 5 2 
1 
(parent) 
15 
Opiates 40 40 10 10  10 
6-MAM 40 4 10 1  5 
Amp 
MA 
MDMA 
MDA 
50 
50 
50 
50 
50 
50 
50 
50 
12.5 
12.5 
12.5 
12.5 
12.5 
12.5 
12.5 
12.5 
3.5 
1 
3.5 
5 
10 
10 
15 
10 
Key: Screen = screening, conf = confirmation 
 
Table 5.1 Comparison of SAMHSA cut-off levels to those achieved in the 
study , (SAMHSA, 2004). 
 
There are certain situations where drug use within the past 2-3 hours could be 
very relevant and a good example of this is driving under the influence of  
drugs.  
Oral fluid has the added advantage that as it reflects free, unbound parent drug, 
(and these are the forms that cross the blood-brain barrier and effect 
performance and behaviour), presence of drug(s) should correlate well with 
impairment, (better than with urine metabolites), (Spiehler, et al., 2002). 
The idea of using oral fluid for roadside drug testing has been around for a long 
time but the problem of low sample volume has been a major issue. An early 
study was carried out in 1983, the aim was to get 3 mL per specimen (by 
spitting) but in reality only between 1 and 1.5 mL was actually obtained. Out of 
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56 drivers, cannabinoids were found in six cases and diazepam in 4, 
(Verstraete, 2005). In a German roadside study, carried out in 1992, 32.6% of 
the samples collected were essentially dry (<0.1mL), and out of the remaining 
samples the mean volume collected was only 0.42 mL. This meant that for the 
majority of samples collected they were not able to screen for the intended full 
panel of drugs, (Verstraete, 2005).  
By the late 1990s, on-site oral fluid testing devices had been developed, and the 
effectiveness of some of these was tested by The Roadside Testing 
Assessment Project (ROSITA) which was set up by the European Commission. 
ROSITA 1 took place in 1999 and 2000 and involved 8 Countries, it compared 
15 urine and 3 saliva on-site tests. Out of 2986 subjects, it was reported that it 
was possible to obtain oral fluid in nearly all the cases. The overall conclusion 
was that the present-generation of on-site oral fluid tests was insufficiently 
sensitive and / or specific to give reliable results for most classes of drugs, in 
addition to this the testing devices were thought to be too complex and time-
consuming, (Verstraete & Puddu, 2000), (Samyn, et al., 1999a). 
The ROSITA-2 project was carried out from 2003 to 2005, and it was set up to 
evaluate the usability and analytical reliability of 9 on-site oral fluid drug testing 
devices. 2046 subjects were included in this study and 2605 device evaluations 
were performed. Results showed that for some devices a very high percentage 
of failures were observed, this was apparently due to either too little or too 
viscous oral fluid. None of the devices met the criteria proposed during the 
ROSITA-1 project (sensitivity >90%, accuracy >95%) for the amphetamines, 
benzodiazepines and cannabis. Only one device met this criteria for cocaine 
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and opiates but it gave 26% failures so could not be recommended. The 
operational evaluations revealed further problems (apart from high failures and 
short samples), in general devices were complicated to operate or results were 
difficult to read or problems were encountered in rain or cold weather. At the end 
of the study none of the devices were considered reliable enough to be 
recommended for roadside screening of drivers, (ROSITA - Roadside Testing 
Assessment, 2010).  
In Germany, Spain and Australia, roadside drug testing is routinely carried out 
yet in the UK, currently police have to demonstrate that driving has been 
impaired in order to prosecute. However, this is all set to change as in May, 
2012, it was revealed that a new driving offence would be created, and this was 
confirmed in the Queen’s speech. It will be an offence to drive a motor vehicle if 
you have certain controlled drugs in your body in excess of specified limits. 
Police will be equipped with hand-held devices to test oral fluid at the roadside. 
An expert panel have the job of deciding which drugs will be covered by the 
offence and the specified limits for each. The Department for Transport state 
that the new offence should be in place by 2015, (Department for transport, 
2012), (BBC News, 2012). A decision is yet to be made about how the presence 
of drugs found at the roadside will be confirmed and this will need careful 
consideration. If more than one drug type is found to be positive, will there be 
sufficient sample volume to confirm all the findings and if not will a protocol be 
put into place to advise how such confirmatory tests could be prioritised.  
In general, for the analysis of drugs in clinical cases, it is possible to choose 
which matrix suits your need best or even use several matrices to give a full 
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picture of an individual’s drug usage, if this is required, desired or necessary. 
However, with post-mortem samples this is far from the truth. The availability of 
matrices is often limited by the nature of the death, e.g. in any type of vehicular 
crash samples can be lost as the body is dismembered, in fires samples can be 
burnt away, in drownings extreme water exposure can affect samples and 
speed up decomposition. In addition to this if a body is not found for a few days 
or more after death, it will start to decompose which means that bacteria that 
exist in the body during life, start to break it down, starting with the intestines 
they break out and move onto the organs, releasing digestive enzymes as they 
go, which help to break down organs and tissues. The greater the extent of this 
process the more difficult it is for the pathologist to collect samples from specific 
sites, in the most advanced cases it is only possible to collect blood from the 
central body cavity. This obviously leads to extreme difficulty for interpretation of 
results.  
As well as these issues, following the revision of the Human Tissue Act, 2004, 
pathologists were suddenly unclear about what samples they were “permitted” 
to collect and as a result of this “confusion”, far fewer samples were collected 
and consequently less alternative matrices were submitted for analysis.  
In addition to this the HT Act also implies that if a diagnostic result can be 
obtained from the analysis of one sample then there is no need to analyse 
further samples, so this also led to the collection of less samples, e.g. the 
sampling of blood from more than one vein or artery was no longer an option.   
This had quite a negative impact on this study, over a period of 26 months only 
10% of the cases received included alternative matrices, with the majority only 
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sending blood and urine for toxicological analysis. This was that a lot less than 
expected, when the study was originally designed.  
Results showed that collection of stomach contents was impacted on the least, 
as it made up 87% of the alternative matrix total submissions. A significant 
proportion of these findings were negative, e.g. no drugs were detected, and 
such results can prove useful to exclude recent oral ingestion of drugs prior to 
death. However, this does not necessarily rule out the possibility of an oral 
overdose because it could take several hours to die from a drug overdose and 
during this time most or all of the drug could have passed from the stomach to 
the small intestine or may even have been absorbed, (Jones, 2008).  
In cases where drugs were found in the stomach contents, this largely indicates 
recent oral ingestion prior to death (although not necessarily as they could be 
present due to back diffusion after death), but it does not mean that a drug 
overdose has definitely been taken. There was evidence from results in this 
study that drugs could be detected in the stomach contents but not be present in 
the blood and could therefore not be responsible for an overdose. There was 
also evidence that often drugs found to be responsible for an overdose, (by the 
measurement of blood concentrations), were found in the stomach contents.   
The main limitation with the analysis of stomach contents is that it is purely for 
drug screening purposes only (and not for quantitation).   
A drug screen can be considered successful, if the results provide an answer to 
the question “are there any drugs present?” It is evident that the variety of 
stomach contents results compared to traditional matrices, and to some extent 
to other alternative matrices, under different case circumstances, can answer 
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this question, and there have been good case examples where drug screening 
results from vitreous humour, bile, liver and muscle could easily do the same.  
However, as useful as drug screening can be, it does not really provide an 
answer to the all-important question: “have drugs (or poisons) either caused or 
contributed to the death in question?” 
To answer this question it is necessary to measure the drugs detected, (through 
screening) and use the concentrations determined, to interpret the findings.  
In order to assist with this, concentrations of drugs in bile and vitreous humour 
would be measured alongside those in blood to see how they compared. It was 
hoped that this information could then be used to interpret concentrations 
measured in alternative matrices, in cases where there were no traditional 
matrices available, as there is little published data available to help with this. 
Unfortunately, mostly due to the relatively low number of suitable submissions, it 
was only possible to quantify drug levels, in a limited number of samples.  
Comparison of blood and vitreous results, and vitreous:blood ratios (of which 
there are 26) shows a mixture of results, between some of the same drugs, and 
then between drug classes. With such a spread of results, there were no clear 
trends, with the exception of vitreous levels being generally lower than the 
corresponding blood levels. Scott and Oliver, 2001, also found inconsistencies 
between blood and vitreous concentrations, in their study; they found some 
correlation between temazepam and diazepam but no correlation for the 
metabolite, desmethyldiazepam, (nordiazepam). 
For bile, it was only possible to measure six concentrations alongside blood and 
these results also showed little trend, other than that the concentrations in bile 
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were higher than in the blood, this was expected as many drugs have been 
shown to accumulate in the bile.  
Overall it seems that any of the alternative matrices investigated in this study 
could be effectively used for drug screening. The use of oral fluid for on-site 
testing would mean that a sample could be collected under supervision and 
analysed. Any subsequent confirmatory testing could be carried out on either 
the remaining oral fluid sample or on a urine sample but this would only need to 
be collected if indicated by the screening test. In the event of a fatal road traffic 
collision, in order to preserve a limited blood sample, vitreous humour and 
stomach contents, could be used for drug screening and then any confirmatory 
tests and/or quantitations could be performed on the blood.    
Where there is a choice of drug matrices for analysis, it is important to consider 
the question being asked, and in accordance with this the drug detection times 
for each matrix, then an informed decision can be made, on the type of analysis 
that would best fit the requirement. 
In cases where only alternative matrices are available, it should be possible to 
determine if any drugs are present or absent but any specific confirmations, and 
or measurements could either be restricted by low sample volume, e.g. 
particularly for oral fluid and vitreous humour, or if they are performed could still 
prove difficult to interpret. 
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5.1 CONCLUSIONS 
 Alternative matrices have proved to be very effective for the screening of 
drugs 
 When analysed alongside traditional matrices or in conjunction with each 
other, the results can provide a very good insight to an individual’s drug 
use 
 Although it is possible to perform confirmatory tests and / or measure 
concentrations in alternative matrices, these extra tests may be 
prevented by limited sample volume, particularly for vitreous humour and 
oral fluid 
 Where concentrations are determined in alternative matrices the results 
can  prove difficult to interpret  
 Alternative matrices can provide a good insight into drug use but are 
some way off replacing traditional matrices 
 For the analysis of clinical cases urine and blood/serum or plasma will be 
the primary matrices, with oral fluid as a secondary choice 
 For the analysis of post-mortem cases blood and urine will be the primary 
matrices with vitreous humour as a secondary choice but there will be 
circumstances where stomach contents, bile and other matrices will be 
used  
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 APPENDICES 7
 
A-1 
APPENDIX A   
Analyte (including 
metabolites)  
Expected 
Ret.Time 
(mins)  
Std. 
Range 
(mg/L)  
ISTD + Concn 
(mg/L)  
ISTD 
Expected 
Ret. Time 
(mins)  
Extraction 
Procedure 
Isocratic 
Conditions 
(% MeCN)  
Total 
Run 
Time 
(mins)  
QC 
concns 
(mg/L)  
Atenolol 1.55 0.625 - 
10 
Cinchonine              
0.5 mg/L 
4.42 Basic 10% 6 0.5, 5.0 
Amitriptyline   
Nortriptyline  
5.26             
4.74 
0.125 – 2  Promazine                
2 mg/L 
3.98 Basic  30% 7 0.1, 10  
Amphetamine  2.28 0.0625 – 
1  
Cinchonine               
1 mg/L 
3.25 Basic  10% 5 0.075, 
0.75  
Caffeine  1.58 3.125 – 
50  
Norfenfluramine     
10 mg/L 
2.48 Basic  25% 6.5 2, 20  
Carbamazepine  2.34 0.625 – 
10  
Clobazam                 
2 mg/L 
3.97 Benzo  40% 7 1, 5  
A-2 
Chlordiazepoxide  
Demoxepam  
1.89             
3.32 
0.1325 - 
5  
Clobazam                 
2 mg/L 
7.64 Benzo  30% 9 0.2, 2  
Citalopram  
 
2.77 0.125 – 2  Brompheniramine 1.91 Basic  30% 5 0.2, 2  
Clobazam      
Norclobazam  
4.58             
3.07 
0.03125 
– 0.5  
Nordiazepam            
2 mg/L  
3.74 Benzo  40% 8 0.1, 1  
Clozapine 1.99 0.25 – 4 Desipramine             
2 mg/L 
4.6 Basic 30% 6 0.2, 2.0 
Codeine  2.9 0.3125 – 
5  
Cinchonine               
2 mg/L 
4.43 Basic  7% 6.5 0.2, 2  
Cocaine  1.69 0.125 – 2  Desipramine             
2 mg/L 
4.08 Basic  30% 6 0.2, 2  
Cyclizine  2.61 0.3125 – 
5  
Promazine                
1 mg/L 
3.69 Basic  30% 6.5 0.2, 2  
Dextropropoxyphene 
Nordextropropoxyphene 
4.68             
4.16 
0.125 – 2  Promazine                
1 mg/L 
3.8 Basic  30% 6 0.15, 5  
A-3 
Diazepam      
Nordiazepam  
5.75             
3.84 
0.3125 – 
5  
Clobazam                 
2 mg/L 
4.15 Benzo  40% 7 0.2, 2  
Diltiazem 3.6 0.625 – 
10 
Desipramine      
2mg/L 
4.77 Basic 30% 6 0.2, 2.0 
Diphenhydramine  2.71 0.625 – 
10  
Desipramine             
2 mg/L 
4.15 Basic  30% 6 0.5, 5  
Dipipanone  10.67 0.3125 – 
5  
Desipramine             
2 mg/L 
4.3 Basic  30% 14 0.1, 1  
Dosulepin (dothiepin)  2.6 0.125 – 2  Clomipramine          
2 mg/L 
4.41 Basic  35% 7 0.15, 1.5  
Fluoxetine    
Norfluoxetine  
3.68 0.3125 – 
2  
Desipramine             
2 mg/L 
7.74 Basic  30% 10 0.15, 1.5  
Hydroxychloroquine  2.74 0.625 – 
10  
Cinchonine               
2 mg/L 
3.23 Basic  10% 6 0.5, 5  
Imipramine     
Desipramine  
4.25             
3.85 
0.125 – 2  Clomipramine          
2 mg/L 
7.74 Basic  30% 10 0.15, 1.5  
Ibuprofen 7.75 6.25 – 
100  
Naproxen                 
10 mg/L 
3.6 Acid 45% 9 10, 50 
A-4 
Lamotrigine 1.74 0.625 – 
10  
Brompheniramine    
5 mg/L   
3.07 Basic  25% 5 1.0, 5.0 
Methadone  5.44 0.125 – 2  Desipramine             
2 mg/L 
4.14 Basic  30% 7 0.1, 1  
Mirtazapine  2,25  0.625 – 
10  
Brompheniramine     
1 mg/L 
3.71 Basic  20% 5 0.15, 1.5  
Naproxen  3.18 0.156 – 
25  
Ibuprofen              
100 mg/L 
6.51 Acidic  45% 13 4, 40  
Nitrazepam  2.66 0.125 – 2  Clobazam                 
2 mg/L 
3.79 Benzo  40% 6 0.1, 1  
Olanzapine  2.73 0.3125 – 
5  
Cinchonine               
5 mg/L 
3.24 Basic  10% 7 0.2, 2  
Oxycodone  2.93 0.125 – 2  Cinchonine               
1 mg/L 
3.52 Basic  10% 6 0.1, 1  
Orphenadrine  4.11 0.625 – 
10  
Desipramine             
1 mg/L 
4.7 Basic  30% 6 1, 5  
Paracetamol 2.56 6.35 – 
100 
2-AP                         
50 mg/L 
4.82 10 10% 6 10, 50 
A-5 
Phenytoin  2.44 0.625 – 
10  
Clobazam                 
2 mg/L 
4.15 Benzo  40% 7 1, 5  
Promazine 2.63 0.625 – 
10 
Clomipramine          
2 mg/L 
4.95 Basic 35% 6.5 1, 5 
Propranolol  2.26 0.625 – 
10  
Desipramine             
2 mg/L 
3.36 Basic  30% 6 1, 5  
Quetiapine  2.42 0.625 – 
10  
Desipramine             
2 mg/L 
4.24 Basic  30% 11 0.15, 15  
Quinine  1.8 1.25 – 20  Brompheniramine     
2 mg/L  
4.48 Basic  20% 6 3, 15  
Salicylate 5.09 31.25 – 
500 
2-AP                       
100 mg/L 
2.48 Acid 20% 6.5 75, 150 
Sertraline       
Norsertraline 
7.15             
6.36 
0.3125 - 
5      
0.03125 - 
0.5 
Desipramine             
2 mg/L 
4.09 Basic  30% 11 0.15, 15  
Temazepam       
Oxazepam 
3.35              
2.43 
0.3125 – 
5  
Clobazam                 
2 mg/L 
3.72 Benzo  40% 7 0.2, 2  
A-6 
Trimethoprim  1.51 0.625 – 
10  
Norfenfluramine        
2 mg/L  
3.17 Basic  20% 5 1, 5  
Tramadol                       
ODT 
4.45             
1.98 
0.125 – 2  Brompheniramine     
2 mg/L    
9.91 Basic  14% 12 0.75, 3  
Trazadone 2.16 0.625 – 
10 
Desipramine             
2 mg/L 
4.86 Basic 30% 6 0.2, 2.0 
Venlafaxine                  
ODV 
2.77              
1.48 
0.625 – 
2.5  
Brompheniramine    
2 mg/L 
3.22 Basic  25% 5 0.4, 4  
Verapamil 6.27 0.3125 – 
5 
Promazine                
2 mg/L 
4.41 Basic 30% 8 0.4, 2.0 
Zolpidem 1.65 0.125 – 2 Promazine                
2 mg/L 
1.89 Basic 30% 5.5 0.1, 1.0 
Zopiclone  1.95 0.125 – 2  Brompheniramine     
2 mg/L 
3.47 Basic  25% 5 0.1, 1  
 
Analytical conditions/methods used for drug quantitation
A-7 
 
